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The novel long noncoding RNA Pnky regulates neurogenesis and 
neural stem cell maintenance in vivo 
 
Rebecca E. Andersen 
 
Abstract 
While it is now appreciated that certain long noncoding RNAs (lncRNAs) have important 
functions in cell biology, relatively few have been shown to regulate development in vivo, 
particularly with genetic strategies that establish cis versus trans mechanisms. We have 
identified Pinky (Pnky) as a lncRNA that regulates neurogenesis in the embryonic and postnatal 
mouse brain. Pnky is a nuclear-enriched lncRNA that is divergent to the neighboring proneural 
transcription factor Pou3f2. In postnatal neural stem cells (NSCs) from the ventricular-
subventricular zone (V-SVZ), Pnky knockdown promotes neuronal lineage commitment and 
expands the transit amplifying cell population, increasing neuron production several-fold. In the 
embryonic cortex, Pnky knockdown increases neuronal differentiation and depletes the NSC 
population prematurely. Furthermore, genetic deletion of Pnky results in the aberrant production 
of neuronal masses along the postnatal V-SVZ. In the developing cortex, Pnky regulates the 
production of projection neurons from NSCs in a cell-autonomous manner, and loss of Pnky 
alters postnatal cortical lamination. Surprisingly, Pou3f2 expression is not disrupted by deletion 
of the entire Pnky gene. Moreover, expression of Pnky from a bacterial artificial chromosome 
(BAC) transgene rescues the differential gene expression and increased neurogenesis of Pnky-
knockout NSCs, as well as the developmental phenotypes of Pnky-deletion in vivo. Thus, 
despite being transcribed divergently from a key developmental transcription factor, the lncRNA 
Pnky regulates neural development in trans.  
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Chapter 1: Introduction 
 
Summary 
During both development and adulthood, the human brain expresses many thousands of 
long noncoding RNAs (lncRNAs), and aberrant lncRNA expression has been associated with a 
wide range of neurological diseases. Although the biological significance of most lncRNAs 
remains to be discovered, it is now clear that certain lncRNAs carry out important functions in 
neurodevelopment, neural cell function, and perhaps even diseases of the human brain. Given 
the relatively inclusive definition of lncRNAs — transcripts longer than 200 nucleotides with 
essentially no protein coding potential — this class of noncoding transcript is both large and 
very diverse. Furthermore, emerging data indicate that lncRNA genes can act via multiple, non-
mutually exclusive molecular mechanisms, and specific functions are difficult to predict from 
lncRNA expression or sequence alone. Thus, the different experimental approaches used to 
explore the role of a lncRNA might each shed light upon distinct facets of its overall molecular 
mechanism, and combining multiple approaches may be necessary to fully illuminate the 
function of any particular lncRNA. To understand how lncRNAs affect brain development and 
neurological disease, in vivo studies of lncRNA function are required. Thus, this introduction 
focuses on a small set of neural lncRNAs that have been experimentally manipulated in mice. 
Together, these examples illustrate how studies of individual lncRNAs using multiple 
experimental approaches can help reveal the richness and complexity of lncRNA function in 
both neurodevelopment and diseases of the brain. 
 
Background 
The human genome produces tens of thousands of long noncoding RNAs (lncRNAs) — 
transcripts of greater than 200 nucleotides that lack evident protein coding potential (Djebali et 
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al., 2012) — and it is now clear that certain lncRNAs can regulate important biological 
processes including those that underlie human disease (Batista and Chang, 2013; Briggs et al., 
2015; Lee, 2012; Mercer and Mattick, 2013; Rinn and Chang, 2012). The developing and adult 
central nervous system (CNS) express a tremendous diversity of lncRNAs, many of which are 
brain-specific (Derrien et al., 2012; Mercer et al., 2008). Aberrant lncRNA expression has been 
associated with some of the most devastating neurological diseases including glioma (Ramos et 
al., 2016), schizophrenia (Barry et al., 2014), Alzheimer’s disease (Faghihi et al., 2008), 
developmental delay (Talkowski et al., 2012), and autism (Ziats and Rennert, 2013). Though 
lncRNAs comprise an extensive class of noncoding transcripts, our general understanding of 
lncRNA function is still in its relative infancy. Nevertheless, the study of individual lncRNAs in 
the context of neural development and disease has provided fascinating and fundamentally 
important insights into the biological roles of this aspect of the noncoding genome.  
Like protein coding messenger RNAs (mRNAs), lncRNAs are transcribed from the 
genome by RNA Polymerase II, and many are also 5’ capped, spliced, and polyadenylated 
(Quinn and Chang, 2015). lncRNA genes can have various genomic orientations (Figure 1.1), 
with some overlapping protein-coding genes in the sense or antisense direction, others located 
between protein coding genes (intergenic), and a subset transcribed divergently from a 
neighboring gene through a shared promoter. While the genomic structure of lncRNAs can be 
sub-classified further (Mattick and Rinn, 2015), the aforementioned basic differences in lncRNA 
gene location and orientation can provide some insight into potential mechanisms through which 
they might function.  
The currently known molecular mechanisms of lncRNA genes are very diverse, including 
the production of functional RNA transcripts (Rinn and Chang, 2012), cis regulation of 
neighboring genes through lncRNA promoter activity and/or transcriptional elongation (Engreitz 
et al., 2016; Kornienko et al., 2013; Li et al., 2013; Ørom et al., 2010), and enhancer-like activity 
of lncRNA loci (Fulco et al., 2016; Paralkar et al., 2016; Yin et al., 2015). Furthermore, recent 
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evidence indicates that certain transcripts currently annotated as lncRNAs can encode 
functional micropeptides (Anderson et al., 2015; Andrews and Rothnagel, 2014; Nelson et al., 
2016). Of note, these functions are not mutually exclusive, and any particular lncRNA gene 
might have multiple molecular roles. Thus, the use of different experimental approaches, such 
as knockdown of the lncRNA transcript versus genetic disruption of the lncRNA gene, may 
reveal different aspects of lncRNA function (Bassett et al., 2014) and could produce different 
phenotypes.  
The expression of many lncRNAs is highly dynamic during CNS development and neural 
stem cell (NSC) differentiation (Mercer et al., 2010; Ramos et al., 2013), and in some cases can 
be regulated by neuronal activity (Barry et al., 2014; Lipovich et al., 2012). Furthermore, 
lncRNAs exhibit a high degree of cell-type specificity, even surpassing that of protein coding 
genes (Cabili et al., 2011; Liu et al., 2016; Mercer et al., 2008; Ramos et al., 2013). For 
instance, some lncRNAs are abundantly expressed in specific cell types, such as radial glia in 
the developing human brain (Liu et al., 2016). Large-scale screens reveal that essential lncRNA 
function appears to be surprisingly cell-type specific, even for lncRNAs that are expressed 
across a wide range of cell types (Liu et al., 2016; Zhu et al., 2016). Therefore, experimental 
manipulations of lncRNAs through both large-scale screens and more in-depth individual 
analyses are key to advancing our understanding of the roles of lncRNAs in neural development 
and disease. 
A growing number of lncRNAs has been found to regulate important biological functions 
in different neural cell types, and several recent reviews provide an excellent survey of such 
lncRNAs (Aprea and Calegari, 2015; Briggs et al., 2015; Clark and Blackshaw, 2014; Hart and 
Goff, 2016; Ramos et al., 2016). This chapter focuses on a smaller subset of lncRNAs that have 
been experimentally manipulated in vivo in mice (Table 1.1). By discussing specific details of 
the experimental methods used to manipulate each of these lncRNAs, I hope to illustrate how 
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studies of individual lncRNAs using multiple approaches can help reveal important insights 
regarding lncRNA function in both CNS development and diseases of the brain. 
 
Overlapping, antisense lncRNAs 
Numerous lncRNA genes overlap coding genes in an antisense direction (Figure 1.1a). 
While some antisense lncRNAs seem to function primarily in cis — local to and dependent upon 
their site of transcription (Guil and Esteller, 2012) — others appear to act in trans, independent 
from their site of transcription. Below, six antisense lncRNAs are reviewed on a case-by-case 
basis with particular focus on the methods used to manipulate lncRNA expression. Despite 
these genes being classified together as antisense lncRNAs, the current data suggest that they 
function via distinct mechanisms.  
BACE1-AS: potential disease significance through the stabilization of BACE1 mRNA 
The lncRNA BACE1-AS is transcribed antisense to b-site APP cleaving enzyme 1 
(BACE1), a protease that plays a role in Alzheimer’s disease (AD) (Vassar, 2001; Vassar et al., 
1999) and is also required for multiple aspects of normal CNS function (Laird et al., 2005; 
Willem et al., 2006). In the human SH-SY5Y neuroblastoma cell line, BACE1-AS is detected in 
both the nucleus and cytoplasm (Faghihi et al., 2008). BACE1-AS knockdown (KD) with small 
interfering RNA (siRNA) decreases BACE1 mRNA and protein (Faghihi et al., 2008). 
Conversely, BACE1-AS overexpression (OE) increases BACE1 levels. Consistent with these 
results in human cell lines, continuous Bace1-AS siRNA infusion into the third ventricle of mice 
for 2 weeks reduces Bace1 mRNA and protein in the cortex, striatum, and hippocampus. Thus, 
BACE1-AS is a lncRNA that positively regulates its antisense partner, BACE1.  
Both of the BACE1-AS splice variants contain sequences complementary to BACE1 
exons (Faghihi et al., 2008), which raises the possibility that the BACE1-AS lncRNA physically 
interacts with BACE1 mRNA. Consistent with this, the overlapping regions of the lncRNA and 
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mRNA transcripts resist degradation in RNase protection assays, suggesting that they form an 
RNA duplex. Furthermore, KD of BACE1-AS reduces BACE1 mRNA half-life, while OE of 
BACE1-AS increases the half-life of the mRNA. Together, these data support a model in which 
BACE1-AS forms a duplex with BACE1 mRNA to increase its stability, leading to increased 
protein production (Faghihi et al., 2008). 
BACE1 is a protease that cleaves amyloid precursor protein (APP), and aberrant 
cleavage is associated with AD (Vassar, 2001; Vassar et al., 1999). The pathogenic APP 
cleavage products exhibit an intriguing functional relationship with BACE1-AS expression. In 
HEK-SW cells that harbor an AD-linked mutation (Su et al., 2003), KD of BACE1-AS decreases 
the APP cleavage products amyloid b (Ab) 1-40 and Ab 1-42 (Faghihi et al., 2008), suggesting 
that BACE1-AS normally promotes APP cleavage. Interestingly, cultured cells treated with Ab 1-
42 protein upregulate BACE1-AS expression (Faghihi et al., 2008; Tamagno et al., 2006). 
Collectively, these results suggest a positive feedback mechanism in which Ab 1-42 induces 
elevated BACE1-AS expression, which increases BACE1 levels and thereby further promotes 
production of Ab 1-42.  
The expression levels of BACE1-AS also suggests a role for this lncRNA in AD. In 
patients with AD, BACE1-AS expression averaged across multiple brain regions is 2-fold higher 
as compared to controls (Faghihi et al., 2008), which is an increase larger than that observed for 
BACE1. Additionally, transgenic APP-tg19959 mice, which have elevated levels of Ab 1-42 and 
are considered an AD model (Oltersdorf et al., 1990), also exhibit increased expression of 
Bace1-AS and Bace1 (Faghihi et al., 2008). From a translational standpoint, it will be very 
interesting to understand the effects of Bace1-AS KD on Bace1 expression and Ab 1-42 
biogenesis in this transgenic mouse model, as this could further implicate BACE1-AS in the 
regulation of these aspects of AD pathology. 
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BDNF-AS: a regulator of the growth factor BDNF 
BDNF-AS is a lncRNA transcribed antisense to brain-derived neurotrophic factor (BDNF) 
(Liu et al., 2005), a secreted neurotrophic polypeptide that regulates neuronal differentiation, 
maturation, and survival (Chapleau et al., 2009; Hasbi et al., 2009; Yoshimura et al., 2009). 
Knockdown of BDNF-AS through siRNA in several human and mouse cell lines induces the 
upregulation of BDNF (Lipovich et al., 2012; Modarresi et al., 2012). Consistent with the role of 
BDNF in promoting neuronal differentiation (Binder and Scharfman, 2004), this resultant 
increase in BDNF upon KD of Bdnf-AS enhances neuronal outgrowth in mouse hippocampal 
neurosphere cultures (Modarresi et al., 2012). Moreover, in the mouse brain, Bdnf-AS KD 
achieved via intraventricular infusion of antisense oligonucleotides (ASOs) also increases BDNF 
and correlates with an increase in cell proliferation in the hippocampal dentate gyrus (Modarresi 
et al., 2012), a region of adult neurogenesis (Gonçalves et al., 2016). Thus, BDNF-AS appears 
to be a negative regulator of BDNF in multiple cell lines as well as in the adult mouse brain. 
BDNF-AS splice variants all have exonic complementarity with BDNF mRNA (Modarresi 
et al., 2012), indicating the potential for lncRNA-mRNA duplex formation, as is observed with 
BACE1-AS and BACE1 transcripts (Faghihi et al., 2008). However, in HEK293T cells, BDNF-AS 
KD does not alter the half-life of BDNF mRNA (Modarresi et al., 2012), indicating that the 
increase in BDNF transcript levels observed with BDNF-AS KD does not relate to a change in 
BDNF transcript stability.  
Certain lncRNA transcripts interact with chromatin modifying proteins and can influence 
the chemical and/or structural state of chromatin at specific loci (Mercer and Mattick, 2013; Rinn 
and Chang, 2012). In HEK293T cells, BDNF-AS KD decreases the levels of histone 3 lysine 27 
trimethylation (H3K27me3) — a histone modification associated with transcriptional repression 
(Aranda et al., 2015) — at the BDNF locus (Modarresi et al., 2012). This change is 
accompanied by a decrease in the enrichment of the H3K27-methyltransferase enhancer of 
zeste homolog 2 (EZH2) (Viré et al., 2005). While these data suggest a role for BDNF-AS in 
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regulating the chromatin state at the BDNF locus, whether BDNF-AS interacts with EZH2 or 
other chromatin modifying complexes has not been reported. It is also possible that the 
observed chromatin state changes at the BNDF locus simply reflect increased local 
transcriptional activity that results from increased levels of BDNF, which can promote 
transcription of its own gene via autoregulatory feedback (Bambah-Mukku et al., 2014). 
Precisely how BDNF-AS functions remains to be fully elucidated, but results from the siRNA- 
and ASO-mediated lncRNA KD experiments suggest that the BDNF-AS transcript itself 
negatively regulates the transcription and/or chromatin state of its antisense partner. 
Evf2: neighboring gene regulation both in cis and in trans 
With its transcriptional start site (TSS) located within the Dlx5/6 bigene cluster, the 
lncRNA Evf2 is transcribed antisense to Dlx6 and contains the entire Dlx6 gene within a large 
intron (Figure 1.2a) (Feng et al., 2006). Evf2 also contains the ultraconserved Dlx5/6 intergenic 
enhancer ei (Feng et al., 2006). In the developing mouse brain, Evf2 transcript is localized to the 
nucleus, and its pattern of expression overlaps that of Dlx5/6 and Dlx1/2 in the medial and 
lateral ganglionic eminences (MGE and LGE, respectively) (Feng et al., 2006; Porteus et al., 
1994). Given that the Dlx family of transcription factors plays critical roles in GABAergic 
interneuron production (Anderson et al., 1997a; Cobos et al., 2005; Pleasure et al., 2000), it has 
been of great interest to determine whether this lncRNA modulates the expression and/or 
function of the Dlx genes. This section describes how our understanding of Evf2 has evolved 
over time with the use of different experimental approaches. 
In early experiments performed in cell culture, Evf2 was found to exhibit activity as a 
DLX2 transcriptional coactivator (Feng et al., 2006). Dlx1/2 is genetically required for the 
expression of the Dlx5/6 bigene cluster (Anderson et al., 1997a, 1997b; Zerucha et al., 2000), 
and transient transfection of Dlx2 expression plasmids can activate reporter constructs 
containing Dlx5/6 enhancers, which are known targets of DLX2 (Zerucha et al., 2000; Zhou et 
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al., 2004). When co-transfected with Dlx2 into the C17 and MN9D mouse neural cell lines, Evf2 
increases Dlx2-dependent activation of these transcriptional reporters (Feng et al., 2006). 
Furthermore, immunoprecipitation of DLX proteins from cultured cells and rat branchial arches 
(Kohtz and Fishell, 2004) enriches for Evf2 transcripts (Feng et al., 2006), indicating that DLX2 
and Evf2 physically interact in vivo. Taken together, these results suggested that Evf2 
transcripts can directly augment the ability of DLX2 protein to activate its downstream targets.  
This initial understanding of Evf2 as a transcriptional co-activator was developed 
primarily from studies of Evf2 expressed from plasmids in cultured cells. To study the role of 
Evf2 transcribed from its endogenous genomic locus, genetic targeting was used to deplete this 
lncRNA in mice. To avoid removal of genomic DNA that could disrupt the known local 
transcriptional enhancers, a triple polyadenylation (polyA) signal was inserted into Evf2 exon 1 
(Evf2TS) to terminate lncRNA transcription before the ei enhancer (Bond et al., 2009) (Figure 
1.2b). This genetic strategy ablated full-length Evf2 transcripts in homozygous Evf2TS/TS mice.  
In the MGE of Evf2TS/TS mice, the binding of DLX transcription factors at the Dlx5/6 
enhancers is reduced (Bond et al., 2009). Surprisingly, however, the reduction of DLX at these 
enhancers correlates with increased levels of Dlx5 and Dlx6. While it possible that the insertion 
of polyA signals at this particular location disrupts uncharacterized DNA regulatory elements, 
siRNA-mediated Evf2 KD in vivo also increases Dlx5 expression in the MGE, suggesting that 
loss of the Evf2 transcript itself underlies the observed transcriptional changes. Moreover, Evf2 
introduced in trans through electroporation can partially reverse the elevated levels of Dlx5 in 
Evf2TS/TS mice. These in vivo genetic studies suggest that Evf2 transcripts normally inhibit Dlx5 
expression in trans.  
In contrast, Evf2 appears to regulate the expression of Dlx6 in cis. Evf2 expressed in 
trans via plasmid electroporation does not reduce Dlx6 expression (Bond et al., 2009), 
suggesting that the increased levels of Dlx6 in Evf2TS/TS mice may result from a disruption of cis 
regulatory mechanisms and thus cannot be rescued in trans. This apparent cis regulation of 
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Dlx6 — but not Dlx5 — may relate to the genomic structure of this locus. Given that Dlx6 exists 
within an intron of Evf2 (Figure 1.2a), active Evf2 transcription might normally inhibit Dlx6 
expression from the same chromosome via transcriptional interference, wherein transcription 
along one DNA strand blocks transcription from the opposite strand (Cech and Steitz, 2014; 
Shearwin et al., 2005). Thus, early termination of Evf2 elongation in the Evf2TS/TS mice could 
alleviate transcriptional interference of Dlx6. Taken together, results from the Evf2TS/TS mice 
indicate that Evf2 can regulate the Dlx5/6 bigene cluster via both cis and trans mechanisms.  
  DNA methylation and methyl CpG binding protein 2 (MECP2) have been investigated as 
mechanistic players underlying Evf2 function. MECP2 is a DNA methyl-binding protein 
associated with transcriptional repression (Nan et al., 1998) and is found at the Dlx5/6 locus 
(Horike et al., 2004). Mecp2-null mice exhibit increased Dlx5/6 expression (Berghoff et al., 
2013), suggesting that Mecp2 normally represses this locus. In the MGE of Evf2TS/TS mice, 
MECP2 enrichment at Dlx5/6 enhancers is decreased (Bond et al., 2009), correlating with the 
increased transcriptional activity. These data suggest that Evf2 is required for the localization of 
MECP2 at Dlx5/6 regulatory regions.  
Interestingly, Evf2TS/TS mice have increased levels of DNA methylation at the Dlx5/6 
enhancers, and transgenic Evf2 expression reduces this excess methylation (Berghoff et al., 
2013). Thus, while Evf2 is necessary for the enrichment of MECP2 at the Dlx5/6 enhancers, 
Evf2 also appears to inhibit DNA methylation of these enhancers in trans. Based on these and 
previous results (Anderson et al., 1997a, 1997b; Bond et al., 2009; Zerucha et al., 2000), the 
authors propose that Evf2 inhibits DNA methylation at Dlx5/6 regulatory regions, facilitating 
antagonistic interactions between MECP2 and DLX proteins (Berghoff et al., 2013). How the 
proposed interactions enable differential control of Dlx5 and Dlx6 remains to be demonstrated. 
Moreover, Evf2 also appears to mediate interactions between DLX1 and the SWI/SNF-
related chromatin remodeler brahma-related gene 1 (BRG1) (Cajigas et al., 2015; Wang et al., 
1996). DLX1 and BRG1 physically interact and co-localize at the Dlx5/6 ei enhancer (Cajigas et 
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al., 2015). Furthermore, Evf2 can directly interact with BRG1, and loss of Evf2 reduces BRG1 
levels at the Dlx5/6 enhancers. While Evf2 inhibits BRG1 ATPase activity in assays using 
recombinant proteins (Cajigas et al., 2015), the functional consequences of Evf2-BRG1 
interactions in vivo remain to be tested. However, considering the previous work, one possibility 
is that Evf2 promotes interactions between BRG1 and DLX1/2, which serve to activate the 
Dlx5/6 locus and counteract repression by MECP2. 
Given that the Dlx genes play crucial roles in the production of forebrain GABAergic 
interneurons (Anderson et al., 1997a; Cobos et al., 2005; Pleasure et al., 2000), disruption of 
Evf2 might be expected to influence this developmental process. Indeed, loss of Evf2 results in 
a 45-60% reduction of GAD1+ GABAergic interneurons in the hippocampus of early postnatal 
Evf2TS/TS mice (Bond et al., 2009). This phenotype correlates with a 30% reduction in Gad1 
expression in the mutant embryonic MGE, which can be partially restored by electroporation of 
Evf2. Surprisingly, the number of GAD1-expressing cells returns to normal in the adult Evf2TS/TS 
hippocampus (Bond et al., 2009). However, impaired synaptic inhibition in the hippocampus 
persists throughout adulthood, demonstrating that the disruption of a neural lncRNA can lead to 
long-lasting changes in CNS function.  
Dlx1as: a role in interneuron production 
Similar to Dlx5/6, the Dlx1/2 bigene cluster also contains a lncRNA gene, Dlx1as (Dinger 
et al., 2008; Jeong et al., 2008; Kraus et al., 2013; Liu et al., 1997; McGuinness et al., 1996). 
Transcribed antisense to Dlx1, Dlx1as overlaps the majority of the Dlx1 gene (Figure 1.2c). 
However, unlike the Evf2-Dlx6 configuration, Dlx1as is not transcribed through the TSS of its 
coding gene partner Dlx1. To genetically disrupt Dlx1as expression in mice, four polyA signals 
were inserted between exons 1 and 2 (Dlx1as4xPA) (Kraus et al., 2013) (Figure 1.2d), promoting 
the termination of Dlx1as transcription before its overlap with Dlx1. However, despite the 
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multiple polyA signals, Dlx1as expression is not completely ablated: in homozygous 
Dlx1as4xPA/4xPA mice, Dlx1as is expressed at ~30% of wild-type levels.  
Dlx1as is normally expressed in the embryonic ganglionic eminences (GEs) (Liu et al., 
1997) in a pattern similar to that of Dlx1/2 (Porteus et al., 1994). In the GEs of Dlx1as4xPA/4xPA 
embryos, Dlx1 transcript levels are moderately (~40%) increased (Kraus et al., 2013), 
suggesting that Dlx1as normally represses Dlx1 expression. Although postnatal Dlx1as4xPA/4xPA 
mice have a 2-fold increase in the number of Dlx1+ cells in the hippocampus, the number of 
interneurons as assessed by Gad67 and Somatostatin expression was not altered in the mutant 
mice (Kraus et al., 2013). Given that overexpression of Dlx1 alone does not alter the number of 
GABAergic interneurons in the mouse brain (Hitoshi et al., 1991), it is perhaps not surprising 
that Dlx1as4xPA/4xPA mice do not exhibit obvious changes in this population of neurons. Whether 
the development of other neuronal (and glial) cell types is affected by Dlx1as genetic disruption 
remains to be reported.  
Dlx1as is also expressed in the neurogenic lineage of the postnatal mouse ventricular-
subventricular zone (V-SVZ) (Dinger et al., 2008; Ramos et al., 2013). In cultured V-SVZ neural 
stem cells, KD of Dlx1as with short hairpin RNA (shRNA) decreases the expression of Dlx1, 
Dlx2 and Dlx5 during differentiation (Ramos et al., 2013). These transcriptional changes 
correlate with a substantial decrease in the production of young neurons.  
The contrasting effects upon gene expression in the embryonic brain of Dlx1as4xPA/4xPA 
mice and V-SVZ cell cultures with Dlx1as KD could reflect potential cell type-specific functions 
of Dlx1as. In a recent genome-scale survey, lncRNA loci were found to have exquisitely cell 
type-specific functions for cell growth and proliferation (Liu et al., 2017). Alternatively, the 
differences observed may relate to the approaches used to reduce Dlx1as levels. In 
Dlx1as4xPA/4xPA mice, transcriptional elongation of Dlx1as is abrogated, whereas with Dlx1as KD, 
transcript levels are depleted without a direct effect upon transcription at the locus. Since Dlx1as 
overlaps Dlx1 (Figure 1.2c), transcription of this lncRNA could potentially reduce expression of 
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Dlx1 through transcriptional interference (Shearwin et al., 2005). Such repression in cis could be 
relieved by the transcriptional termination in Dlx1as4xPA/4xPA mice, but not by shRNA-mediated 
Dlx1as KD in V-SVZ NSCs. Additional approaches such as Dlx1as OE and attempted 
transgenic rescue of Dlx1as4xPA/4xPA may be helpful in addressing these and other possibilities. 
The mechanism by which Dlx1as regulates Dlx1 expression is still unclear, but given that 
Evf2 can regulate its neighboring coding genes via both cis and trans mechanisms (Bond et al., 
2009), it may be important to address both possibilities for Dlx1as as well. Since Dlx1/2 are 
required for the expression of Evf2 (Anderson et al., 1997b; Zerucha et al., 2000), Dlx1as may 
indirectly affect Evf2 expression through regulating Dlx1. Interestingly, genetic deletion of Dlx5 
or Dlx6 decreases Dlx1as expression in the developing branchial arches (Jeong et al., 2008). 
Given that Evf2 regulates the expression of both Dlx5 and Dlx6 (Bond et al., 2009), Evf2 may 
also indirectly regulate Dlx1as, adding an additional layer to the much studied cross-talk 
between the Dlx1/2 and Dlx5/6 bigene clusters (Anderson et al., 1997a; Liu et al., 1997; 
McGuinness et al., 1996; Zerucha et al., 2000). 
KCNA2-AS: implications for neuropathic pain 
KCNA2-AS is an antisense lncRNA that overlaps most of the KCNA2 gene, which 
encodes a voltage-gated potassium channel (Zhao et al., 2013). Decreased expression of 
KCNA2 correlates with neuropathic pain (Ishikawa et al., 1999; Kim et al., 2002), which can 
arise from damage to peripheral nerves (Campbell and Meyer, 2006). While KCNA2-AS has not 
been studied in the context of the CNS, its role in the peripheral nervous system (PNS) 
highlights how a lncRNA might serve as a therapeutic target for an important neurological 
condition.  
KCNA2-AS and KCNA2 are both expressed in the dorsal root ganglia (DRG) of rat, 
mouse, monkey, and human (Zhao et al., 2013). In the rat DRG, Kcna2-AS positive neurons 
generally express low levels of Kcna2. Peripheral nerve injury caused by lumbar spinal nerve 
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ligation (SNL) increases Kcna2-AS expression in neurons of the ipsilateral DRG, and these cells 
with elevated levels of Kcna2-AS exhibit decreased expression of Kcna2 (Zhao et al., 2013). 
These dynamic, reciprocal changes in Kcna2-AS and Kcna2 levels suggest a model in which 
expression of the Kcna2-AS lncRNA normally represses the expression of its antisense gene 
partner, Kcna2. 
The transcription factor myeloid zinc finger 1 (MZF1) (Luo et al., 2009) binds to the 
Kcna2-AS promoter, and upon SNL, MZF1 levels increase and become further enriched at the 
Kcna2-AS promoter (Zhao et al., 2013). Moreover, MZF1 OE in cultured rat DRG neurons 
increases Kcna2-AS, while decreasing Kcna2 levels. Taken together, these data support a 
model in which peripheral nerve injury increases the expression of MZF1, which directly 
upregulates Kcna2-AS expression, thereby decreasing the expression of Kcna2. Consistent with 
this model, Kcna2-AS OE is sufficient to decrease Kcna2, however the mechanism by which 
this lncRNA can down-regulate its antisense coding gene partner in trans has not been 
reported.  
In vivo, OE of Kcna2-AS in the rat DRG also decreases levels of Kcna2, resulting in 
altered voltage-gated potassium current density and resting membrane potentials (Zhao et al., 
2013). These electrophysiological changes correspond to behavioral abnormalities associated 
with neuropathic pain, such as mechanical and cold hypersensitivity. Thus, increased levels of 
Kcna2-AS transcript appear to drive neuropathic pain via suppression of Kcna2 expression. 
Supporting this notion, KD of Kcna2-AS prior to SNL blocks the downregulation of Kcna2 
normally observed after peripheral nerve injury. Importantly, Kcna2-AS KD also attenuates the 
neuropathic pain symptoms of mechanical, cold, and thermal hypersensitivity. These data raise 
the intriguing possibility that KD of Kcna2-AS can ameliorate — or perhaps even prevent — 
neuropathic pain symptoms that arise from injury to the peripheral nerves.  
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Ube3a-ATS: a role in imprinting with relevance to Angelman syndrome 
Some of the earliest-studied lncRNAs are involved in the regulation of gene dosage 
(Mohammad et al., 2009). The classic example is the lncRNA XIST, which is required for X-
chromosome inactivation in female cells (Brown et al., 1992; Engreitz et al., 2013; Penny et al., 
1996; Plath et al., 2002). Other lncRNAs play a role in imprinting, a process by which autosomal 
genes are expressed from a single allele in a parent of origin-specific manner (Bartolomei and 
Ferguson-Smith, 2011). For instance, the lncRNA Air interacts with the histone 
methyltransferase G9a to enable imprinting of its neighboring genes in the mouse placenta 
(Nagano et al., 2008). Similarly, Kcnq1ot1 interacts with G9a as well as Polycomb repressive 
complex 2 (PRC2) to mediate imprinting (Pandey et al., 2008; Terranova et al., 2008). 
Investigating how lncRNAs regulate imprinting may be useful for understanding diseases 
caused by abnormal gene dosage, and could potentially lead to strategies for the reactivation of 
silenced alleles for therapeutic purposes.  
Ube3a-ATS is a nuclear, neural-expressed antisense lncRNA that is involved in the 
repression of paternal Ube3a (Meng et al., 2012), which is imprinted specifically in neurons 
(Rougeulle et al., 1997; Vu and Hoffman, 1997; Yamasaki et al., 2003). Ube3a-ATS is part of an 
extremely long transcript that extends over 1000 kb through multiple genes including the 3’ end 
of Ube3a. The relationship between Ube3a-ATS and Ube3a is of particular interest because of 
its implications for Angelman syndrome, a disorder characterized by neurological symptoms 
including seizures and intellectual disability. Angelman syndrome is caused by mutations in the 
maternal UBE3A allele, which results in complete loss of functional UBE3A protein in neurons 
due to silencing of the intact paternal copy (Albrecht et al., 1997; Kishino et al., 1997; Matsuura 
et al., 1997). Therefore, a potential therapeutic strategy is to reduce levels of UBE3A-ATS, thus 
relieving silencing of the normal paternal UBE3A (Meng et al., 2013, 2015). 
In a mouse model of Angelman syndrome, genetic and pharmacological reduction of 
Ube3a-ATS expression has shown therapeutic promise. Premature termination of Ube3a-ATS 
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via the insertion of a triple polyA cassette relieves silencing of the paternal Ube3a allele, 
rescuing neurological deficits associated with Angelman syndrome (Meng et al., 2013). 
Moreover, a single intraventricular administration of ASOs targeting Ube3a-ATS reduces levels 
of this lncRNA in the brain, partially de-repressing paternal Ube3a for 4 months (Meng et al., 
2015). This ASO treatment even ameliorates certain Angelman syndrome-associated 
phenotypes, such as aberrant contextual fear behavior. Given the sustained lncRNA KD 
achieved with a single intraventricular injection of ASOs, the targeting of neural lncRNAs with 
ASOs may be clinically feasible, at least for those that are expressed in non-dividing neurons. 
 
Non-overlapping lncRNAs 
Non-overlapping lncRNAs can vary greatly in terms of their distance from their nearest 
neighboring gene, with some only a few bases apart and others separated by megabases 
(Cabili et al., 2011) (Figure 1.1b). A subset of lncRNAs can carry out enhancer-like roles (Ørom 
et al., 2010), and the act of transcription of some lncRNAs appears to facilitate the expression of 
their close gene neighbors (Engreitz et al., 2016). However, even in these cases where non-
overlapping lncRNAs have roles in cis, is still possible that the lncRNA transcript itself has 
additional functions, and work from mouse ES cells suggests that many lncRNAs function in 
trans (Guttman et al., 2011). 
Six3OS: a mediator of retinal progenitor cell differentiation 
The lncRNA Six3OS (originally Rncr1) is transcribed divergently from Six3, a 
transcription factor that is critical for eye development (Zhu et al., 2002). Six3OS is largely co-
expressed with its coding gene partner in cells of the developing mouse retina (Alfano et al., 
2005; Blackshaw et al., 2004; Geng et al., 2007; Rapicavoli et al., 2011). In situ hybridization 
(ISH) reveals Six3OS transcripts in both the nucleus and cytoplasm of embryonic retinal 
progenitor cells (RPCs) (Rapicavoli et al., 2011).  
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There are multiple isoforms of Six3OS, and OE of the most abundant isoform in perinatal 
RPCs via in vivo plasmid electroporation indicates a functional relationship between this lncRNA 
and Six3. RPCs are multipotent, giving rise to rod cells, bipolar cells, amacrine cells, and Müller 
glia (Cepko, 2014). Six3OS OE in RPCs has a relatively modest effect, reducing the proportion 
of syntaxin (syn)-expressing amacrine cells (Rapicavoli et al., 2011). In contrast, as previously 
reported (Zhu et al., 2002), Six3 OE in RPCs produces a much broader range of phenotypes, 
affecting the rod bipolar cells and rod photoreceptors, in addition to increasing the proportion of 
syn+ amacrine cells (Rapicavoli et al., 2011). Interestingly, when Six3OS is co-electroporated 
with Six3, these Six3-induced phenotypes are not observed. These results indicate that, at least 
in the context of overexpression, Six3OS can counteract the effects of Six3. 
Interestingly, shRNA-mediated KD of Six3 and Six3OS generates results that would not 
have been predicted by the phenotypes of their OE (Rapicavoli et al., 2011). Despite the 
opposing effects of Six3OS and Six3 in the context of overexpression, Six3OS KD produces 
phenotypes similar to those observed with Six3 KD. Furthermore, combined KD of Six3OS and 
Six3 reveals complex functional relationships between this lncRNA and its coding gene 
neighbor. For example, some retinal cell populations that are not affected by KD of either 
Six3OS or Six3 alone are altered upon their combined KD (Rapicavoli et al., 2011). Surprisingly, 
in other cell populations in which the single KDs result in similar phenotypes, the combined KD 
actually rescues these effects. These complex, non-additive phenotypes suggest an epistatic 
association between these two genes and demonstrate the elaborate relationship that a lncRNA 
can share with its neighbor.  
How Six3OS functionally interacts with Six3 is still not clear. Genetic deletion of Six3 
does not alter expression of Six3OS (Geng et al., 2007), indicating that neither an intact Six3 
locus nor SIX3 protein are required for expression of the Six3OS lncRNA. Given that neither KD 
nor OE of Six3OS transcript affects SIX3 protein abundance (Rapicavoli et al., 2011), it appears 
that Six3OS can modulate the function of Six3 without changing the levels of SIX3 protein. It 
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remains to be tested whether the Six3OS locus itself can regulate Six3 expression in cis, 
potentially via enhancer-like activity (Groff et al., 2016).  
While Six3OS was not found to directly interact with SIX3 protein, both RNA 
immunoprecipitation and protein microarray analyses indicate that Six3OS binds to the EYA 
family of proteins as well as EZH2 (Rapicavoli et al., 2011). EYA family proteins are important 
transcriptional co-regulators in retinal development (Bonini et al., 1993; Pignoni et al., 1997) and 
can interact directly with proteins of the SIX family (Jemc and Rebay, 2007). However, it 
remains to be determined how the Six3OS interactions with EYA and EZH2 might influence cell 
fate outcomes. 
Six3OS is also expressed in V-SVZ NSCs and is downregulated during neuronal 
differentiation (Ramos et al., 2013). In V-SVZ cultures, shRNA-mediated KD of Six3OS results 
in 2-fold fewer neuroblasts and 3-fold fewer oligodendrocyte lineage cells, accompanied by a 
corresponding increase in the proportion of glial fibrillary acidic protein (GFAP)-expressing glial 
cells. Thus, similar to the studies from the retina (Rapicavoli et al., 2011), these results suggest 
that Six3OS can regulate cell fate decisions in neural precursor cells of the CNS.  
Pnky: a regulator of neurogenesis from postnatal and embryonic neural stem cells 
The intergenic lncRNA Pnky neighbors the gene Brn2 (Pou3f2) (Ramos et al., 2013, 
2015), which encodes a transcription factor with key roles in neocortical development (Sugitani 
et al., 2002) and direct neuronal reprogramming (Vierbuchen et al., 2010). Pnky and Brn2 are 
separated by 2.2 kb and are transcribed in divergent directions, and therefore do not share any 
overlapping regions (Ramos et al., 2015).  
Pnky is neural-specific, and is enriched in the nucleus of V-SVZ NSCs (Ramos et al., 
2013, 2015). Throughout postnatal and adult life, mouse V-SVZ NSCs give rise to transit 
amplifying cells that divide two to three times before generating neuroblasts (Doetsch et al., 
1999; Lim and Alvarez-Buylla, 2014). These neuroblasts migrate through the rostral migratory 
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stream to the olfactory bulb where they differentiate into interneurons (Lim and Alvarez-Buylla, 
2014). Over this course of V-SVZ neuronal differentiation, levels of Pnky transcript decrease 
(Ramos et al., 2013, 2015).  
In V-SVZ NSC cultures, shRNA-mediated KD of Pnky increases neuroblast production 
3-4 fold, indicating that Pnky influences V-SVZ neurogenesis (Ramos et al., 2015). Time-lapse 
microscopy analysis of individual V-SVZ NSCs reveals that Pnky regulates multiple aspects of 
V-SVZ neurogenesis. Firstly, Pnky KD increases neurogenic commitment by ~50% (Ramos et 
al., 2015). Furthermore, with Pnky KD, the transit amplifying population undergoes additional 
rounds of cell division. Combined, these effects greatly increase the number of neuroblasts 
produced from this population of postnatal NSCs.  
Pnky also regulates neurogenesis from embryonic NSCs (Ramos et al., 2015). The 
cortical ventricular zone — where embryonic NSCs are located — is enriched for Pnky 
transcripts in both the mouse and human. Pnky KD in mouse embryonic ventricular zone cells 
via in utero electroporation of shRNA constructs promotes neurogenic differentiation in vivo, 
increasing the proportion of SATB2+ young neurons while decreasing the SOX2+ NSC 
population. Thus, reducing Pnky transcript levels in NSCs from both the embryonic and 
postnatal brain promotes neuronal differentiation.  
This increase in neurogenesis observed with Pnky KD suggests a role for Pnky that is 
distinct from several other lncRNAs known to have neurodevelopmental function. For instance, 
KD of lncRNAs megamind (Lin et al., 2014), RMST (Ng et al., 2012, 2013), Six3OS (Ramos et 
al., 2013; Rapicavoli et al., 2011) and Dlx1as (Ramos et al., 2013) can all decrease 
neurogenesis, suggesting that these other lncRNAs are required to positively regulate neuronal 
differentiation. Similarly, genetic deletion of Linc-Brn1b appears to decrease the proliferation of 
embryonic cortical intermediate progenitors, reducing upper layer neurogenesis (Sauvageau et 
al., 2013). As noted above, mice lacking Evf2 have defective interneuron production (Bond et 
al., 2009). Thus, unlike the aforementioned lncRNAs that appear to potentiate neuronal 
 19 
production, Pnky appears to restrain neurogenesis from NSCs, perhaps serving to control their 
long-term self-renewal and/or rate of neuronal production.  
While Pnky is relatively close to its neighbor Brn2, both genes appear to have their own 
promoters: each TSS region has a separate conserved CpG island that exhibits dynamic 
chromatin state changes characteristic of gene promoters (Ramos et al., 2013), including the 
H3K4me3 modification associated with transcriptional activity as well as the repression-
associated H3K27me3 (Venkatesh and Workman, 2015) (Figure 1.3). Furthermore, while Pnky 
expression decreases during neurogenesis, Brn2 transcript levels increase in transit amplifying 
cells (Ramos et al., 2013), suggesting that these gene neighbors are not always co-expressed. 
Given that some lncRNAs can regulate the expression of gene neighbors in cis, one 
possibility is that Pnky regulates Brn2 expression. However, KD of Pnky in V-SVZ cultures does 
not significantly alter expression of Brn2 or any of the other genes within a 5 MB window, 
suggesting that the Pnky transcript does not regulate gene expression in cis, at least in this 
experimental context (Ramos et al., 2015). Whether the act of Pnky transcription (and/or the 
Pnky locus itself) can regulate expression of Brn2 or other neighboring genes remains to be 
shown.  
Pnky transcripts are located in multiple foci throughout the nucleus of neural cells 
(Ramos et al., 2015). The presence of Pnky transcripts in more than two spatially disparate 
locations indicates that this lncRNA can localize in regions of the nucleus that are far from the 
two Pnky loci, suggesting that this lncRNA has trans roles. Many lncRNAs with trans function 
regulate gene expression through interaction with specific proteins (Yang et al., 2015). 
Biotinylated-Pnky pulldown as well as RNA immunoprecipitation analysis reveal that 
polypyrimidine tract binding protein 1 (PTBP1) (Keppetipola et al., 2012) interacts with Pnky in 
cultured V-SVZ NSCs (Ramos et al., 2015). Interestingly, the lncRNAs megamind (Lin et al., 
2014), MEG3 (Zhang et al., 2017), and XIST (Maenner et al., 2010) also interact with PTBP1, 
but the potential significance of these other lncRNA-PTBP1 interactions has not been reported.  
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PTBP1 is localized in the nucleus of NSCs and appears to function as a repressor of 
neuronal differentiation. In the embryonic brain, genetic deletion of Ptbp1 results in precocious 
neuronal differentiation (Shibasaki et al., 2013), and KD of PTBP1 alone in fibroblasts leads to 
direct neuronal trans-differentiation (Xue et al., 2013). In V-SVZ NSC cultures, PTBP1 KD 
increases the size of neurogenic colonies, which is a phenotype similar to that of Pnky KD 
(Ramos et al., 2015). The individual KDs of either PTBP1 or Pnky produce gene expression 
changes as well as mRNA splicing changes that are highly similar, suggesting that this splicing 
factor and lncRNA regulate a common set of transcripts in NSCs. Furthermore, double KD of 
PTBP1 and Pnky does not have a synergistic or additive effect upon transcriptional changes 
observed with the single KDs, suggesting that Pnky and PTBP1 function in the same molecular 
pathway. Taken together, these data indicate that Pnky and PTBP1 physically and genetically 
interact and regulate proper splicing and gene expression in V-SVZ NSCs. 
Gomafu: from retinal development to schizophrenia 
Gomafu (also known as MIAT or Rncr2) was identified as a lncRNA that is dynamically 
expressed during retinal development (along with Six3OS, see above) (Blackshaw et al., 2004). 
Gomafu is intergenic, located 20 kb away from its nearest protein coding neighbor (Blackshaw 
et al., 2004), and is expressed widely in the developing nervous system, localizing to multiple 
foci within the nucleus (Sone et al., 2007).  
In the developing mouse retina, Gomafu is expressed in a large proportion of the 
progenitor cells, with its expression decreasing postnatally and becoming undetectable by 
adulthood (Rapicavoli et al., 2010). In vivo electroporation experiments indicate developmental 
roles for Gomafu in RPCs (Rapicavoli et al., 2010). While OE of Gomafu does not produce any 
overt phenotype, shRNA-mediated KD of this lncRNA increases the production of Müller glia 
and amacrine cells, suggesting that Gomafu normally represses these neural cell fates.  
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Given that the Gomafu lncRNA is normally found in the nucleus, the mis-localization of 
Gomafu transcripts to the cytoplasm might be expected to have a dominant-negative effect via 
the sequestration of its nuclear binding partners in the cytoplasmic compartment (Miyazaki et 
al., 2007; Zhang et al., 2004). Indeed, Gomafu transcripts fused to IRES-GFP sequences 
localize in the cytoplasm, and OE of this Gomafu-IRES-GFP construct in the developing retina 
causes phenotypes similar to those observed with Gomafu KD (Rapicavoli et al., 2010). As OE 
of Gomafu alone does not have an observable phenotype, the effect of Gomafu-IRES-GFP OE 
has been attributed to this mis-localization of Gomafu sequences. Transfection of Gomafu-
IRES-GFP fusion constructs also enabled the dissection of distinct functional domains of 
Gomafu. For instance, when fused to IRES-GFP, OE of the 5’ end increases the proportion of 
amacrine cells while the 3’ end increases the Müller glial cell population (Rapicavoli et al., 
2010). Thus, distinct regions of the Gomafu transcript appear to regulate different aspects of 
RPC fate determination, perhaps through interactions with unique binding partners.  
Since lncRNAs exhibit relatively low evolutionary conservation at the primary sequence 
level (Johnsson et al., 2014; Ulitsky, 2016), any regions of conservation may provide insights 
into lncRNA function. Gomafu orthologs identified in mouse, human, chicken, and xenopus all 
contain multiple consensus recognition sites for the splicing factor quaking (QKI) (Rapicavoli et 
al., 2010). Furthermore, Gomafu physically interacts with QKI (Barry et al., 2014) and other 
splicing factors including serine/arginine-rich splicing factor 1 (SRSF1) (Barry et al., 2014) and 
splicing factor 1 (SF1) (Tsuiji et al., 2011). 
Since QKI has been implicated in schizophrenia (Aberg et al., 2006b, 2006a), an 
interaction between GOMAFU and QKI could be relevant for this disorder. Interestingly, KD of 
GOMAFU in human iPSC-derived neurons increases the levels of the DISC1 and ERBB4 splice 
variants that have been associated with schizophrenia (Barry et al., 2014; Morikawa and 
Manabe, 2010), while GOMAFU OE in these cells has the opposite effect (Barry et al., 2014). In 
schizophrenia patient samples, GOMAFU levels are reduced, further suggesting a connection 
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between GOMAFU dysregulation and aberrant RNA splicing in schizophrenia (Barry et al., 
2014). Additionally, GOMAFU expression is regulated by neuronal activity, becoming 
significantly decreased with depolarization (Barry et al., 2014). Thus, while GOMAFU 
downregulation may be important for splicing changes in the context of normal neuronal activity, 
its constitutive downregulation could be relevant to the neuropathology underlying 
schizophrenia.  
Gomafu has also been implicated in anxiety-related behaviors in mice (Spadaro et al., 
2015). Upon fear conditioning, Gomafu is significantly downregulated in the medial prefrontal 
cortex. Moreover, Gomafu KD through ASO infusion into the prefrontal cortex enhances 
freezing behavior during fear conditioning. This in vivo KD also increases behaviors related to 
anxiety, such as stereotypic grooming and avoidance of an open field. In primary cortical neuron 
cultures, KD of Gomafu upregulates Crybb1 (Spadaro et al., 2015), a chaperone protein that 
has been associated with schizophrenia (Gill et al., 1996; Takahashi et al., 2003). Interestingly, 
in these cultures Gomafu physically interacts with the PRC1 complex member BMI1 (Haupt et 
al., 1991; Meng et al., 2010), and KD of Gomafu reduces BMI1 occupancy at the Crybb1 
promoter (Spadaro et al., 2015). Therefore, Gomafu may directly regulate Crybb1 expression 
through a physical interaction with the repressor BMI1. Taken together, these results 
demonstrate that Gomafu can modulate neuronal function and potentially impact 
neuropsychiatric disorders through multiple molecular mechanisms. 
Recently, a Gomafu knockout mouse has been reported (Ip et al., 2016). Surprisingly, 
loss of Gomafu did not result in any overt developmental phenotypes in the hippocampus, 
despite the high level of Gomafu expression reported in hippocampal CA1 neurons (Sone et al., 
2007). This could reflect different requirements for Gomafu in different cell types, or 
developmental compensation by parallel genetic pathways. Alternatively, this could be due to 
differences resulting from constitutive deletion of the entire locus as opposed to acute 
knockdown of the transcript. Nevertheless, these mice did present moderate behavioral 
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abnormalities, including a hyperactivity phenotype that could be exacerbated by treatment with 
the psychostimulant methamphetamine (Ip et al., 2016). Given that these mice exhibit 
behavioral defects without any obvious developmental aberrations, it is possible that a relatively 
subtle effect on neurodevelopment and/or change in neuronal function underlies the behavioral 
abnormalities. These considerations may be particularly important for the study of complex 
neuropsychiatric diseases that are difficult to fully model in mice. 
 
Concluding Remarks 
From this survey of the data regarding the function of a small set of neural lncRNAs, it is 
apparent that this class of noncoding transcripts is extremely diverse in terms of biological roles 
and molecular mechanisms. This diversity, while intriguing, presents a challenge for determining 
the function of lncRNAs, as it is currently difficult to predict whether a particular lncRNA has 
important cellular function, much less how that lncRNA might operate at the level of molecular 
mechanism. Further complicating these issues, it appears that certain lncRNAs — despite being 
expressed in many different cell types — have biological functions that are exquisitely cell type-
specific (Liu et al., 2017). Thus, manipulating lncRNA expression can lead to complex 
phenotypes that vary with the cell type being analyzed and the timing of the lncRNA 
perturbation. Using a combination of different, complementary strategies may therefore prove 
especially important for revealing the functions of lncRNAs.  
Given the extraordinary diversity of lncRNA structure and function, it can be useful to 
sub-set this class of noncoding transcripts based on certain aspects of their genomic structure. 
Many antisense lncRNAs affect the expression of their partner genes transcribed from the 
opposite strand. However, despite this functional similarity, the mechanisms by which such 
regulation is achieved can be quite distinct. For example, Evf2 regulates the expression of its 
gene neighbors Dlx5 and Dlx6 via both cis and trans mechanisms (Bond et al., 2009), while 
BACE1-AS transcripts interact directly with the BACE1 mRNA, influencing mRNA stability 
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(Faghihi et al., 2008). Thus, while it might be reasonable to hypothesize that antisense lncRNAs 
regulate their partner genes, it is currently not possible to predict how they might do so.  
Non-overlapping lncRNAs are perhaps even more challenging to decipher, particularly 
when they do not include any known genomic regulatory elements. Even when they are close to 
another gene, lncRNAs may not have any regulatory relationship with that neighbor. Given the 
many different possibilities, determining the molecular mechanism through which an intergenic 
lncRNA functions can be quite difficult. Therefore, an initial genetic characterization of whether 
the lncRNA acts in cis or in trans (or both) may provide a crucial foundation for developing any 
mechanistic understanding of how the lncRNA functions.  
This chapter focused on a small set of lncRNAs in order to provide a more in-depth 
discussion of their neural functions. However, there are several other lncRNAs that also have 
important roles in the nervous system. For instance, Taurine Upregulated Gene 1 (Tug1) is 
required for proper photoreceptor differentiation (Young et al., 2005) and interacts with the 
PRC2 complex to repress p53-dependent cell cycle regulation (Khalil et al., 2009). LncOL1 also 
interacts with components of the PRC2 complex to promote oligodendrocyte maturation and is 
required for proper myelination as well as remyelination following injury (He et al., 2017). Notch 
signaling in the developing human cortex is mediated by LncND, which sequesters the 
microRNA miR-143-3p to regulate the expression of Notch receptors (Rani et al., 2016). RMST 
influences the differentiation of human embryonic stem cells into dopaminergic neurons through 
interacting with SOX2 and enabling its binding to specific target promoters (Ng et al., 2012, 
2013). Cyrano and megamind (also known as TUNA) are required for proper neural 
development in zebrafish, and their loss can be rescued by their human or mouse orthologs 
(Ulitsky et al., 2011). Moreover, megamind expression is altered in Huntington’s disease, with 
megamind levels exhibiting a negative correlation with disease grade (Lin et al., 2014). 
Additionally, a set of knockout mice for 18 intergenic lncRNAs has been reported (Sauvageau et 
al., 2013). This set includes Linc-Brn1b, which is expressed in the neural progenitors of the VZ 
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and SVZ in the developing embryonic cortex. Linc-Brn1b appears to positively regulate the 
expression of its neighboring gene Brn1, a neurogenic transcription factor, and loss of Linc-
Brn1b reduces the proliferation of intermediate progenitors and decreases the production of 
upper layer neurons (Sauvageau et al., 2013). While this set of knockout mice is further 
analyzed, additional lncRNAs with neural functions may be identified. 
As the lncRNA field continues to mature, additional approaches will be used to 
manipulate lncRNA expression. For some lncRNAs, a conditional knockout allele will allow 
targeting of a particular subset of cells with precise control over the timing of deletion. For 
example, given that Pnky appears to function in trans and does not overlap known genes or 
enhancers (Ramos et al., 2015), this lncRNA may be suitable for conditional knockout methods. 
For other lncRNAs, this traditional genetic approach may not be possible due to their complex 
genomic configurations, such as overlapping important coding genes and/or enhancers. In 
these cases, perhaps CRISPR interference-based approaches can be used to affect the 
expression of the lncRNA while avoiding any alterations to the underlying DNA (Liu et al., 2017). 
Methods that specifically target the lncRNA transcript, such as KD through shRNA or ASOs, 
may assist in distinguishing the function of the transcript from potential regulatory roles of the 
locus itself. BAC transgenics could also be used to assess lncRNA overexpression or to attempt 
to rescue loss of the endogenous lncRNA. Combining multiple complementary approaches will 
provide important insights into how lncRNAs carry out their roles. Moving forward, a precise 
understanding of the intricate molecular mechanisms through which lncRNAs function will be 
essential for revealing how specific lncRNAs can play important roles in neural development 
and disease.  
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Figure 1.1: Examples of possible genomic configurations of lncRNAs. 
a, Antisense lncRNAs overlap other genes in the antisense direction, but lncRNAs can also 
overlap other genes in the sense direction. The overlapping regions may include exons, 
resulting in mature transcripts that share identical regions or have sequence complementarity, 
depending on the direction of overlap. b, Non-overlapping lncRNAs can vary with respect to the 
distance to the nearest neighboring gene. Intergenic lncRNAs (lincRNAs) do not overlap known 
genes or regulatory elements, and may be transcribed in either direction relative to their nearest 
neighbors. A subset of intergenic lncRNAs known as divergent lncRNAs can share promoters 
(indicated in yellow) with their closely neighboring genes, and are transcribed in the opposite 
direction.  
non-overlapping lncRNAsb
overlapping, antisense lncRNAsa
neighbor
lncRNA
(+)
(-)
neighbor lncRNA
divergent
neighbor lncRNA
intergenic
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Figure 1.2: The genomic configurations of Evf2 and Dlx1as, and the genetic mouse lines 
created to disrupt their transcription. 
a, The lncRNA Evf2 exists within the Dlx5/6 bigene cluster. The ei and eii enhancer elements 
are shown in yellow. Evf2 overlaps the ei enhancer element and contains the entire Dlx6 gene 
within an intron. Evf2 is transcribed from the same strand as Dlx5 and the opposite strand from 
Dlx6. b, The Evf2TS allele includes a 3x polyA transcriptional stop (red) in the first exon of Evf2 
to terminate transcription before the ei enhancer element. c, Dlx1as is transcribed antisense to 
Dlx1 and contains exonic sequences that overlap with Dlx1 exons. d, The Dlx1as4xPA allele 
includes a 4x polyA transcriptional stop (red) inserted before the second exon to terminate 
transcription before overlap with Dlx1. 
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Figure 1.3: The lncRNA Pnky is transcribed in a diverging manner from its nearest 
neighboring gene, Pou3f2 (Brn2). 
While Pnky and Pou3f2 are relatively close, they appear to have independent promoters as 
indicated by separate conserved CpG islands that exhibit dynamic chromatin modifications. In 
embryonic stem cells (ESC), these promoters are enriched with both the H3K4me3 modification, 
which correlates with active transcription, and the repression-associated H3K27me3. In V-SVZ 
NSCs only H3K4me3 is enriched, demonstrating cell type-specific chromatin modifications at 
these regions. 
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Chapter 2: The long noncoding RNA Pnky regulates neuronal 
differentiation of embryonic and postnatal neural stem cells 
 
Summary 
While thousands of long noncoding RNAs (lncRNAs) have been identified, few lncRNAs 
that control neural stem cell (NSC) behavior are known. Here, we identify Pinky (Pnky) as a 
neural-specific lncRNA that regulates neurogenesis from NSCs in the embryonic and postnatal 
brain. In postnatal NSCs, Pnky knockdown potentiates neuronal lineage commitment and 
expands the transit amplifying cell population, increasing neuron production several-fold. Pnky 
is evolutionarily conserved and expressed in NSCs of the developing human brain. In the 
embryonic mouse cortex, Pnky knockdown increases neuronal differentiation and depletes the 
NSC population. Pnky interacts with the splicing regulator PTBP1, and PTBP1 knockdown also 
enhances neurogenesis. In NSCs, Pnky and PTBP1 regulate the expression and alternative 
splicing of a core set of transcripts that relates to the cellular phenotype. These data thus unveil 
Pnky as a conserved lncRNA that interacts with a key RNA processing factor and regulates a 
critical stage of neurogenesis from embryonic and postnatal NSC populations.  
 
Introduction 
 Neural stem cells (NSCs) exist in both the embryonic and postnatal mammalian brain. In 
the embryonic cortical ventricular zone (VZ) and adult ventricular-subventricular zone (V-SVZ), 
NSCs are glial cells that can both self-renew and differentiate to yield intermediate progenitors 
that divide once or more before producing migratory young neurons (Kriegstein and Alvarez-
Buylla, 2009). The production of proper numbers of neuronal progenitors from NSCs is a key 
aspect of brain development, and defects at this stage of the neurogenic lineage may underlie a 
number of human developmental disorders (Lui et al., 2011). 
 31 
 The mammalian genome encodes many thousands of lncRNAs – transcripts >200 
nucleotides long that have no evidence of protein coding potential – and emerging data indicate 
that lncRNAs can have critical biological functions (Batista and Chang, 2013; Lee, 2012; Mercer 
and Mattick, 2013; Rinn and Chang, 2012). Although transcription factors, microRNAs, and 
signaling pathways that control the transition between NSCs and neurogenic progenitors have 
been studied intensively (Ihrie and Álvarez-Buylla, 2011; Kriegstein and Alvarez-Buylla, 2009; 
Lui et al., 2011), lncRNAs that regulate this critical, early stage of neurogenesis have not been 
identified.  
In this chapter we describe the unique developmental function of a neural-specific 
lncRNA we have named Pinky (Pnky) and provide insights into its molecular function. We have 
previously shown that knockdown of lncRNAs Dlx1as and Six3os in V-SVZ NSCs results in 
decreased neurogenesis (Ramos et al., 2013). Similarly, loss-of-function studies of different 
lncRNAs in ESC-derived NSCs (Lin et al., 2014; Ng et al., 2013), zebrafish brain (Ulitsky et al., 
2011), and mouse central nervous system (Bond et al., 2009; Rapicavoli et al., 2011; 
Sauvageau et al., 2013) all demonstrate a loss of neuronal populations. In contrast, postnatal V-
SVZ NSCs with Pnky-knockdown (Pnky-KD) generated 3-4 fold more neurons. To understand 
this phenotype, we used time-lapse microscopy to study lineage commitment and cell 
proliferation at the single-cell level. We cloned the human PNKY transcript and discovered its 
expression in the VZ of the embryonic human brain, and we demonstrated a role for Pnky in the 
development of the embryonic mouse cortex in vivo. Using mass spectrometry, we found that 
Pnky bound to PTBP1, an RNA-splicing factor that is a potent regulator of neural development 
(Keppetipola et al., 2012), direct cell reprogramming (Xue et al., 2013), and brain tumor growth 
(Ferrarese et al., 2014). Further analysis indicated that Pnky and PTBP1 modulate the 
expression and alternative splicing of an overlapping set of transcripts, and double-knockdown 
epistasis experiments suggested that Pnky and Ptbp1 function in the same pathway. Overall, 
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our work demonstrates that an evolutionarily conserved lncRNA can regulate neurogenesis from 
NSCs in both the embryonic and postnatal brain.  
 
Results 
 Throughout adult life, V-SVZ NSCs give rise to transit amplifying (TA) cells, which 
generate neuroblasts (NB) that migrate to the olfactory bulb where they differentiate into 
interneurons (Doetsch et al., 1999; Lois and Alvarez-Buylla, 1994; Luskin, 1998; Peretto et al., 
1997). Pnky (previously called lnc-pou3f2) is a lncRNA that we initially identified as being 
expressed in the adult V-SVZ (Ramos et al., 2013). RACE cloning followed by Sanger 
sequencing demonstrated Pnky to be an 825 nucleotide (nt) polyadenylated RNA encoded from 
three exons (Figure 2.1A). Analysis with the Coding Potential Calculator (CPC) (Kong et al., 
2007), PhyloCSF (Lin et al., 2011), and the Coding-Potential Assessment Tool (CPAT) (Wang 
et al., 2013) indicated that the Pnky transcript has no protein-coding potential (Figure 2.S1A). 
Analysis of available RNA-seq datasets indicated that Pnky is specifically expressed in neural 
tissues and lineages but is not expressed in the dentate gyrus, which contains another 
population of adult NSCs (Figure 2.1B). Furthermore, like many key developmental genes, the 
promoter of Pnky was “bivalent” with both histone 3 lysine 27-trimethylation (H3K27me3) and 
histone 3 lysine 4-trimethylation (H3K4me3) in embryonic stem cells (ESCs), coherent with its 
repressed but “poised” transcriptional state (Figure 2.1A). In contrast, in ESC-derived NSCs 
(ESC-NSCs) and V-SVZ NSCs, the Pnky promoter was monovalent with H3K4me3, consistent 
with its active transcription (Figures 2.1A and 2.S1B).  
 Nuclear fractionation of V-SVZ NSC cultures followed by RT-qPCR analysis 
demonstrated Pnky to be enriched in the nucleus as compared to coding mRNAs, which were 
enriched in cell lysates containing cytoplasm (Figure 2.1C). Consistent with the nuclear 
fractionation studies, in situ hybridization (ISH) for Pnky demonstrated predominantly nuclear 
localization of the transcript (Figures 2.1D and 2.S1C).  
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 ISH of adult mouse brain tissue revealed prominent expression of Pnky in the V-SVZ 
(Figure 2.1E). To investigate whether Pnky expression is dynamic within the neurogenic 
lineage, we analyzed gene expression of V-SVZ cells acutely isolated from the brain through 
fluorescent activated cell sorting (FACS) (Ramos et al., 2013). Briefly, activated neural stem 
cells (NSCs) express both glial fibrillary acidic protein (GFAP) and the epidermal growth factor 
receptor (EGFR). Transit amplifying cells are GFAP- but retain EGFR expression, and 
neuroblasts express cell surface marker CD24 (Pastrana et al., 2009). Pnky expression was 
highest in NSCs, and decreased by 5.6-fold (p=0.0003, Student’s t-test) in migratory 
neuroblasts (Figure 2.1F). Thus, Pnky is normally downregulated during lineage progression in 
vivo. 
 To investigate the role of Pnky in neurogenesis, we first used V-SVZ NSC monolayer 
cultures that recapitulate key features of neuronal differentiation as well as glial cell production 
(Figure 2.1G). Pnky was expressed in cultured NSCs in self-renewal conditions. Upon 
differentiation, Pnky remained expressed in GFAP+ astrocytes, but was down regulated in 
TUJ1+ neuronal cells (Figure 2.S1D), similar to the pattern of expression seen in vivo. After 
lentiviral transduction with control (shCtrl-GFP) or Pnky (shPnky-1-GFP and shPnky-2-GFP) 
knockdown constructs, GFP+ NSCs were isolated through FACS and cultured. Pnky 
knockdown was efficient in both self-renewing NSCs and after their differentiation (Figures 
2.S1E and 2.S1F). Cells in these purified cultures uniformly expressed SOX2, a neural stem cell 
marker (Figure 2.S1G). Flow cytometric analysis of these infected cells indicated that the 
majority (66.0%) were also positive for both GFAP and NESTIN (Figure 2.S1H), markers of V-
SVZ NSCs. Therefore, the majority of cells transduced with Pnky-KD or control vectors were 
GFAP+, NESTIN+, SOX2+ V-SVZ NSCs.  
Pnky-KD NSCs incorporated the thymidine analog 5-ethynyl-2'-deoxyuridine (EdU) at the 
same rate as control NSCs, suggesting that proliferation in self-renewal conditions was not 
affected (Figures 2.1H and 2.S1I). However, Pnky-KD NSCs generated 3-fold more TUJ1+ 
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neuroblasts after 7 days (7d) of differentiation (Figures 2.1I and 2.1J). To further analyze the 
effect of Pnky-KD in the NSC population, we used a molecular-genetic method of targeting 
knockdown to V-SVZ NSCs (Doetsch et al., 1999; Park et al., 2014). We derived NSC cultures 
from G-TVA mice, which express the chicken retroviral receptor TVA from the GFAP promoter. 
For viral transduction of these cultures, we used shRNA lentiviruses pseudotyped with chicken 
viral EnvA protein, which restricts infection to the GFAP+ cells (Figure 2.S1J). In G-TVA NSCs, 
Pnky-KD did not affect NSC proliferation in self-renewal conditions (Figure 2.S1K). However, 
after differentiation, G-TVA NSC cultures produced a 3.56-fold more neuroblasts as compared 
to control (Figure 2.S1L). Thus, Pnky-KD targeted to the GFAP+ NSC population in V-SVZ 
cultures also resulted in increased neuronal production during differentiation.  
V-SVZ transit amplifying cells express DLX2 and normally divide several times before 
giving rise to neuroblasts (Doetsch et al., 2002; Ponti et al., 2013). With Pnky-KD, there were 
1.8 to 3.2 fold more EdU+, DLX2+ cells at 2d of differentiation, suggesting that Pnky plays a role 
at the transit amplifying stage of neuronal differentiation (Figures 2.1K and 2.S1M).  
 To further investigate how Pnky-KD increases neuronal production, we plated NSCs 
infected with Pnky-KD or control vector with large numbers of uninfected NSCs (ratio of infected 
GFP+ NSCs to uninfected NSCs was approximately 1:5000, Figure 2.2A). After 4d of 
differentiation, these cultures produced well-isolated clusters of GFP+ cells (Figure 2.2B). With 
Pnky knockdown, the proportion of GFP+ cell clusters containing TUJ1+, GFP+ cells was 
increased (Figure 2.2C). Furthermore, these clusters also contained greater numbers of TUJ1+, 
GFP+ neuroblasts (Figure 2.2D). These data suggested that the increased neurogenesis 
resulted from both a shift towards neuronal lineage commitment and an increase in cell 
amplification within the neurogenic lineage. 
To more directly observe the clonal behavior of individual NSCs with Pnky-KD, we used 
time-lapse microscopy to image GFP+ cells every 15 min for 3d (Figure 2.2E). We followed the 
fate of 316 GFP+ Pnky-KD NSCs and 531 GFP+ control NSCs. After differentiation, we could 
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identify both TUJ1+ neurogenic clones (Figure 2.S2A) and GFAP+ glial clones (Figures 2.S2B 
and 2.S2C). Clones arising from NSCs with Pnky-KD were 48% more likely to be neurogenic 
(Figure 2.2F). Thus, Pnky-KD increased the likelihood that NSCs produced neurogenic 
progenitors.  
Neurogenic clones with Pnky-KD contained 2.74 fold more neuroblasts than control 
(Figure 2.S2D). This increase in neurogenesis was in part related to an increase in progenitor 
cell divisions before differentiation into neuroblasts: while control progenitors divided 3.93 
(SD=4.68, n=44) times and gave rise to 2.05 (SD=1.42) generations of daughter cells, Pnky-KD 
resulted in 8.94 (SD=7.64, n=33) divisions and 3.45 (SD=1.41) generations (Figures 2.2G and 
2.2H). The average cell cycle length was not affected by Pnky-KD (19.4 hours vs. 19.1 hours, 
p=0.89) (Figure 2.S2E), suggesting that the increased number of divisions related to the 
maintenance of a proliferative cell state and not an accelerated cell cycle. Time-lapse imaging 
also enabled direct observation of cell death, and the number of GFP+ neurogenic progeny 
(neuroblasts) that underwent cell death was reduced 57% by Pnky-KD (Figure 2.2I). Thus, 
Pnky-KD promoted neuronal lineage commitment from postnatal V-SVZ NSCs, increased the 
number of divisions of neurogenic progenitors, and reduced cell death (Figures 2.2J and 
2.S2F).  
 To investigate whether Pnky also regulates neurogenesis from other NSC populations, 
we next examined the embryonic brain. Pnky transcripts were detected in embryonic mouse 
brain tissue by RNA-seq (Figure 2.1B), and ISH revealed its expression in the cortical VZ – 
where embryonic NSCs reside – at embryonic day 14.5 (E14.5) and E16.5 (Figures 2.3A, 
2.S3A, and 2.S3B). Pnky has two regions of high conservation among vertebrates (Figures 
2.3B and 2.S3C), and using strand-specific RNA-seq of gestational week 16 (GW16) human 
cortical samples, we detected a non-coding transcript divergent to POU3F2 that included the 
conserved sequences. RACE cloning identified human PINKY (PNKY) as a polyadenylated 
1592 nt transcript containing the two conserved elements and expressed from a conserved 
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promoter region (Figure 2.3B). As in the developing mouse brain, ISH of GW14.5 human cortex 
demonstrated PNKY expression in the VZ, with decreased levels in the subventricular zone and 
intermediate zone (SVZ/IZ), where young neurons begin to differentiate (Figures 2.3C and 
2.S3D).  
 To investigate the role of Pnky in the mouse embryonic VZ, we electroporated Pnky-KD 
(shPnky-2-GFP) or control (shCtrl-GFP) construct into VZ cells at E13.5 (Figure 2.3D). Two 
days later, we analyzed GFP+ cells in the VZ, SVZ/IZ, and cortical plate (CP) (Figure 2.3E). 
With Pnky knockdown, there was a 35% decrease in the proportion of GFP+ cells in the VZ and 
a 26% increase in GFP+ cells in the SVZ/IZ (Figure 2.3F). We did not detect apoptotic GFP+ 
cells as assessed by cleaved caspase-3 staining (not shown). At this time point in cortical 
development, SOX2+ NSCs in the VZ produce proliferative TBR2+ progenitor cells in the 
SVZ/IZ that differentiate into SATB2+ young neurons. With Pnky knockdown, the proportion of 
SOX2+, GFP+ cells was reduced (Figure 2.3G). While Pnky knockdown did not affect the 
proportion of TBR2+, GFP+ TA cells or their proliferation (Figures 2.S3E-J), the proportion of 
SATB2+, GFP+ young neurons was increased (Figure 2.3H). These data indicate that Pnky 
regulates the production of young neurons from embryonic brain NSCs in vivo (Figure 2.S3K).  
Many lncRNAs regulate gene expression through interactions with specific protein 
partners. To identify Pnky-interacting proteins, we incubated biotinylated Pnky (S) or antisense 
Pnky (AS) control RNA with V-SVZ NSC nuclear extract and used mass spectrometry to identify 
proteins that bound to the transcripts (Figures 2.S4A and 2.S4B). Polypyrimidine tract-binding 
protein 1 (PTBP1) was identified as a binding partner of Pnky, and this interaction was 
confirmed by Western blot analysis (Figure 2.4A). While both Pnky and control RNA 
nonspecifically bound other RNA binding proteins including HNRNPK and ELAVL1 (Figures 
2.4A and 2.S4C), only Pnky RNA enriched for PTBP1, suggesting that the interaction between 
Pnky and PTBP1 is specific (Figure 2.4A). Furthermore, RNA immunoprecipitation with PTBP1 
antibodies enriched for Pnky transcript but not U1 or beta-actin mRNA (Figure 2.4B). 
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PTBP1 is expressed in NSCs and functions as a repressor of neuronal differentiation. In 
the embryonic brain, loss of Ptbp1 results in precocious neuronal differentiation (Shibasaki et 
al., 2013), and in fibroblasts, Ptbp1 knockdown leads to direct neuronal trans-differentiation 
(Xue et al., 2013). PTBP1 was detected in the nucleus of V-SVZ NSCs (Figure 2.S4D), and 
Ptbp1 knockdown resulted in larger neuronal colonies (Figure 2.4C), similar to the phenotype 
observed with Pnky-KD (Figure 2.2D). 
In NSCs, PTBP1 negatively regulates the expression of Ptpb2, which is required for the 
generation of neuronal precursors (Boutz et al., 2007; Licatalosi et al., 2012). Using a PTBP2-
specific antibody (Polydorides et al., 2000), we found the Pnky transcript did not specifically bind 
PTBP2 (Figure 2.S4E). During neurogenesis, Ptbp1 is normally down-regulated, and Ptbp2 is 
increased (Keppetipola et al., 2012). Therefore we next characterized the relationship between 
Ptbp1, Ptbp2, and Pnky expression. Upon Ptbp1 knockdown in V-SVZ NSCs, Ptbp2 transcripts 
were upregulated, as expected (Figure 2.S4F). Ptbp1 knockdown did not decrease Pnky 
expression (Figure 2.S4F). Pnky-KD had no effect on Ptbp1 expression and caused a small 
reduction (25%) in Ptbp2 (Figure 2.S4G). Thus, the increase in neuronal differentiation 
observed with Pnky-KD does not appear to relate to changes in Ptbp1 or Ptbp2 expression. 
PTBP1 regulates mRNA transcript levels and pre-mRNA splicing during neuronal 
differentiation (Keppetipola et al., 2012; Yap et al., 2012; Zheng et al., 2012). To determine 
whether Pnky and PTBP1 regulate a common set of transcripts, we performed RNA-seq of V-
SVZ NSCs with either Pnky knockdown or Ptbp1 knockdown. The overlap of differentially 
expressed genes was highly significant (Figure 2.4D and Table 2.1, 815 genes, P = 3.8x10-152) 
and enriched for Gene Ontology terms (Huang et al., 2009) related to cell-cell adhesion, 
synpatogenesis and neurogenesis (Table 2.2). Furthermore, using DEX-seq (Anders et al., 
2012) to analyze differential exon usage, we found that Pnky knockdown and Ptbp1 knockdown 
also resulted in a common set of splice variants (Figure 2.4E and Table 2.3, 101 exons, P = 
1.3x10-52). Thus, these data demonstrate that Pnky and its associated protein PTBP1 regulate 
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an overlapping set of transcripts that underlies their role in regulating neurogenesis from V-SVZ 
NSCs.  
To further assess whether Pnky and Ptbp1 function in the same pathway, we performed 
an epistasis experiment. The lack of synergistic or additive effects upon combined loss of an 
lncRNA and coding gene pair suggests that they function in the same molecular pathway 
(Dimitrova et al., 2014). Therefore, we used FACS to isolate NSCs with double knockdown of 
Pnky and Ptbp1 as well as NSCs with each single knockdown (Figures 2.S4H-I). We then 
analyzed the expression of several genes (Ntsr2, Igfbp5, Scrg1, and Ppp1r3c) that had been 
commonly upregulated by both Pnky-KD and PTBP1 knockdown in RNA-seq experiments 
(Figure 2.4D). As expected, Ntsr2, Igfbp5, Scrg1, and Ppp1r3c all had increased expression in 
the cells with single-knockdown as compared to control (Figures 2.4F-H and 2.S4J). 
Importantly, the combined knockdown of Pnky and Ptbp1 did not further enhance this gene 
expression (Figures 2.4F-H and 2.S4J). These data indicate a genetic interaction between 
Pnky and Ptbp1 and suggest that they function in the same pathway to regulate gene 
expression in NSCs.  
 
Discussion 
Taken together, our data indicate that Pnky is a conserved, neural-specific, nuclear 
lncRNA that interacts with PTBP1 and regulates the production of neurons from NSCs. While 
other lncRNAs have been found to function in central nervous system development – with 
lncRNA loss-of-function resulting in decreased neurogenesis (Bond et al., 2009; Chalei et al., 
2014; Lin et al., 2014; Ng et al., 2013; Rapicavoli et al., 2011; Sauvageau et al., 2013; Ulitsky et 
al., 2011) – Pnky knockdown increased the production of neurons, suggesting a distinct 
developmental role for this lncRNA in controlling neurogenesis from NSCs. Our data are 
consistent with a model in which Pnky serves to “restrain” neuronal commitment, regulating the 
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production of young neurons from NSCs in the developing embryonic cortex as well as those in 
the postnatal V-SVZ.  
In the developing cortex, we found that Pnky-KD resulted in an increase in young 
neurons and decreased the NSC population in the VZ. This did not appear to involve a change 
in the proliferation of the transit amplifying cells of this embryonic lineage. In V-SVZ NSCs from 
the postnatal brain, Pnky-KD also promoted neuronal differentiation, and we additionally 
observed greater numbers of divisions of the neurogenic progenitor cells. Thus, the phenotypes 
of Pnky-KD in these two very different NSC populations are largely similar in that neuronal 
differentiation is increased. Interestingly, Pnky does not appear to regulate all NSC populations, 
as we did not detect Pnky transcripts in the dentate gyrus, which harbors another population 
adult NSCs. 
Our studies indicated that Pnky interacts with PTBP1, which is a key regulator of neural 
development (Shibasaki et al., 2013). PTBP1 is also a powerful mediator of cell reprogramming 
(Xue et al., 2013), and its depletion from fibroblasts can lead to direct trans-differentiation into 
neurons. Moreover, PTBP1 is a potent driver of brain tumor growth and invasiveness (Ferrarese 
et al., 2014). During neuronal differentiation, PTBP1 is normally downregulated, and there is an 
increase in PTBP2. We did not find evidence for a specific interaction between Pnky and PTPB2 
or other nuclear RNA-binding proteins such as HNRNPK and ELAVL1. These data suggest that 
Pnky and PTPB1 – a splicing factor with critical functions in both normal development and brain 
tumors – are part of a specific ribonucleoprotein complex in NSCs.  
Given this physical interaction between Pnky and PTBP1, we worked towards 
understanding whether this lncRNA and protein partner function together. First, we found that 
both Pnky and PTPB1 knockdown in V-SVZ NSCs promoted neurogenesis. Furthermore, Pnky-
KD promoted neuronal differentiation in the developing cortex, and mice with Ptbp1 loss-of-
function also exhibit precocious cortical neurogenesis. Thus, Pnky-KD and loss of PTBP1 
produce similar phenotypic results. Second, we found that Pnky-KD and PTBP1-knockdown 
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produced gene expression changes as well as splicing changes that were highly similar, 
indicating that Pnky and PTPB1 regulate a common set of transcripts related to neuronal 
differentiation. Third, our epistasis experiment indicated that Pnky and PTBP1 double 
knockdown does not produce changes greater than single knockdowns. Thus, the physical 
interaction between Pnky and PTBP1 along with the evidence for their genetic interaction is 
consistent with a model in which they function together in a common molecular pathway. 
Whether the physical interaction between Pnky and PTPB1 is required for their regulation of 
neuronal differentiation remains to be tested directly. Future work may reveal an interplay 
between lncRNAs and PTBP1 in different biological contexts, including cancer and direct cell 
reprogramming. 
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Figure 2.1: The lncRNA Pinky is expressed in SVZ-NSCs and regulates neuronal 
differentiation. 
A, UCSC genome browser view of the Pnky locus. Also shown are ChIP-seq tracks for 
H3K4me3 and H3K27me3 in ESCs and V-SVZ NSCs. B, Fragments per kilobase per million 
mapped reads (FPKM) values for Pnky in indicated tissues. C, Subcellular fractionation followed 
by RT-qPCR for indicated lncRNAs and mRNAs. Error bars are propagated standard deviation 
from technical triplicate wells. D, Branched-DNA in situ hybridization for Pnky in V-SVZ NSC 
cultures. Nuclei are counter-stained with 4',6-diamidino-2-phenylindole (DAPI). Scale bar = 10 
µm. E, Branched-DNA in situ hybridization for Pnky in adult mouse coronal tissue section. Pnky 
stains brown, and nuclei are counter-stained with hematoxylin. V = ventricle, CC = corpus 
collosum, STR = striatum. Scale bar = 50 µm. F, Results of microarray expression analysis from 
FACS-isolated neural stem cells (NSC), transit amplifying cells (TA), and neuroblasts (NB). 
Value in NSCs set to 0. G, Schematic of V-SVZ NSC culture system. H, Quantification of EdU 
labeling counted from GFP+ cultures of V-SVZ NSCs infected with control or Pnky-KD 
constructs. I, Immunocytochemistry for TUJ1 (red) after 7d of differentiation in control or Pnky-
KD GFP+ cultures. Nuclei are counter-stained with DAPI (blue). Scale bar = 50 µm. J, 
Quantification of TUJ1+ NBs produced after 7d differentiation. K, Quantification of the number 
of TA cells, defined as being co-labeled with DLX2 and EdU, after 2d of differentiation. Error 
bars for (H), (J), and (K) are standard deviation from triplicate wells, * p < 0.05, **p < 0.01, 
Student’s t-test. See also Figure 2.S1.  
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Figure 2.2: Pinky knockdown leads to an expansion of neurogenic transit amplifying 
progenitors. 
A, Schematic of experimental design. B, Representative images of isolated colonies after 4d 
differentiation. Immunocytochemistry for TUJ1 (red) and GFP (green). Nuclei are counterstained 
with DAPI (blue). Scale bar = 50 µm. C, Quantification of the fate of isolated GFP+ colonies. 
Error bars are standard deviation from triplicate experiments. D, Quantification of the number of 
TUJ1+ neuroblasts found in individual neurogenic colonies. E, Representative frames from time-
lapse video of control (top) or Pnky-KD (bottom) single cells. Time in differentiation medium is 
indicated. Yellow arrows indicate daughter cells resulting from a recent division, red arrows 
indicate cell death. Scale bar = 25 µm. F, Bar graph representing the percentage of initial 
tracked progenitors that gave rise to neuroblasts. N= 531 GFP+ shCtrl NSCs and 316 GFP+ 
shPnky NSCs. G, Violin plots overlaying box-and-whisker plots of total number of divisions 
undergone by a single initial neurogenic progenitor and all of its daughter cells. N = 44 shCtrl 
and 33 shPnky progenitors. H, Violin plots overlaying box-and-whisker plots of the number of 
generations per initial neurogenic progenitor for shCtrl and shPnky. N = 44 shCtrl and 33 
shPnky progenitors. I, Violin plots overlaying box-and-whisker plots of % of progeny per single 
neurogenic progenitor that underwent cell death. N = 44 shCtrl and 33 shPnky progenitors. J, 
Tree diagram for the frames shown in (E) and corresponding time-lapse movies. X indicates tht 
the cell underwent cell death. *p < 0.05 ***p<0.001, Student’s t-test. See also Figure 2.S2.  
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Figure 2.3: Pinky is expressed in the developing mouse and human cortex and regulates 
the differentiation of mouse cortical progenitors in vivo. 
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A, In situ hybridization for Pnky in embryonic day 16.5 (E16.5) mouse brain. B, Genome 
browser track demonstrating that the mouse Pnky transcript has two regions of high 
conservation, determined by PhyloP score (yellow boxes). Human PNKY genomic region is 
shown below with conservation indicated. For clarity, the mouse –strand is shown left to right. C, 
In situ hybridization for PNKY in gestational week 14.5 (GW14.5) human brain. D, Schematic of 
in utero electroporation of mouse embryonic brain. E, Cortical sections at E15.5, 2d after 
electroporation with shCtrl (left) or shPnky (right). Immunostained for GFP (top) and with DAPI 
counterstain (bottom). VZ = ventricular zone, SVZ/IZ = subventricular zone/intermediate zone, 
CP = cortical plate. F, Quantification of GFP+ cell distribution in indicated zones as a 
percentage of total GFP+ cells. G, Left: Cortical sections at E15.5, 2d after electroporation with 
shCtrl or shPnky. Immunostained for GFP (green) and SOX2 (red), with DAPI nuclear 
counterstain (blue). Yellow box indicates region expanded in the subsequent panels. 
Arrowheads indicate co-labeled cells. Right: quantification of SOX2+, GFP+ cells as a 
percentage of total GFP+ cells. H, Left: Cortical sections immunostained for GFP (green) and 
SATB2 (red), with DAPI nuclear counterstain (blue). Yellow box indicates region expanded in 
the subsequent panels. Right: Quantification of SATB2+, GFP+ cells as a percentage of total 
GFP+ cells. All error bars are standard deviation, n=4 brains of each condition from 3 separate 
surgeries. *p<0.05, **p<0.01. All scale bars = 50 µm. See also Figure 2.S3.  
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Figure 2.4: Pinky interacts with PTBP1 and regulates RNA expression and splicing. 
A, Immunoblot for PTBP1 or HNRNPK following RNA-pulldown experiment with biotin-labeled 
sense (S) or anti-sense (AS) Pnky RNA incubated with V-SVZ NSC nuclear extract. IN = input 
V-SVZ nuclear extract. B, RT-qPCR detection for indicated RNA recovered by PTBP1-specific 
antibody normalized to control FLAG antibody. Error bars are propagated standard deviation 
from technical triplicates. C, Quantification of number of TUJ1+ neuroblasts found in individual 
neurogenic colonies with Ptbp1-knockdown or control. D, Venn Diagram demonstrating the 
overlap between genes differentially expressed (FDR < 0.05) upon Ptbp1 or Pnky knockdown. 
Heatmap representation of the differential expression of the overlapping gene set in shCtrl, 
shPnky, and shPtbp1 biological duplicate cultures. E, Venn Diagram demonstrating the overlap 
between exons showing differential usage (FDR < 0.01) upon Ptbp1 or Pnky knockdown. 
Heatmap representation of the differential usage of the overlapping gene set in shPnky and 
shPtbp1 cultures compared to control. F-H, RT-qPCR detection of expression of indicated 
genes normalized to Gapdh. Expression in each condition is shown relative to control (shCtrl-
GFP, shCtrl-mCherry). Error bars are 95% confidence intervals from 3 separate cultures. See 
also Figure 2.S4 and Tables 2.1-2.3. 
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Figure 2.S1: Characterization of the long noncoding RNA Pnky and Pnky-KD cultures. 
A, Table of protein-coding scores derived from CPAT, CPC, and PhyloCSF, and the cut-off for 
determining that a transcript is likely to encode a protein. B, Genome browser view of the Brn2 
and Pnky loci with H3K4me3 and H3K27me3 ChIP-seq tracks for embryonic stem cells (ES), 
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mouse embryonic fibroblasts (MEF), ESC-derived neural stem cells (ESC-NSCs), and V-SVZ 
NSCs. Yellow boxes indicate promoter regions defined by CpG islands. C, In situ hybridization 
using branched DNA probes targeting Pnky and negative control bacterial transcript DAPB in V-
SVZ-NSC cultures. Nuclei are counter-stained with DAPI. Scale bar = 10 μm. D, In situ 
hybridization using branched DNA probes targeting Pnky in V-SVZ-NSC cultures after 4 days of 
differentiation, immunostained with GFAP (green) or Tuj1 (red). Nuclei are counter-stained with 
DAPI (blue). Scale bar = 20 μm. E, Schematic of Pnky RNA and the regions targeted by 
shPnky-1 and shPnky-2. F, Pnky knockdown efficiency in purified cultures in proliferation 
medium (left) or differentiation medium (right). Fold change was calculated with the delta-delta 
Ct method, normalized to shCtrl and Rplp0 housekeeping gene. Error bars are standard 
deviation propagated by least-squares method from technical triplicate. G, V-SVZ NSC cultures 
in proliferation conditions immunostained with SOX2 (red). Nuclei are counter-stained with DAPI 
(blue). Scale bar = 50 μm. H, FACS plot of GFAP and NESTIN expression in GFP+ cells from 
V-SVZ cultures infected with control lentivirus. I, Purified cultures of V-SVZ-NSCs infected with 
shCtrl (left) or shPnky-2 (right) labeled with EdU for 1h and stained for incorporated EdU with 
Click-iT chemistry. Nuclei are counterstained with DAPI (blue). Scale bar = 50 μm. J, Schematic 
depicting targeting of shRNA constructs to NSCs with the TVA-EnvA system. K, Quantification 
of EdU labeling counted from purified cultures of GTVA V-SVZ NSCs infected with control or 
Pnky-knockdown constructs. L, Quantification of Tuj1+ NBs produced from purified cultures of 
GTVA V-SVZ NSCs after 4d differentiation. M, Purified cultures immunostained with DLX2 
(green) and stained for EdU (red) after 3h of labeling in differentiation medium. Nuclei are 
counterstained with DAPI. Scale bar = 50 μm. 
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Figure 2.S2: Analysis of time-lapse imaging of V-SVZ cultures.  
A, Frames from time-lapse movies, demonstrating a neurogenic clone. Immediately after 
imaging, plate was fixed and immunostained for GFP (green) and Tuj1 (red). White arrow 
indicates initial tracked NSC. Scale bar = 50 μm. B, Frames from time-lapse movies, 
demonstrating a glial clone undergoing one division. White arrow indicates initial tracked NSC 
 49 
and yellow arrows indicate daughter cells resulting from a division. Immediately after imaging, 
plate was fixed and immunostained for GFP (green) and GFAP (red). Scale bar = 50 μm. C, Bar 
graph representing the number of glial cell divisions per clone as a proportion of all glial clones. 
N = 481 shCtrl cells and 272 shPnky cells. D, Violin plot overlaying box-and-whisker plot 
representing the total number of progeny produced per initial neurogenic NSC. N = 44 shCtrl 
and 33 shPnky progenitors. E, Violin plot overlaying box-and-whisker plot representing the cell 
cycle length from the first to second divisions of shCtrl and shPnky cells. N= 27 shCtrl divisions 
and 45 shPnky divisions. F, Schematic depicting the role of Pnky in postnatal V-SVZ NSCs. 
Left: Normal lineage progression of neuronal production from V-SVZ NSCs (blue) to DLX2+ 
transit amplifying cells (TA, green) to Tuj1+ young neurons (red). Bottom: Pnky-KD promotes 
neuronal production. With Pnky-KD, a greater proportion of NSCs commit to the neurogenic 
lineage, and TA cells undergo more cell divisions. **p <0.01, Student’s t-test. 
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Figure 2.S3: Pnky is evolutionarily conserved and expressed in the developing mouse 
and human cortex. 
A, In situ hybridization of Pnky in embryonic day 14.5 (E14.5) mouse brain. Scale bar = 100 μm. 
B, In situ hybridization for Pnky in E16.5 mouse brain. Scale bar = 100 μm. Black box indicates 
area of detail shown at right and in Figure 2.3A. Scale bar for high magnification image = 25 μm. 
C, Genome browser view of exons 2 and 3 of mouse Pnky and PhastCons scores across 
indicated vertebrates. The blue box highlights a sequence conserved to zebrafish. In the 
sequence logo, a score of 2 bits indicates bases are perfectly conserved across all genomes 
shown. D, In situ hybridization of PNKY in human gestational week 14.5 (GW14.5) brain. Scale 
bar = 500 μm. Black box indicates area of detail shown at right and in Figure 2.3C. Scale bar for 
high magnification image = 50 μm. E, Left: Cortical sections at E15.5, 2d after electroporation 
with shCtrl or shPnky, stained for GFP (Green) and TBR2 (Red), with DAPI nuclear 
counterstain. Yellow box indicates region expanded in the subsequent panels. Right: 
quantification of TBR2+ GFP+ cells as a percentage of total GFP+ cells. Scale bar = 25 μm. F, 
Left: Cortical sections at E15.5, 2d after electroporation with shCtrl or shPnky, stained for GFP 
(green) and EdU (white), with DAPI nuclear counterstain. Yellow box indicates region expanded 
in the subsequent panels. Right: quantification of EdU+ GFP+ cells as a percentage of total 
GFP+ cells. Scale bar = 25 μm. G, Quantification of TBR2+EdU+GFP+ cells as a percentage of 
total GFP+ cells at E15.5, 2d after electroporation with shCtrl or shPnky. H, Quantification of 
TBR2+GFP+ cells as a percentage of total GFP+ cells at E14.5, 1d after electroporation with 
shCtrl or shPnky. I, Quantification of BrdU+GFP+ cells as a percentage of total GFP+ cells at 
E14.5, 1d after electroporation with shCtrl or shPnky. J, Quantification of TBR2+BrdU+GFP+ 
cells as a percentage of total GFP+ cells at E14.5, 1d after electroporation with shCtrl or 
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shPnky. K, Schematic depicting the role of Pnky in regulating embryonic corticogenesis. Top: 
Normal lineage progression of neuronal production from radial glial SOX2+ NSCs (purple) to 
TBR2+ intermediate neurogenic progenitors (blue) to SATB2+ young neurons (green). Bottom: 
Pnky-KD promotes progression through the neurogenic lineage, resulting in a depletion of NSCs 
and an increase in young neurons. The population of TBR2+ intermediate progenitors is not 
affected. 
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Figure 2.S4: Characterization of the interaction of Pnky and PTBP1. 
A, Sypro Ruby-stained SDS-PAGE protein gel of proteins retrieved with biotinylated Pnky RNA 
or control RNA. Blue box indicates area excised and sent for mass spectrometry. B, Top 
proteins identified by mass spectrometry from excised bands, excluding keratin contaminant 
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peptides. C, Immunoblot for ELAVL1 from RNA-pulldown experiment with biotin-labeled sense 
(S) or anti-sense (AS) Pnky RNA incubated with N2A nuclear extract. D, Immunostaining for 
PTBP1 (red) in purified V-SVZ NSC cultures infected with control or shPTBP1. Nuclei are 
counterstained with DAPI. Scale bar = 25 μm. E, FPKM values calculated by Cufflinks for Ptbp1 
or Ptbp2 upon control or Pnky knockdown. Error bars represent 95% confidence intervals. 
**FDR<0.01. F, FPKM values calculated by Cufflinks for Pnky or Ptbp2 upon control or Ptbp1 
knockdown. Error bars represent 95% confidence intervals. **FDR<0.01, ***FDR<0.001. G, 
Immunoblot for PTBP2 from RNA-pulldown experiment with biotin-labeled sense (S) or anti-
sense (AS) Pnky RNA incubated with N2A nuclear extract. H-J, RT-qPCR detection of 
expression of indicated gene normalized to Gapdh. Expression in each condition is shown 
relative to control (shCtrl-GFP, shCtrl-mCherry). Error bars are 95% confidence intervals. Data 
are from 3 separate purified cultures. 
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Table 2.1: Differential expression of genes regulated by Pnky and PTBP1. 
Genes that are differentially expressed (FDR<.05) in both shPnky and shPTBP1 cells. Log2 of 
average fold change over control from two biological replicates is shown. 
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Table 2.2: Gene ontology terms for Pnky and PTBP1 co-regulated genes. 
Gene ontology terms with their DAVID p-value for set of genes that are differentially expressed 
by both Pnky and PTBP1 knockdown. 
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Table 2.3: Differential exon usage for genes regulated by Pnky and PTBP1. 
Differential exon usage upon Pnky knockdown or PTBP1 knockdown compared to control.  
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Experimental Procedures  
Accession Numbers 
All data are deposited in NCBI GEO under accession number GSE65542. 
ChIP-seq analysis 
V-SVZ ChIP-seq library generation and analysis is described in ref. 13 and available in 
NCBI GEO under accession GSE45282. ESC, ESC-NSC, and MEF ChIP-seq data was 
originally described in (Mikkelsen et al., 2007), and analyzed in (Ramos et al., 2013). 
RNA-seq analysis 
Published RNA-seq datasets were downloaded from GSE29184 and GSE36026, and 
abundance estimation was performed using Cufflinks v2.1.1. Experiments were done in 
biological duplicates. RNA was extracted using TRIzol and loaded onto RNeasy columns 
(QIAGEN) for on-column DNase treatment. Strand-specific, poly(A) selected cDNA libraries 
were generated using TruSeq Stranded mRNA kit (illumina) according to the manufacturer’s 
protocol. Library validation and normalization were performed using RT-PCR and Quant-iT 
PicoGreen (Invitrogen). Cluster generation and high-throughput sequencing were performed on 
a HiSeq 2500 (Illumina), using the paired-end 100 bp protocol. Reads were aligned to the 
mouse genome mm9, using Tophat v2.0.10 with the following arguments: -p 6 --library-type fr-
firststrand. Differential expression was assessed using Cuffdiff v2.1.1 with the following 
arguments: -b genome.fa -u --library-type fr-firststrand. A transcriptome index that includes all 
UCSC genes and the Pnky sequence was used for Tophat and Cufflinks. Alternative splicing 
was analyzed using DEXSeq v1.8.0, using a FDR threshold of 0.01. 
V-SVZ NSC cultures and differentiation assay 
The brain of postnatal day 5-7 (P5-7) mice was removed from the skull and placed in 
ice-cold L15 media and a 0.5 mm thick coronal slab was obtained. V-SVZ was dissected from 
and dissociated with 0.25% trypsin with occasionally agitation for 20 min at 37°C, and 
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resuspended in N5 medium (DMEM/F12 with Glutamax, 5% Fetal Bovine Serum, N2 
supplement, 35 µg/mL bovine pituitary extract, 20 ng/mL EGF, 20 ng/mL FGF, 
antibiotic/antimycotic). For most experiments, C57/B6 mice were used. For GTVA experiments, 
the GFAP-TVA mouse (Holland and Varmus, 1998) was used. 
Cells were split 1:2 to passage 6 or 7 before switching to differentiation medium 
(DMEM/F12 with Glutamax, 2% FBS, N2 supplement, 35 µg/mL bovine pituitary extract, 
antibiotic/antimycotic). For analysis of cell fate, cells were fixed with 4% PFA and stained with 
anti-Tuj1 (Covance, 1:1000), anti-GFAP (Dako, 1:500), or anti-DLX2 (1:500). For EdU 
incorporation assays, 10µM EdU was added to culture medium for 1 hour (Figure 2.1H and 
2.S1K) or 3 hours (Figure 2.1K) before fixing.  
Nuclear fractionation 
~10 million V-SVZ NSCs were resuspended in 10 mL PBS, 2 mL nuclear isolation buffer 
(1.28 M sucrose, 40 mM Tris, pH 7.5, 20 mM MgCl2, 4% Triton X-100), 6 mL of water, and 
incubated on ice for 20 mins with frequent mixing. Nuclei were then pelleted at 2500xg for 15 
mins, resuspended in lysis buffer (150 mM KCl, 25 mM Tris pH 7.5, 5 mM EDTA, 0.5% Igepal, 
0.5 mM DTT) and incubated on ice for 30 mins. For whole cell lysate, cell pellet was 
resuspended in lysis buffer and incubated on ice for 30 mins. RNA was extracted using Trizol 
LS according to manufacturer’s instructions. 1 µg of RNA was used for first-strand synthesis 
with the Transcriptor First Strand cDNA Synthesis kit (Roche) using oligo-dT primers. cDNA was 
used for qPCR with Sybr Green master mix (Roche), run on a Light Cycler 480 (Roche).  
Branched DNA in situ hybridization  
Branched DNA in situ was performed on adult tissue according to manufacturer’s 
instructions using the RNAScope 2.0 high definition BROWN kit (ACD). For V-SVZ cultures, 
cells were grown on laminin and poly-d-lysine coated Labtek 8-well chamber slides and fixed 
with 4% PFA. In situ was performed on cells according to manufacturer’s instructions using the 
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RNAScope 2.0 high definition BROWN kit with the following modification: Pretreat solution 2 
was added to cells and they were steam treated for 10 mins. No protease was used.  
FACS-purified V-SVZ lineage and microarray 
Purification of the V-SVZ lineage and subsequent custom lncRNA microarray 
hybridization has been described in (Ramos et al., 2013) and (Pastrana et al., 2009). Raw data 
is available at NCBI GEO under accession GSE45282. Processed data is available at 
http://neurosurgery.ucsf.edu/danlimlab/lncRNA/ 
Knockdown lentiviral constructs 
All shRNA sequences were designed using the Dharmacon siDESIGN tool. shRNA 
oligos were ordered from ELIM Biosystems, annealed, and ligated into the PSICO-R vector 
(Ventura et al., 2004), which carries a GFP or mCherry marker. shRNA targeting luciferase was 
used as a control. To establish purified cultures, GFP+ cells or GFP+, mCherry+ double positive 
cells were sorted using a FACS Aria II.  
Time-lapse imaging  
Near-clonal density cultures were established by trypsinization and subsequent mixing of 
infected GFP+ cultures (shCtrl or shPnky) with wildtype, uninfected cultures at a ratio of 1:200 
to give ~15 GFP+ cells/high powered field and cultured in proliferation media for 8 hours to 
allow cells to adhere to the plate. Cultures were switched to differentiation medium and imaged 
on a Leica SP5 inverted confocal microscope fitted with a Life Imaging Services microscope 
temperature control system. Cultures were maintained at 37°C and 5% CO2, 21% O2 and 8 
optical sections were taken every 15 minutes for 3 days. Optical sections were summed and 
movies assembled with ImageJ. Cell fate was determined by morphology and representative 
fields were confirmed by fixing and staining for TUJ1 and GFAP. Cell cycle length was 
quantified as the amount of time between the first division of an NSC and the next division of 
each daughter that divided. 
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Human Fetal Tissue  
 Fetal cortical tissue was collected from elective pregnancy termination specimens at San 
Francisco General Hospital, usually within 2h of the procedure. Research protocols were 
approved by the Committee on Human Research (institutional review board) at University of 
California, San Francisco. 
In situ hybridization  
In situs were performed as described (Jensen and Wallace, 1997). Briefly, DIG-labeled 
RNA probes were synthesized using the T7 high yield RNA synthesis kit (NEB) and a 
Digoxigenin RNA labeling mix (Roche), probes were hybridized overnight at 65 degrees. After 
washing, anti-digoxigenin Fab fragment (Roche) was added and incubated overnight at 4°C. 
Slides were washed and color reaction was carried out in 10% polyvinyl alcohol with NBT/BCIP 
(Roche) for 24-48 hours. 
For mouse Pnky, the full-length transcript was cloned using SMARTer RACE cDNA 
amplification kit with RNA isolated from V-SVZ NSC cultures and cloned into the PGEM-Teasy 
vector (Promega). For human Pnky, a fragment corresponding to bp 367-1592 was cloned and 
used as an in situ probe.  
In utero electroporation  
In utero electroporation was performed on E13.5 embryos from timed-pregnant wildtype 
Swiss-Webster mice (Simonsen labs) as described (Saito, 2006). Constructs used were PsicoR-
shLuciferase (shCtrl), and PsicoR-shPnky-2 (shPnky). Embryos were harvested 24 or 48 hours 
later. One hour before harvesting, mice were given a single injection of either BrdU or EdU. 
Brains were fixed in 4% PFA, washed in PBS, and then equilibrated in 20% sucrose before 
embedding in 1:1 OCT:20% sucrose and sectioning on Cryostat. 
 1-3 non-adjacent coronal sections per brain were imaged for quantification. Optical 
sections through the dorso-lateral telencephalon containing GFP+ electroporated cells were 
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acquired at constant separation on a Leica SP5 Upright Confocal microscope. Three to four 
optical sections through the center were summed using ImageJ. Four animals from three 
separate surgeries were quantified for each experiment. For quanification of GFP+ cells in each 
zone, sections were costained with Nestin and Dcx. VZ was defined as NESTIN+DCX-, and CP 
was NESTIN-DCX+.  
Antibodies  
 Goat anti-SOX2 (Santa Cruz Biotechnology), chicken anti-NESTIN (Aves), mouse anti-
NESTIN (Millipore), rabbit anti-GFAP (DakoCytomation), chicken anti-GFP (Abcam), goat anti-
GFP (Abcam), mouse anti-TUJ1 (Covance), mouse anti-PTBP1 (Invitrogen), guinea pig anti-
DCX (Millipore), rabbit anti-SATB2 (Abcam), rabbit anti-TBR2 (Abcam), chicken anti-TBR2 
(Millipore), rat anti-BrdU (Abcam). Guinea pig anti-DLX2 is described in (Kuwajima et al., 2006). 
For FACS-analysis of infected V-SVZ cultures, directly conjugated 555-Nestin and 647-GFAP 
(BD Pharmigen) were used. 
RNA Immunoprecipitation Assay (RIP)  
RIP assay was performed as described in (Rinn et al., 2007). ~10^7 V-SVZ cells or N2A 
cells were trypsinized and resuspended in 2 ml PBS, 6 ml water, 2 ml nuclear isolation buffer 
(1.28 M sucrose, 40 mM Tris pH 7.5, 20 mM MgCl2, 4% Triton X-100) and incubated on ice for 
20 mins. Nuclei were then pelleted at 2500 x g for 20 mins at 4°C. Nuclear pellets were 
resuspended in 1 mL RIP buffer (150 mM KCl, 25 mM Tris pH 7.4, 5 mM EDTA, 5 mM MgCl2, 
0.5% NP-40 0.5 mM DTT, PI tablet (Roche), and 100 u/ml RNAse OUT (Invitrogen)), and 
sheared with 20 strokes in a dounce homogenizer. Nuclear debris was pelleted by centrifugation 
at max speed for 10 mins at 4°C. Nuclear lysate was split into two aliquots and 8 ug antibodies 
were added. Antibodies used were anti-PTBP1 (Invitrogen) and anti-FLAG (Sigma). IP was 
performed rotating at 4°C overnight. The next day, 50 ul washed Dynabeads Protein G were 
added and incubated for an additional 2 hours. Beads were washed on magnetic rack 3x with 
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RIP buffer, and resuspended in Trizol after final wash. Trizol extraction was carried out 
according to manufacturers’ instructions, cDNA was made using the Transcriptor First Strand 
cDNA synthesis kit (Roche) with both oligo-dT and random hexamer primers. Transcripts were 
detected with qPCR as described above. 
RNA-pulldown 
Biotinylated RNA pulldown was performed as described in (Hacisuleyman et al., 2014). 
~107 V-SVZ-NSCs or N2A cells were pelleted and nuclei obtained as described for RIP protocol. 
To generate biotinylated RNA, Pnky sense and antisense were cloned into the PGEM-Teasy 
vector (Promega), which contains a T7 promoter. Biotinylated RNA was synthesized using the 
T7 High Yield Synthesis Kit (NEB) and biotinylated UTP (Roche). RNA probes were purified 
using the RNeasy mini kit (Qiagen). Immediately before use, 30 pmol RNA was resuspended in 
RNA structure buffer (10 mM HEPES pH 7, 10 mM MgCl2), heated to 65°C, then slow-cooled to 
4°C in a thermocycler. RNA was run on a 1% agarose gel to ensure integrity and correct size.  
To generate lysate, nuclear pellet was resuspended in RIP buffer with 1% NP-40 and 
rotated for 30 mins at 4°C, and then debris was cleared by centrifugation at max speed for 30 
mins. For preclear, 40 µL/pulldown MyOne T1 beads (Invitrogen) were washed/prepared 
according to manufacturer’s instructions and added to the lysate. Mixture was rotated at 4°C for 
1 hour, beads were removed with magnetic rack and discarded. Precleared lysate was diluted 
1:2 in RIP buffer without NP-40 (Final concentration of NP-40 = 0.5%), and probes and yeast 
tRNA (final concentration = 0.1 µg/µL) (Invitrogen) were added. Binding reaction is carried out 
overnight at 4°C. The next day, 40 µL washed MyOne T1 beads are added for an additional 1 
hour. Tubes are added to the magnetic rack and washed 3 x 10 mins at 4°C on the rack with 
wash buffer (RIP buffer with 1% NP-40 and 300 mM KCl). After final wash, 1X NuPage running 
buffer is added and beads are boiled for 10 mins to elute protein. 
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Mass spectrometry 
Selected SDS PAGE-separated bands were excised and in-gel digested with trypsin 
according to the established protocols (Jiménez et al., 1998). LC MS analyses of tryptic 
peptides utilized LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, San Jose, CA) 
equipped with a NanoLC Ultra System (Eksigent, Dublin, CA), as described (Roan et al., 2014). 
MS/MS data were interrogated with Mascot 2.2.04 search engine (Matrix Science) following 
their conversion to the .mgf format with an aid of Mascot Deamon (Matrix Science): Rodentia 
taxonomy of UniProt database (release 2014_01, 26206 entries) was searched. Dynamic 
modifications included sulfoxide oxidatation at Met, deamidation at Asn or Gln, and Gln to pyro-
Glu conversion at N-terminus. Carbamidomethyl at Cys was included as a static modification. 
One missed tryptic cleavage was allowed. Precursor and fragment ion mass tolerances were 
set to 5 ppm and 0.2 Da, respectively. A target-decoy strategy with a 0.045 target false 
discovery (FDR) rate was used for protein identification (Elias and Gygi, 2007). Relative 
abundances of proteins in the sense and antisense samples were estimated on the basis of two 
independent approaches: spectral counting (Liu et al., 2004; Lundgren et al., 2010) and the 
exponentially modified protein abundance indices (emPAI) . Spectral counting utilized peptides 
identified at or above identity. Protein molar content (mol %) was calculated as described by 
(Ishihama et al., 2005) using emPAI values generated by the Mascot algorithm: only peptides 
identified at or above homology threshold are included. 
(http://www.matrixscience.com/help/quant_empai_help.html).  
RT-qPCR Analysis:  
Sequences for some primers were found with PrimerBank (Wang et al., 2012). For averaging 
qPCR results over biological replicates in double KD experiments, the method suggested in 
(Willems et al., 2008) was used.  
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Pnky sequences: 
>Human PINKY 
TAAGCAGTGGTATCAACGCAGAGTACATGGGGAGGCGCCAGGGGCCCGGTTGGCGCGAA
CGCCGGGTTCCGAGCACCCTGGGCTTCCTTGTCTGCCTCCCAGCGCGGCACCTCTTCGG
GGCTCCCGAAACCTGAGCTCTCGCTGGTTTTAGGTCCAGACGGGGGCCTCTCCACCGGTT
CCTCCCCCGCCCCGGGCTCTGGGGCCCATTCTTTGGGCTGACCCTGTCAGGGCAGAGTC
CGCGCGTCTGCCTGCCATTCTCCGCCCGCATAAAAGCACGTTGAAGGTGTCTCGGGCAGA
CACCTCCAGGTTTTGAATCAGTTTATTCCCTTTCACTGTTCAAAGCAGCTGTTCAAATACAC
AGGCTGCTTACGTTGACGTGGAGAGGATTTCAAACAACGCTAAAATGCTTTGAACTGACAA
GGTGTCTTGATATCTCCCTCACTCCATCCAGCACAGCTCCTCGAGATCACTCGCTAGGACA
ATGGCTGAGCAGGCGATTCGTGCGGGCCTCGCCACCTCGGGGCGCGGACTGCGGGGTG
TCCTAAGCCCCTTCCGCAAGGACAGGATGGAGGCACCTGTAAGGAGATGCTGGCGCCAC
CCCAGCTTCTCCCAGGTCCGGAGGAACCTCTACTCAGTCAATACCCTGAGCTGGACTTGT
CTGAAGAAACGGAGCCGACTCCCTCTTGCCGGGGTGCGCTGAGTGGAGGGGAAACATCC
TCGAATAACAGAACTACACCAAAAAGACACCCATGTTATCTCTCACACTTTCACACTCCTCG
AGATAGTGAGCCGGACCTGGGTCTTAGTAGCACCCAGTACCTTGACACAAACCTCCCAAAT
TTCCACCTGAGTAACAGTTATGGGGTCAGTCCATGCACTGTAACTTGAACTCTAATTTATTA
ACTATTTCATCTAGTAAACACACTCACACCATATATAAAATAGCATTTATTTATTTCTATATAC
CAGGAGTTGGCAGAAAACCCACCGTGACCACTCCCATACATTGAGCTGGAGGCACACAAT
TACTAAAACAGAGGTGAGATGGTATTCATTTGATCTTAATTTTTTCTTATTTATGTAGTCCCA
GGATAATAGAAATCAGGAAACAAAAGAAAACAAAGAATTTTCTGAGGAGATGGCCATTGGG
GGAGTGGAGGTAGCAGCTGGTTTAAACCTAAGTAAAACTAGAAAAAGAAACTGCTGTTTCC
TTTTTCTTATATCCACCTTAGAGGATCATGTTTGAACGTCCCTACTCCTCCTCCTCTTTTTAA
AAAGCCTTGTCTCAGTCATTCATTCCTGTGCTTCCTGCTCTTCTGCTAGACCCCAGCAGCT
GTTTGATTTGGTGAGGCCCCCCTCCAACCTCTGAGTGGAACTTCTTTTCTAAGGGCCTGCA
GAATGTCAAAACTGAGGCTCTGGCTTCGGAGCTAGAGCTTTGAACAGCCAATCCACACAAA
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AAGGCAGCTGGCTGCTTTAATGAAAACTGCTATAAAGCTTCAAGAACTTTAGCCTTGGGGG
ATGCATTTATAAGGAACATGGAAAATGCATTTCCAAGTTGCTGGTTCTTGGGAGAGGCATA
ATAAACATTTACC 
>Mouse Pinky 
GGGAGAAGCAACTTCCTCTGGTCTTCTGGAGGTGTAACCTACGTGCCCAGTAGGATATACT
GCCGGGTTGTGAAATGTCCACGCCTCTCCCCAACTGTCTTCCTTCCCAGCCCTCCGGGCT
TGGCTTTCTTGCTTCCCCAGGAGTTCAAATCTCCAACCTGCGGAAGAATTCAGCTGCTTGA
AAGGACTTAAGGCAGTGTGCGGAGGACATCTCCTTTCTCCGCCAGTAAAGAGAGCTGTTC
AAAGACCGAGGCTGCTTACGATGACGTGGAGAGGATTTCAAACAACCTTAACAGGCTTTGA
ACTGACAAGAAGCGGTGATATCTGCCTCACTCTGGCACAGCTCCTCCAGTGCACTTGCTAG
GACAATGGCTGAGAAAGCACTTGGTGCTGGCCTcTCTGCCGGGGGCGAGGACTGCCCAAA
CCCCAGAGACCCTAAGGCAGGAGTTGCTGCACTaCAATGGAGAGGTCTTGTcTTAGGCTGC
ACCTCAGGTTCTcTCAGATcTTCTGGAAGGGCGTTATTCAGCGGTACTGTGGTTGCGCTGT
GCCAGCAGCTGCTTGATGGAGACCTCTTCTCCCCaCATCTGAATGGAACGTCTTTGCCCAG
AGTcTACAGAATGTCAAAACTGAGGCTCCGACCTCAGAGCTACAGCTTTAAGGACCACTCC
ACACAAAGAGGCAGCTGGTTGCTTTAATGAAAACTGCCTTTAAGCTTCAAGAACTGAGGCC
TTGGGGAATCCATTTATAAGGAGCCTAGAAAATGCATTTCCAAGTTGTATGTTcTTAGGAGA
TACAAAATAAAATTTACCTGAAAAAATTAATTGT 
shRNA sequences:  
Luciferase_F: 
TGAGCTGTTTCTGAGGAGCCTTCAAGAGAGGCTCCTCAGAAACAGCTCTTTTTTC 
Luciferase_R: 
TCGAGAAAAAAGAGCTGTTTCTGAGGAGCCTCTCTTGAAGGCTCCTCAGAAACAGCTC 
Pnky_sh1_F: 
TGGACAATGGCTGAGAAAGCTTCAAGAGAGCTTTCTCAGCCATTGTCCTTTTTTC  
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Pnky_sh1_R: 
TCGAGAAAAAAGGACAATGGCTGAGAAAGCTCTCTTGAAGCTTTCTCAGCCATTGTCC 
Pnky_sh2_F: 
TGATGACGTGGAGAGGATTTTTCAAGAGAAAATCCTCTCCACGTCATCTTTTTTC 
Pnky_sh2_R: 
TCGAGAAAAAAGATGACGTGGAGAGGATTTTCTCTTGAAAAATCCTCTCCACGTCATC 
shPTBP1_F:  
TGGGTGAAGATCCTGTTCAATTCAAGAGATTGAACAGGATCTTCACCCTTTTTTC 
shPTBP1_R:  
TCGAGAAAAAAGGGTGAAGATCCTGTTCAATCTCTTGAATTGAACAGGATCTTCACCC 
qPCR Primer Sequences:  
Pnky_F1: TCTCCTTTCTCCGCCAGTAA 
Pnky_R1: CACCGCTTCTTGTCAGTTCA 
Pnky_F2: GCAGGAGTTGCTGCACTACA 
Pnky_R2: GTACCGCTGAATAACGCCCT 
GAPDH_F: GGGAAATTCAACGGCACAGT 
GAPDH_R: AGATGGTGATGGGCTTCCC 
U1_F: ACGAAGGTGGTTTTCCCAG 
U1_R: GTCCCCCACTACCACAAA 
B-Act_F: CTAAGGCCAACCGTGAAAAG 
B-Act_R: ACCAGAGGCATACAGGGACA 
PTBP1_F: AGTGCGCATTACACTGTCCA 
PTBP1_R: CTTGAGGTCGTCCTCTGACA 
Igfbp5_F: CCCTGCGACGAGAAAGCTC 
Igfbp5_R: GCTCTTTTCGTTGAGGCAAACC 
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Ppp1r3c_F: TGATCCATGTGCTAGATCCACG 
Ppp1r3c_R: ACTCTGCGATTTGGCTTCCTG 
Ntsr2_F: TTCACCGCGCTCTATTCGC 
Ntsr2_R: AGGGGTAGTGGGACCACAC 
Scrg1_F: CCTTGGGCTAACTTTGCTGTT 
Scrg1_R: TGGACATTTGCATCTATCAGCTT 
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Chapter 3: The long noncoding RNA Pnky is a trans-acting regulator 
of cortical development in vivo 
 
Summary 
While it is now appreciated that certain long noncoding RNAs (lncRNAs) have important 
functions in cell biology, relatively few have been shown to regulate development in vivo, 
particularly with genetic strategies that establish cis versus trans mechanisms. Pnky is a 
nuclear-enriched lncRNA that is transcribed divergently from the neighboring proneural 
transcription factor Pou3f2. Here we show that conditional deletion of Pnky from the developing 
cortex regulates the production of projection neurons from neural stem cells (NSCs) in a cell-
autonomous manner, altering postnatal cortical lamination. Surprisingly, Pou3f2 expression is 
not disrupted by deletion of the entire Pnky gene. Moreover, expression of Pnky from a BAC 
transgene rescues the differential gene expression and increased neurogenesis of Pnky-
knockout NSCs, as well as the developmental phenotypes of Pnky-deletion in vivo. Thus, 
despite being transcribed divergently from a key developmental transcription factor, the lncRNA 
Pnky regulates development in trans. 
 
Introduction 
The mammalian genome produces tens of thousands of distinct long noncoding RNAs 
(lncRNAs) – transcripts longer than 200 nucleotides (nt) that do not encode proteins (Djebali et 
al., 2012) – and a growing number of lncRNAs have been shown to play important biological 
roles in cultured cells. However, because genetic studies of lncRNA function in vivo are 
currently lacking, the biological significance of most lncRNAs for the development of tissues and 
organs in vivo is unclear (Nakagawa, 2016). Moreover, for most lncRNAs that have been 
discovered to have function, the mechanism(s) by which they regulate cell biology remain 
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enigmatic (Bassett et al., 2014; Kopp and Mendell, 2018). A fundamentally important question is 
whether the lncRNA locus functions in cis – regulating local gene transcription on the same 
chromosome – and/or in trans – producing a molecule that functions at cellular locations distant 
from where it is produced. 
Pnky is an 825 nt, evolutionarily-conserved, nuclear-enriched, polyadenylated lncRNA 
that is expressed in neural stem cells (NSCs) both in vitro and in vivo (Ramos et al., 2015). We 
have previously shown that short-hairpin RNA (shRNA)-mediated Pnky knockdown (KD) 
increases neuronal production from NSCs in culture as well as in the developing cortex (Ramos 
et al., 2015). However, methods that directly target lncRNA transcripts for degradation, such as 
the use of shRNAs and antisense oligonucleotides (ASOs), do not clearly distinguish between 
cis- and trans-acting mechanisms, particularly for lncRNAs that localize to the nucleus (Kopp 
and Mendell, 2018; Wagschal et al., 2012). In addition to reducing potential trans-activities of a 
lncRNA, KD of the lncRNA can also modulate local gene expression (Luo et al., 2016; Ørom et 
al., 2010; Wang et al., 2011). Finally, in addition to potential off-target effects and issues related 
to partial KD, the use of shRNAs and ASOs for in vivo developmental studies can be technically 
challenging (Kaczmarek et al., 2017). 
For a relatively small number of lncRNAs, genetic deletions have been used to reveal 
developmental phenotypes in vivo (Bassett et al., 2014). However, in addition to testing 
potential trans function, genetic deletions can also perturb cis-regulatory mechanisms (e.g., 
through the removal of transcriptional enhancers). The insertion of poly-adenylation (poly-A) 
signals into lncRNAs can disrupt transcriptional elongation and reveal in vivo phenotypes 
(Anderson et al., 2016; Bond et al., 2009), but given that transcriptional activity local to the 
lncRNA transcriptional start site (TSS) can often regulate nearby genes, poly-A insertion may 
not inactivate all potential lncRNA functions. Despite these and other known shortcomings, 
genetic methods are powerful tools for studying phenotypes in vivo and understanding 
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molecular mechanism, particularly when different genetic strategies are combined in a 
complementary manner.  
In this chapter, we integrated multiple genetic approaches to investigate the function and 
molecular mechanism of the lncRNA Pnky in brain development. The TSS of Pnky is located 
~2.2kb from that of the neighboring gene Pou3f2 (Dominguez et al., 2013), which is transcribed 
in the opposite direction. This “divergent” orientation has been described for approximately 20% 
of mammalian lncRNAs and has been found to predict a cis regulatory interaction with the 
coding gene neighbor (Luo et al., 2016). Surprisingly, Pnky-deletion did not disrupt the 
expression of Pou3f2. To test the alternative hypothesis – that Pnky regulates neural 
development in trans – we generated transgenic mice that express Pnky at physiological levels 
from an integrated bacterial artificial chromosome (BAC) construct. Pnky expressed from this 
BAC rescued the differential gene expression and cellular phenotype of Pnky-knockout NSCs, 
as well as the developmental phenotypes of Pnky-deletion in vivo. Thus, the integration of these 
complementary genetic strategies reveals that Pnky functions in trans to regulate brain 
development in vivo. 
 
Results 
Generation of a conditional Pnky deletion allele  
To enable temporal and cell type-specific control over Pnky loss-of-function in vivo, we 
used a Cre-loxP strategy. In the design of this genetic approach, we remained agnostic about 
the specific mechanism(s) by which Pnky might function. We therefore generated a conditional 
Pnky allele that removes the broad range of potential lncRNA mechanisms (both cis and trans) 
by flanking the entire Pnky gene including its TSS with loxP sites (Figures 3.1A-B), and we 
produced mice with this “floxed” Pnky allele (PnkyF). 
The genetic removal of an entire lncRNA locus might not produce the same phenotype 
as degradation of the lncRNA transcript itself (Bassett et al., 2014; Nakagawa, 2016). In NSC 
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cultures from the postnatal mouse ventricular-subventricular zone (V-SVZ), shRNA-mediated 
Pnky KD increases neurogenesis by 3-4 fold (Ramos et al., 2015). We therefore investigated 
whether acute Pnky conditional knockout (Pnky-cKO) in V-SVZ NSC cultures would also 
increase neurogenesis. V-SVZ NSC cultures were established from postnatal PnkyF/F or wild-
type (Pnky+/+) mice that carried the tamoxifen-inducible UBC-Cre-ERT2 transgene. To induce 
Cre-mediated recombination, cultures were treated with 4-hydroxytamoxifen (4-OHT) (Figure 
3.S1A). In PnkyF/F;UBC-Cre-ERT2 cultures, 4-OHT treatment abolished Pnky expression (-
95.6%) (Figure 3.1C), and these Pnky-cKO NSCs exhibited increased neurogenesis, producing 
nearly 6-fold more neurons than control cultures (Figures 3.1D-E). Thus, conditional deletion of 
the entire Pnky gene produces a phenotype similar to that of Pnky transcript KD in cultured 
NSCs. 
Divergent lncRNAs are transcribed in the opposite direction of nearby genes in a “head-
to-head” configuration (Luo et al., 2016), and Pnky is divergent to the proneural transcription 
factor Pou3f2 (Dominguez et al., 2013). In a study of 12 different lncRNAs divergent to 
transcription factors, shRNA-mediated lncRNA KD consistently downregulates the coding gene 
neighbor (Luo et al., 2016). We re-analyzed RNA-sequencing (RNA-seq) data of shRNA-
mediated Pnky KD in V-SVZ NSCs (Ramos et al., 2015) and did not observe differential 
expression of Pou3f2 or any other gene +/- 2.5 MB from Pnky (Figure 3.S1B). However, it is 
unclear whether shRNA-mediated KD affects the processes of transcription and splicing of RNA 
transcripts (Wagschal et al., 2012; West et al., 2004). This mechanistic consideration is 
important as some lncRNAs – independent of the specific transcripts themselves – regulate 
their divergent gene neighbor through these processes (Engreitz et al., 2016). Surprisingly, 
Pnky-cKO did not affect the abundance of Pou3f2 transcript in V-SVZ NSCs (p = 0.40) (Figure 
3.1C). Thus, Pou3f2 expression in cultured NSCs does not appear to require the Pnky 
transcript, processes related to its local transcription, splicing of the lncRNA, or potential 
regulatory elements contained within the deleted DNA sequence. 
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Pnky regulates development of the mouse neocortex  
 The mammalian neocortex is a dorsal brain structure comprised of six layers of 
projection neurons, and the proper development of these layers is critical to cognitive function 
(Lodato and Arlotta, 2015; Molyneaux et al., 2007; Rubenstein, 2011). In addition to projection 
neurons, the cortex contains many interneurons that are dispersed throughout. In the embryonic 
brain, cortical projection neurons are born locally from NSCs in the dorsal brain (pallium), 
whereas cortical interneurons arise from ventral regions (subpallium). During development, 
changes in the production of cortical interneurons can modulate the genesis of projection 
neurons (Silva et al., 2018), and vice versa (Lodato et al., 2011). Pnky is expressed in NSCs in 
both the pallium and subpallium of the embryonic brain (Ramos et al., 2015). Thus, to 
investigate whether Pnky directly regulates the production of cortical projection neurons, we 
focused our in vivo analysis on the cell lineages derived from pallial NSCs. 
 We targeted Pnky-cKO to pallial NSCs with Emx1Cre, which expresses Cre in the pallium 
beginning at ~ embryonic day (E) 9.5 (Briata et al., 1996; Gorski et al., 2002; Simeone et al., 
1992) (Figure 3.S1C). Embryonic brain NSCs reside in the ventricular zone (VZ), and in situ 
hybridization (ISH) revealed Pnky expression in the pallial VZ by E10.0 (Figure 3.S1D). In 
PnkyF/F;Emx1Cre mice, Pnky expression in the pallium was ablated as assessed by ISH, with 
very few Pnky transcripts detected in the pallium at E10.0 (Figure 3.S1D), and none by E13.5 
(Figure 3.1F) or postnatal day (P) 14 (Figure 3.S1E). As expected, in the subpallium of 
PnkyF/F;Emx1Cre mice, Pnky expression was not decreased (Figures 3.1F and 3.S1D). Thus, 
before the onset of cortical neurogenesis, PnkyF/F;Emx1Cre mice have undergone Pnky-cKO 
selectively in the NSCs that give rise to cortical projection neurons. 
 Despite evidence of homozygous Pnky deletion, the expression of POU3F2 in the 
PnkyF/F;Emx1Cre pallium was indistinguishable from that of littermate controls (Figures 3.1G and 
3.S1F). Consistent with these immunohistochemical (IHC) results, RNA-seq analysis of acutely-
dissected E12.5 pallium showed that Pnky-cKO abolished Pnky expression (Figure 3.S1G) 
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without perturbing Pou3f2 transcript levels (adjusted p = 0.37) (Figure 3.S1H). While Pnky-cKO 
resulted in differential expression of genes with roles in cortical development and neurogenesis, 
including Lhx9 (Peukert et al., 2011) and Fezf2 (Molyneaux et al., 2005; Zhang et al., 2014), 
differential expression was not observed within +/- 20 MB of Pnky (Table 3.1). Moreover, we did 
not find POU3F2 binding motifs within the promoter region of any of the differentially-expressed 
genes (data not shown). The E12.5 cortex of PnkyF/F;Emx1Cre mice also exhibited changes in 
alternative splicing (Figure 3.S1I and Table 3.2), affecting transcripts with known 
neurodevelopmental roles such as Ank3 (Durak et al., 2015) and Tcf12 (Mesman and Smidt, 
2017). Thus, in the early embryonic pallium, Pnky-cKO affects the abundance and splicing of 
transcripts related to neural development, but does not disrupt the expression of Pou3f2 mRNA 
or protein. 
 The development of the laminar structure of the cortex progresses temporally in an 
“inside-out” manner: NSCs first give rise to projection neurons for the deep layers (5 and 6), 
while later-born neurons migrate past them to form the upper layers (2/3 and 4) (Lodato and 
Arlotta, 2015). In mice, the birth of deep layer neurons peaks around E13.5. As compared to 
littermate controls, the PnkyF/F;Emx1Cre cortex of E13.5 mice had increased numbers of CTIP2+ 
neurons in the cortical plate (CP) (+24.3%) (Figures 3.2A-B). This increase in neurogenesis 
was accompanied by a decrease in proliferating VZ cells as determined by analysis of 
phosphorylated histone H3 (pH3) (-17.3%) (Figures 3.2C-D) and phosphorylated Vimentin 
(pVIM) (-11.8%) (Figures 3.S2A-B). Thus, consistent with prior results obtained with shRNA-
mediated Pnky KD (Ramos et al., 2015), Pnky-cKO targeted to pallial NSCs increases neuronal 
production but decreases the pool of proliferative NSCs. 
 Given the increase in early-born CTIP2+ neurons at E13.5 (Figures 3.2A-B), we 
assessed for changes in the number of deep layer neurons at P14, when the laminar structure 
of the cortex is fully evident. As compared to littermate controls, PnkyF/F;Emx1Cre mice exhibited 
an increased number of CTIP2+ neurons in layer (L) 6, the deepest cortical layer (+8.1%) 
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(Figures 3.2E-F). Since the number of proliferative VZ cells was reduced in PnkyF/F;Emx1Cre 
mice at E13.5 (Figures 3.2C-D and 3.S2A-B), and the peak of upper layer neurogenesis occurs 
later (~E15.5), we considered that upper layer neurogenesis might be affected in 
PnkyF/F;Emx1Cre mice. As compared to littermate controls, the P14 cortex of PnkyF/F;Emx1Cre 
mice exhibited fewer CUX1+ neurons in the upper cortical layers (-14.4%) (Figures 3.2G-H). 
Furthermore, we used 5-bromo-2’-deoxyuridine (BrdU) to label neurons born at E15.5, and the 
P14 cortex of PnkyF/F;Emx1Cre mice also had reduced numbers of BrdU+;CUX1+ cells in the 
upper layers (-14.5%) (Figure 3.S2C). Essentially all BrdU+ cells in all mice were located in the 
upper layers, and there was no change in the proportion these cells that were also CUX1+ (p = 
0.25) (Figure 3.S2D), indicating that Pnky-deletion does not simply cause a loss of CUX1 
expression or mis-specification. Thus, Pnky-cKO in the early embryonic pallium causes 
malformation of the postnatal neocortex, increasing the number of deep layer neurons while 
decreasing the population of upper layer neurons. 
To determine whether Pnky function is cell-autonomous, we targeted Pnky-cKO to a 
small cohort of NSCs by injecting a Cre-expressing adenovirus (Ad:Cre) (Figures 3.S3A-B) into 
the lateral ventricles of E13.5 PnkyF/F mice or wild-type (Pnky+/+) littermate controls in utero 
(Figures 3.3A and 3.S3C). For fate-tracing analysis, these mice carried the Ai14 transgenic 
reporter that expresses tdTomato after Cre-mediated recombination (Figure 3.3B). Two days 
after Ad:Cre injection, PnkyF/F;Ai14 mice exhibited an increase in the proportion of tdTomato+ 
cells that were found in the CP (+82.7%) (Figures 3.3C-D), as well as in the proportion of 
CTIP2+ CP cells (+86.4%) (Figure 3.3E). To investigate whether this increase in early 
neurogenesis leads to changes in the postnatal cortex, we analyzed mice 20 days post-injection 
(at P14). Consistent with Pnky-cKO at E13.5 causing an overproduction of deep layer neurons 
at the expense of the later upper layer neurons, the postnatal cortex of PnkyF/F;Ai14 mice 
exhibited an increase in the ratio of CTIP2+ deep layer to CUX1+ upper layer cells within the 
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tdTomato+ population (+19.9%) (Figures 3.3F-G and 3.S3D). These results indicate that Pnky 
regulates cortical neurogenesis in a cell-autonomous manner. 
Pnky functions in trans to regulate cortical development 
Given the lack of evidence for Pnky regulating Pou3f2 or other genes in cis, we 
developed genetic methods to test whether Pnky functions in trans. We obtained a bacterial 
artificial chromosome (BAC) containing ~170kb of the genomic sequence surrounding Pnky and 
removed the coding sequence of Pou3f2, the only other complete gene in this BAC (Figures 
3.4A and 3.S4A). We then generated transgenic mice (BACPnky) that express Pnky from this 
modified BAC construct and bred them with mice carrying the PnkyF allele. We established 
cortical NSC (cNSC) cultures from Pnky+/+, PnkyF/F, and PnkyF/F;BACPnky E12.5 embryos, and 
used Ad:Cre to induce recombination. Three days later, we performed RNA-seq from these 
cultures as well as paired untreated control cultures (Figure 3.S4B). While the addition of 
Ad:Cre to PnkyF/F cultures abolished the expression of Pnky, the presence of BACPnky 
maintained Pnky at approximately 20% of wildtype levels (Figure 3.4B). 
In these undifferentiated cNSCs, Pnky-cKO resulted in the differential expression of 55 
other genes (Figure 3.4C and Table 3.3), including genes known to have roles in 
neurodevelopment such as Miat (Gomafu) (Aprea et al., 2013; Barry et al., 2014; Spadaro et al., 
2015) and Erbb4 (Perez-Garcia, 2015). None of the differentially-expressed genes contained 
POU3F2 binding motifs within their promoter regions (data not shown). Strikingly, the vast 
majority (47 of 55, 85.5%) of the genes that were differentially expressed with Pnky-cKO was 
significantly rescued by the presence of BACPnky, such that these genes were no longer 
differentially expressed in PnkyF/F;BACPnky cultures (Figure 3.4D). Of the 27 genes that were 
increased in Pnky-cKO cultures, 21 (77.8%) were decreased by the presence of BACPnky. 
Similarly, 92.9% (26 of 28) of the genes downregulated by Pnky-cKO were increased by 
BACPnky. Of note, the transcriptional changes related to BACPnky were significantly restricted to 
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those genes differentially expressed in Pnky-cKO cells (p = 1.33x10-51, hypergeometric test). 
Thus, expression of Pnky from a BAC transgene specifically rescues the transcriptional changes 
that result from deletion of endogenous Pnky. 
In postnatal V-SVZ NSCs, Pnky physically interacts with PTBP1 (Ramos et al., 2015) – 
an mRNA splicing factor that regulates neurogenesis in NSCs (Zhang et al., 2016). RNA 
immunoprecipitation (RIP) with PTBP1 antibodies also enriched the Pnky transcript from cNSC 
cultures (Figure 3.4E). In cNSCs, Pnky-cKO affected 220 splicing events as compared to 
Pnky+/+ controls (Figure 3.4F and Table 3.4), and 22 of these events were rescued (no longer 
significantly differentially spliced) by the presence of BACPnky (p = 1.99x10-8, hypergeometric 
test) (Figure 3.4G). We also compared the splicing changes that occur upon loss of Pnky with 
two previously-generated datasets of PTBP1 KD in different neural cells (Raj et al., 2014; 
Ramos et al., 2015). Interestingly, 47 events were also differentially spliced upon PTBP1 KD in 
at least one dataset, and 13 of these were differentially spliced in both PTBP1 datasets (χ2=7.7; 
p = 0.0006) (Figure 3.S4C). These data suggest that in addition to regulating the abundance of 
specific transcripts (Figures 3.4C-D), Pnky also influences mRNA splicing. 
After removal of mitogenic growth factors, cNSCs produce neurons in culture (Figure 
3.S4B). Coherent with the increase in cortical neurogenesis observed with Pnky-cKO in vivo 
and the analysis of V-SVZ NSCs in vitro, cNSCs with Pnky-cKO produced ~3-fold more neurons 
as compared to the Pnky+/+ controls (+2.88 fold) (Figures 3.4H-I). The presence of BACPnky in 
Pnky-cKO cNSCs reduced neurogenesis to levels observed in Pnky+/+ cultures (p = 0.41) 
(Figures 3.4H-I), indicating that the BACPnky transgene can rescue the neurogenic phenotype of 
Pnky-cKO in vitro. 
To investigate whether BACPnky can rescue the phenotype of Pnky-deletion in vivo, we 
generated mice with germline Pnky-deletion (Pnkynull/null) and crossed these two mouse lines to 
produce Pnkynull/null;BACPnky mice (Figure 3.S4D). While Pnkynull/null mice had no detectable Pnky 
transcripts, Pnkynull/null;BACPnky mice exhibited a similar pattern and level of Pnky expression as 
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Pnky+/+ animals (Figures 3.4J and 3.S4E). Therefore, expression of Pnky from the BAC mimics 
that from the endogenous Pnky locus. In comparison to Pnky+/+ littermates, E13.5 Pnkynull/null 
embryos had fewer CTIP2+ neurons in the CP (-16.6%) (Figures 3.4K-L). This decrease in 
neurogenesis may relate to the constitutive absence of Pnky causing an earlier loss of 
proliferative NSCs. Consistent with this notion, we observed a decrease in proliferative pH3+ 
progenitor cells in the VZ of Pnkynull/null mice (-9.7%) (Figures 3.4M-N), and the overall thickness 
of the cortex was also reduced in these animals (Figure 3.S4F). Importantly, the presence of 
the BACPnky transgene was sufficient to rescue all of these phenotypes in Pnkynull/null;BACPnky 
mice (Figures 3.4K-N and 3.S4F). Thus, the expression of Pnky in trans from a BAC rescues 
the phenotype of Pnky-deletion in the developing cortex in vivo. 
To determine whether loss of Pnky and the resulting alterations in early embryonic 
cortical development lead to persistent defects in the cortex, we analyzed Pnkynull/null mice and 
Pnky+/+ littermates at P14. Similar to the changes we had found in E13.5 embryos, we observed 
a decrease in CTIP2+ deep layer neurons (-11.9%) (Figures 3.5A-B). Since the layering of the 
cortex is evident by this age, we were also able to quantify the CTIP2+ cells by layer. While 
there was a decrease in L6 CTIP2+ cells, it did not reach statistical significance (-11.7%, p = 
0.056) (Figure 3.5C). However, we did observe a significant decrease in the number of L5 
CTIP2+ cells (-12.5%) (Figure 3.5D). Furthermore, there was also a decrease in the CUX1+ 
upper layer population (-9.1%) (Figures 3.5E-F). Thus, loss of Pnky persistently alters the 
abundance of multiple neuronal subpopulations in the cortex. As we have previously shown that 
Pnky is conserved in human (Figure 2.3B) and similarly expressed in the VZ of the developing 
cortex (Figure 2.3C), it will be important to determine whether human PNKY also regulates 
cortical neurogenesis. Interestingly, we find that human PNKY is expressed in human cerebral 
organoids, and seems to be enriched around the VZ-like regions of the organoid (Figure 3.5G). 
Cerebral organoids may therefore serve as a tractable model system for future studies to 
determine the function of human PNKY. 
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Discussion 
There are currently few genetic studies of lncRNA function in vivo, and thus the 
biological significance of most lncRNAs during mammalian development is unclear (Bassett et 
al., 2014; Nakagawa, 2016). Using a combination of genetic methods in mice to systematically 
study the function and genetic mechanism of Pnky, we show that this lncRNA functions in trans 
to regulate the development of the neocortex. By targeting conditional Pnky deletion to specific 
cell types in the embryonic brain, we found that Pnky regulates the genesis of neocortical 
projection neurons in a cell-autonomous manner. Surprisingly, Pnky-deletion did not produce 
evidence that this lncRNA regulates gene expression in cis. Moreover, when expressed from a 
BAC transgene, Pnky rescued both the differential gene expression and cellular phenotype of 
cultured Pnky-cKO NSCs. BACPnky was also sufficient to rescue the in vivo phenotypes of Pnky-
deletion in the developing cortex, indicating that Pnky functions in trans. 
The production of projection neurons for the different layers of the mammalian neocortex 
is a critical, highly regulated aspect of brain development (Lodato and Arlotta, 2015). For 
instance, deletion of the transcription factor Eomes/Tbr2 in the embryonic brain decreases the 
CUX1+ upper layers by ~20% (Arnold et al., 2008). Pnky-cKO targeted to NSCs in the early 
embryonic pallium with Emx1Cre altered postnatal cortical lamination such that there were ~10% 
more deep layer 6 neurons and ~15% fewer upper layer neurons. This postnatal phenotype 
corresponded to an increase in early neurogenesis (during deep layer production) in vivo at the 
expense of proliferating VZ cells, which later give rise to upper layer neurons. Coherent with 
these in vivo observations, acute Pnky-cKO in cultured NSCs also increased neurogenesis. This 
in vitro phenotype was previously observed with shRNA-mediated Pnky KD, indicating that 
deletion of the Pnky gene has similar effects to targeting the transcript. The cellular phenotypes 
of Pnky-cKO and Pnky KD were more dramatic in cultured NSCs as compared to those in the 
developing cortex, suggesting that there are mechanisms in vivo that can partially compensate 
for the loss of Pnky transcript. 
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Interestingly, constitutive deletion of the lncRNA locus for linc-Brn1b also results in more 
(~20%) deep layer neurons and fewer (~10%) upper layer cells in the postnatal cortex 
(Sauvageau et al., 2013). However, in contrast to Pnky-KO, deletion of linc-Brn1b reduces 
expression of its neighboring transcription factor, Pou3f3 (Sauvageau et al., 2013), which is a 
paralog of the Pnky neighbor Pou3f2. Another lncRNA, linc-Brn1a (a.k.a. Pou3f3os) is divergent 
to Pou3f3, and shRNA-mediated KD of this lncRNA also reduces levels of Pou3f3 (Luo et al., 
2016). Thus, even closely related genes such as Pou3f2 and Pou3f3 appear to have very 
different functional relationships with nearby lncRNAs. 
Divergent lncRNAs are strongly predicted to regulate the expression of transcription 
factor gene neighbors (Luo et al., 2016). Even the processes of lncRNA transcription and 
splicing, independent of the mature lncRNA transcript itself, can regulate expression of the 
divergent gene neighbor (Engreitz et al., 2016; Kopp and Mendell, 2018). For example, the 
lncRNA upperhand (Uph) is divergent to the transcription factor Hand2, and insertion of a poly-A 
cassette into Uph abolishes the expression of Hand2 in cis, resulting in severe cardiac defects 
in vivo (Anderson et al., 2016). However, ASO-mediated KD of Uph does not affect Hand2 
levels. Importantly, Uph is transcribed through known enhancers of Hand2, and transcription of 
this lncRNA appears to establish a more permissive chromatin state for these enhancers. In 
contrast, Pnky-deletion did not affect expression of Pou3f2. Of note, the Pnky locus is not 
known to harbor transcriptional enhancers, and we have not observed strong enhancer-like 
activity of Pnky DNA sequences in cell culture reporter assays (unpublished observations). We 
therefore speculate that whether a divergent, functional lncRNA has cis and/or trans 
mechanisms relates in part to the local presence (or absence) of transcriptional enhancers. 
Divergent lncRNAs can also regulate the function of the protein that arises from the 
coding gene neighbor. For instance, the lncRNA Paupar – which is transcribed through an 
enhancer of its neighbor Pax6 – not only regulates Pax6 expression but also physically interacts 
with the PAX6 transcription factor to affect its regulation of target genes (Pavlaki et al., 2018; 
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Vance et al., 2014). In the developing retina, the divergent lncRNA Six3OS appears to act as a 
molecular scaffold, regulating the activity of its transcription factor neighbor, SIX3 (Rapicavoli et 
al., 2011). While modulation of POU3F2 activity is a plausible mechanism of Pnky function, we 
have not observed interactions between Pnky transcript and POU3F2 protein (not shown), and 
Pnky-deletion did not affect the expression of potential POU3F2 target genes. 
It remains possible that Pnky regulates Pou3f2 in other cellular contexts, or alters 
transcriptional dynamics that might not change steady-state levels of mRNA (Imayoshi and 
Kageyama, 2014; Lenstra et al., 2016). Importantly, lncRNA mechanisms are not necessarily 
mutually exclusive, and there are examples of lncRNAs that carry out multiple distinct molecular 
roles through both cis and trans mechanisms (Cajigas et al., 2018; Pavlaki et al., 2018; Vance 
et al., 2014). However, the rescue of Pnky-deletion phenotypes by BACPnky strongly suggests 
that Pnky primarily functions in trans in NSCs. While BACPnky also contains the untranslated 
regions (UTRs) of Pou3f2, and it is conceivable that these sequences contribute to the rescue, it 
is remarkable that essentially all of the differential gene expression resulting from Pnky-deletion 
was significantly and specifically rescued by BACPnky. Pnky RNA physically interacts with 
PTBP1, a factor that regulates both transcript abundance and splicing, and BACPnky rescued 
~10% of the differentially-spliced events in Pnky-cKO NSCs. While there was significant overlap 
between the differentially-spliced events upon Pnky-cKO and Ptbp1-KD, how Pnky might affect 
PTBP1-dependent splicing remains to be discovered. Furthermore, Pnky may have additional 
roles that are independent of PTBP1. Future work to more comprehensively identify proteins 
that interact with Pnky will be important to further determine the mechanism(s) by which this 
lncRNA regulates transcript abundance and splicing, and ultimately neural development. 
The developing brain expresses many thousands of different lncRNAs, and there are 
emerging examples of lncRNAs with relevance to neurodevelopmental disorders (Briggs et al., 
2015; Meng et al., 2015), underscoring the need to determine the functions of lncRNAs during 
brain development in animal models. While efforts have been made to predict lncRNA biology 
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from their underlying DNA sequence and genomic location (Engreitz et al., 2016; Liu et al., 
2017; Luo et al., 2016), at this point in this emerging field of research, testing individual lncRNAs 
systematically will likely be required to decipher fundamental aspects of their developmental 
function and mechanism. Because the range of potential mechanisms of lncRNAs is 
fundamentally more broad (cis and trans) than protein coding genes or microRNAs, it is unlikely 
that any one experimental method will be sufficient to lay the groundwork for understanding 
molecular mechanism, and instead an integration of multiple approaches will often be required 
(Liu and Lim, 2018). Moving forward, in vivo studies of lncRNA function will serve as a crucial 
foundation for understanding how this class of noncoding transcripts can regulate normal brain 
development and contribute to neurological disorders. 
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Figure 3.1: Generation of a conditional deletion allele for the lncRNA Pnky. 
Quantifications: mean +/- SD. NS = not significant, ** = p < 0.01, *** = p < 0.001, unpaired two-
tailed t test. A, Schematic of Pnky locus and loxP site insertions. B, Pnky levels in V-SVZ 
cultures by qRT-PCR. Biological replicate littermates, normalized to Pnky+/+ mean. C, Pnky and 
Pou3f2 in ethanol (EtOH)- or 4-OHT-treated V-SVZ cultures by qRT-PCR. Technical replicates, 
normalized to EtOH-treated mean. D, Tuj1 ICC in d4 differentiated V-SVZ cultures. Scale bar = 
25µm. E, Quantification of (D). Technical replicates with independent EtOH or 4-OHT treatment, 
normalized to EtOH-treated cultures for each genotype. F, ISH of Pnky (brown puncta) in 
coronal brain sections, with hematoxylin nuclear counterstain (blue). Red boxes = regions of 
pallium (1) and subpallium (2) enlarged in adjacent panels. Scale bars = 250µm (hemispheres) 
and 25µm (insets). G, POU3F2 IHC with DAPI nuclear stain (blue). Yellow boxes = regions of 
pallium enlarged in adjacent panels. Scale bars = 200µm (hemispheres) and 50µm (insets). See 
also Figure 3.S1.  
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Figure 3.2: Pnky regulates cortical neurogenesis in vivo. 
Quantifications: mean +/- SD of biological replicates, normalized to littermate controls. * = p < 
0.05, two-tailed ratio paired t test. A, CTIP2 IHC with DAPI (blue). Locations of CTIP2+ cells in 
CP depicted below. Scale bar = 50µm. B, Quantification of (A). C, pH3 IHC with DAPI (blue). 
Locations of pH3+ cells in VZ depicted below. Scale bar = 50µm. D, Quantification of (C). E, 
CTIP2 IHC in the deep layers of P14 cortex, with DAPI (blue). Dotted line = border between L5 
and L6. Locations of CTIP2+ cells within yellow boxes depicted to the right. Scale bar = 100µm. 
F, Quantification of (E). G, CUX1 IHC in the upper layers of P14 cortex, with DAPI (blue). 
Locations of CUX1+ cells within yellow boxes depicted to the right. Scale bar = 100µm. H, 
Quantification of (G). See also Figure 3.S2.  
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Figure 3.3: Pnky functions cell-autonomously in the developing cortex. 
Quantifications: mean +/- SD of biological replicates, normalized to littermate controls. * = p < 
0.05, ** = p < 0.01, two-tailed ratio paired t test. A, Schematic of in utero Ad:Cre viral injections. 
B, Schematic of Ai14 transgenic Cre reporter. C, IHC of tdTomato and CTIP2 at E15.5. 
Arrowheads = double-positive cells within CP, demarcated by dotted line. Yellow boxes = 
regions enlarged below. Scale bars = 50µm and 20µm (insets). D, Quantification of proportion of 
tdTomato+ cells in the CP. E, Quantification of proportion of tdTomato+ cells located in CP and 
CTIP2+. F, IHC for tdTomato, CTIP2, and CUX1 at P14. Dotted line = border between deep and 
upper cortical layers. Yellow boxes = regions enlarged in adjacent panels. Arrowheads = 
double-positive cells. Scale bars = 100µm and 20µm (insets). G, Quantification of ratio of 
CTIP2+ deep layer cells to CUX1+ upper layer cells within tdTomato+ population at P14. See 
also Figure 3.S3.  
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Figure 3.4: BAC transgenic expression of Pnky rescues loss of the endogenous gene. 
Quantifications: mean +/- SD of separate biological replicates, except as indicated in (I). NS = 
not significant, * = p < 0.05, *** = p < .001. A, Schematic of BACPnky transgene. B, Pnky 
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expression in untreated or +Ad:Cre cNSC cultures by RNA-seq. Normalized to Pnky+/+ mean for 
each treatment group. C, Volcano plot of differentially-expressed genes upon Pnky-cKO. Three 
genes with fold changes outside this range are not displayed here (see D). D, Log2 fold 
changes of all significantly differentially-expressed genes in PnkyF/F +Ad:Cre cultures (circles). 
Arrowheads = log2 fold changes for these genes in PnkyF/F;BACPnky +Ad:Cre cultures. E, 
Enrichment following RIP with PTBP1 antibodies from cNSC cultures. Four technical replicates 
from 2 separate experiments, normalized to levels of b-actin. F, Alternatively-spliced events in 
cNSCs upon Ad:Cre treatment. Significant events in PnkyF/F +Ad:Cre samples that did not 
overlap with events in Pnky+/+ +Ad:Cre samples were analyzed further. G, Log2 fold changes of 
rescued alternatively-spliced events. H, Tuj1 ICC in d7 differentiated cNSC cultures. Scale bar = 
50µm. I, Quantification of Tuj1+ area from (H). Mean +/- SD from technical triplicates comprised 
of cells pooled from three biological replicates. Normalized to uninfected controls and to Pnky+/+ 
+Ad:Cre values. Statistical analysis = one-way ANOVA with Turkey’s multiple comparisons test. 
J, ISH of Pnky (brown puncta) with hematoxylin counterstain (blue). Representative section with 
red box indicating approximate region of pallium enlarged below. Scale bars = 250µm and 25µm 
(insets). K, CTIP2 IHC with DAPI (blue). Locations of CTIP2+ cells in CP depicted below. Scale 
bar = 50µm. L, Quantification of (K), two-tailed ratio paired t test. M, pH3 IHC with DAPI (blue). 
Locations of pH3+ cells in VZ depicted below. Scale bar = 50µm. N, Quantification of (M), two-
tailed ratio paired t test. See also Figure 3.S4 and Tables 3.3 and 3.4. 
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Figure 3.5: Loss of Pnky leads to persistent defects in the postnatal cortex. 
Quantifications: mean +/- SD of biological replicates, normalized to littermate controls. * = p < 
0.05, ** = p < 0.01, two-tailed ratio paired t test. Scale bars = 100µm. A, CTIP2 IHC in the deep 
layers of P14 cortex, with DAPI (blue). Dotted line = border between L5 and L6. Locations of 
CTIP2+ cells within yellow boxes depicted to the right. B-D, Quantifications of (A). E, CUX1 IHC 
in the upper layers of P14 cortex, with DAPI (blue). Locations of CUX1+ cells within yellow 
boxes depicted to the right. F, Quantification of (E). G, Human PNKY ISH in week 11 human 
cerebral organoid.  
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Figure 3.S1: Conditional deletion of Pnky in cultured cells and in vivo. 
Quantifications displayed as mean +/- SD. NS = not significant, *** = p < 0.001. A, Schematic of 
V-SVZ cultures. B, Circos plot of genomic locations of differentially-expressed genes upon 
Pnky-KD in V-SVZ cultures (Ramos et al., 2015). Expanded region depicts genes within 2.5 MB 
of Pnky. C, Schematic of Emx1Cre expression during mouse development. D-E, ISH of Pnky 
(brown puncta) with hematoxylin counterstain (blue). For E10.0 (D), representative coronal 
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section with red boxes to indicate approximate regions of pallium (1) and subpallium (2) 
enlarged in adjacent panels. Scale bars = 250µm and 25µm (insets). For P14 (E), 
representative coronal hemisphere with red boxes to indicate approximate regions of upper (1) 
and deep (2) cortical layers enlarged in adjacent panels. Scale bars = 500µm and 25µm 
(insets). F, IHC of POU3f2 with DAPI nuclear stain (blue). Scale bars = 500µm and 100µm 
(insets). G-H, Levels of Pnky (G) or Pou3f2 (H) in E12.5 cortical tissue by RNA-seq. ND = not 
detected. I, Significant differentially-spliced events from biological triplicate samples. Gene 
names depicted within graph, with specific event names along y-axis. Events with black border 
= highly supported. Difference in percent spliced in (dPSI) calculated as PSI(Pnky-cKO) – 
PSI(ctrl). 
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Figure 3.S2: Loss of Pnky disrupts cortical development. 
Quantifications displayed as mean +/- SD from separate biological replicates, normalized to 
littermate controls. NS = not significant, * = p < 0.05, two-tailed ratio paired t test. A, pVIM IHC, 
with DAPI nuclear stain (blue). Locations of pVIM+ cells in VZ depicted below. Scale bar = 
50µm. B, Quantification of (A). C, Quantification of BrdU+;CUX1+ cells in upper layers of P14 
cortex. BrdU administered at E15.5. D, Quantification of the proportion of BrdU+ cells that also 
express CUX1 in the P14 cortex. BrdU administered at E15.5. 
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Figure 3.S3: Pnky deletion from a small cohort of cells in the developing cortex. 
A, Schematic of cNSC culture derivation to test Ad:Cre-mediated deletion of Pnky. B, Pnky 
expression in Ad:Cre-treated cNSC cultures, quantified by qRT-PCR. Mean +/- SD from 
separate biological replicates, normalized to paired uninfected controls and to average Pnky+/+ 
+Ad:Cre value. *** = p < 0.001, two-tailed ratio paired t test. C, Schematic of genetic crosses 
used to produce littermates for in utero experiments. D, CTIP2 and CUX1 IHC at P14, following 
in utero injection of Ad:Cre at E13.5. Arrowheads = tdTomato+ cells, as shown in Figure 3.3F. 
Scale bar = 20µm. 
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Figure 3.S4: Loss of Pnky is rescued by transgenic expression from a BAC. 
Quantifications displayed as mean +/- SD. * = p < 0.05, ** = p < 0.01, two-tailed ratio paired t 
test. A, Diagram of the BAC used to generate BACPnky transgenic mouse line. Coding sequence 
(CDS) of Pou3f2 was removed, leaving untranslated regions (UTRs) intact. B, Schematic 
depicting cNSC culture experiments in the figures indicated. C, Overlap of differentially-spliced 
events upon Pnky-KO or PTBP1-KD (Raj et al., 2014; Ramos et al., 2015). Difference in percent 
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spliced in (dPSI) = PSI(experimental) – PSI(ctrl). D, Diagram of genetic crosses for BAC rescue 
experiments. E, ISH of Pnky (brown puncta) in E13.5 and P14 sections, with hematoxylin 
counterstain (blue). For E13.5, representative coronal section (also in Figure 3.4J) with red box 
to indicate approximate regions of subpallium enlarged in adjacent panels. Scale bars = 250µm 
and 25µm (insets). For P14, representative coronal hemisphere with red boxes to indicate the 
approximate regions of upper (1) and deep (2) cortical layers enlarged in adjacent panels. Scale 
bars = 500µm and 25µm (insets). F, Quantification of cortical thickness. Littermate biological 
replicates, normalized as indicated in (D).  
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Table 3.1: Pnky knockout in vivo alters transcript abundance. 
Significant differentially-expressed genes in the E12.5 cortex upon loss of Pnky through 
Emx1Cre, from biological triplicate samples. The threshold for statistical significance was set as 
an adjusted p value of 0.1 or lower. Sex-linked genes were excluded. 
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Table 3.2: Pnky knockout in vivo alters transcript splicing. 
Significant differentially-spliced events in the E12.5 cortex upon loss of Pnky through Emx1Cre, 
from biological triplicate samples. PSI = percent spliced in. Difference in PSI (dPSI) was 
calculated as PSI(Pnky-cKO) – PSI(ctrl). 
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Table 3.3: BACPnky rescues transcript abundance changes in Pnky-KO cNSCs. 
Significant differentially-expressed genes in cNSC cultures upon loss of Pnky from PnkyF/F 
+Ad:Cre samples relative to Pnky+/+ +Ad:Cre samples. Biological triplicate samples were used, 
and statistical analysis was performed incorporating pairing of each biological sample treated 
with Ad:Cre to its own untreated control. The threshold for statistical significance was set as an 
adjusted p value of 0.1 or lower. 
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Table 3.4: Altered splicing in Pnky-KO cNSCs overlaps PTBP1-regulated events. 
Significant differentially-spliced events in cNSC cultures upon loss of Pnky from PnkyF/F +Ad:Cre 
samples relative to untreated controls. Events that also occurred in Pnky+/+ +Ad:Cre samples 
relative to untreated controls were removed. PSI = percent spliced in. Difference in PSI (dPSI) 
was calculated as PSI(Pnky-cKO) – PSI(ctrl). dPSI values from re-analysis of previous PTBP1-
KD experiments (Raj et al., 2014; Ramos et al., 2015) are also included. 
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Experimental Procedures 
Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-Tubulin b3 (Tuj1) Biolegend Cat. # 801201 
Anti-POU3F2 Cell Signaling Technology Cat. # 12137 
Anti-CTIP2 Abcam Cat. # ab18465 
Anti-phospho-histone H3 (pH3) Millipore Sigma Cat. # 06570 
Anti-phosphorylated vimentin (pVim) MBL Cat. # D076-3 
Anti-CUX1 Santa Cruz Cat. # sc-13024 
Anti-BrdU Abcam Cat. # ab6326 
Anti-tdTomato Takara Cat. # 632496 
Anti-tdTomato Sicgen Cat. # AB8181-200 
Anti-PTBP1 ThermoFisher Cat. # 32-4800 
Bacterial and Virus Strains  
Ad:Cre Alvarez-Buylla Lab Merkle et al., 2007 
Chemicals, Peptides, and Recombinant Proteins 
4-Hydroxytamoxifen (4-OHT) Millipore Sigma Cat. # H7904 
5-Bromo-2′-deoxyuridine (BrdU) Millipore Sigma Cat. # B5002 
Critical Commercial Assays 
RNAscope 2.5 HD Assay — BROWN Advanced Cell Diagnostics Cat. # 322300 
RNAscope Probe-Mm-Pnky Advanced Cell Diagnostics Cat. # 405551 
Deposited Data 
RNA-seq: Emx1-Cre cortex and cNSC cultures This work GEO: GSE127987 
Experimental Models: Organisms/Strains 
Mouse: wild-type: C57BL/6J The Jackson Laboratory MGI: 3028467 
Mouse: UBC-Cre-ERT2: Ndor1Tg(UBC-cre/ERT2)1Ejb The Jackson Laboratory Ruzankina et al., 
2007 
Mouse: Emx1Cre: Emx1tm1(cre)Krj The Jackson Laboratory Gorski et al., 2002 
Mouse: Ai14: Gt(ROSA)26Sortm14(CAG-tdTomato)Hze The Jackson Laboratory Madisen et al., 2010 
Mouse: E2a-Cre: Tg(EIIa-cre)C5379Lmgd The Jackson Laboratory Lakso et al., 1996 
Mouse: PnkyF This work N/A 
Mouse: Pnkynull This work N/A 
Mouse: BACPnky This work N/A 
Oligonucleotides 
qPCR: Rplp0 F: CCGATCTGCAGACACACACT Ramos et al., 2013 N/A 
qPCR: Rplp0 R: ACCCTGAAGTGCTCGACATC Ramos et al., 2013 N/A 
qPCR: Pnky F: TCTCCTTTCTCCGCCAGTAA Ramos et al., 2015 N/A 
qPCR: Pnky R: CACCGCTTCTTGTCAGTTCA Ramos et al., 2015 N/A 
qPCR: Pou3f2 F: ATGTGCAAGCTGAAGCCTTT Bonvin et al., 2012 N/A 
qPCR: Pou3f2 R: CTCACCACCTCCTTCTCCAG Bonvin et al., 2012 N/A 
qPCR: U1 F: ACGAAGGTGGTTTTCCCAG Ramos et al., 2015 N/A 
qPCR: U1 R: GTCCCCCACTACCACAAA Ramos et al., 2015 N/A 
qPCR: b-actin F: CTAAGGCCAACCGTGAAAAG Ramos et al., 2015 N/A 
qPCR: b-actin R: ACCAGAGGCATACAGGGACA Ramos et al., 2015 N/A 
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Recombinant DNA 
BAC containing the mouse Pnky locus BACPAC Resources 
Center 
Clone RP23-451I6 
Software and Algorithms 
Hisat2 v2.1.0 Kim et al., 2015 https://ccb.jhu.edu/s
oftware/hisat2/index.
shtml 
DESeq2 Love et al., 2014 https://bioconductor.
org/packages/releas
e/bioc/html/DESeq2.
html 
fdrtool Strimmer, 2008 https://CRAN.R-
project.org/package
=fdrtool 
Homer findMotifs.pl Heinz et al., 2010 http://homer.ucsd.ed
u/homer/motif/ 
VAST-TOOLS v.1.0; VAST-TOOLS diff module Braunschweig et al., 2014; 
Irimia et al., 2014; Han et 
al., 2017 
https://github.com/va
stgroup/vast-tools 
Kallisto v0.43.1 Bray et al., 2016 https://github.com/p
achterlab/kallisto/rel
eases 
Fiji / ImageJ Schindelin et al., 2012 https://fiji.sc 
Prism 7 GraphPad Software N/A 
Adobe Photoshop Adobe Systems Inc. N/A 
Adobe Illustrator Adobe Systems Inc. N/A 
 
Mus musculus 
All mice were group-housed and maintained in the University of California, San 
Francisco Laboratory Animal Resource Center under protocols approved by the Institutional 
Animal Care and Use Committee. All relevant ethical regulations were followed. Mice of both 
sexes were used for all experiments, and were analyzed at multiple ages between E10.0 and 
P14 as described in the text and figure legends for each experiment. All samples were analyzed 
relative to littermates. For Emx1Cre experiments, control samples were Pnky+/+;Emx1Cre or any 
combination of Pnky alleles in the absence of Emx1Cre. Details regarding mouse strains are as 
follows (see also Key Resources Table): 
UBC-Cre-ERT2: Tg(UBC-cre/ERT2)1Ejb, described in (Ruzankina et al., 2007). 
Emx1Cre: Emx1tm1(cre)Krj, described in (Gorski et al., 2002). 
Ai14: Gt(ROSA)26Sortm14(CAG-tdTomato)Hze, described in (Madisen et al., 2010). 
E2a-Cre: Tg(EIIa-cre)C5379Lmgd, described in (Lakso et al., 1996). 
 115 
Generation of the Pnky conditional (PnkyF) mouse line 
A conditional allele of Pnky was created by inGenious Targeting Laboratory through 
homologous recombination in C57BL/6 x 129/SvEv hybrid embryonic stem (ES) cells. The 
targeting construct contained a Neomycin resistance cassette to enable drug selection of 
recombined cells. Targeted ES cells were microinjected into C57BL/6 blastocysts. Resulting 
chimeras with a high percentage agouti coat color were mated to C57BL/6 FLP mice to remove 
the Neomycin resistance cassette. The resulting PnkyF allele has the entire Pnky gene flanked 
by loxP sites, with one loxP site 727 bp upstream of the TSS and the other 938 bp downstream 
of the transcriptional end site (TES). 
Generation of the Pnky constitutive deletion (Pnkynull) mouse line 
Constitutive deletion of Pnky was obtained through mating the PnkyF line to the 
germline-expressed E2a-Cre mouse line. Progeny with germline deletion of Pnky were then 
mated to wild-type mice to obtain Pnkynull/+ founders that lacked the E2a-Cre transgene. 
Generation of the BACPnky mouse line 
BAC clone RP23-451I6 was obtained from the BACPAC Resources Center and modified 
as shown (Figure 3.S4A) to remove the coding sequence (CDS) from Pou3f2, leaving the UTRs 
intact. Modifications were made as described in (Warming et al., 2005), and using the detailed 
protocols found at https://ncifrederick.cancer.gov/research/brb/protocol.aspx. We primarily used 
“Recombineering Protocol #3” and referred to “Recombineering Protocol #1” for additional 
details. The modified BAC was microinjected into C57BL/6 zygotes by the Transgenic Gene 
Targeting Core (Gladstone Institutes, UCSF). 
Polymerase chain reaction (PCR)-based genotyping of Pnky and BACPnky 
DNA from small tissue samples was prepared by boiling in 100µL of lysis buffer (0.2mM 
EDTA, 25mM NaOH) for 1 hr, followed by quenching in 100µL of neutralization buffer (40mM 
Tris HCl pH 7.5). Genotyping was performed using GoTaq (Promega, M3001) and the following 
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reaction components, for a final volume of 12µL per reaction: 7.76µL of H2O, 2.4µL of 5x buffer, 
0.36µL of 50mM MgCl2, 0.24µL of 10mM DNTPs, 0.12µL of primer mix (with each primer at 
10µM), 0.12µL of GoTaq, 1µL of sample DNA. Reactions were incubated on a thermocycler as 
follows: 94°C for 2 min; 35 cycles of 94°C for 30 seconds (s), 60°C for 30 s, and 72°C for 1 min; 
72°C for 5 min; 4°C hold. Reaction products were separated on a 2% agarose gel with ethidium 
bromide. The following primers were used (all listed 5’ to 3’): 
Primers for PnkyF, Pnky+, and Pnkynull alleles: 
Pnky GT F: TAAGCTCAAACTCCGGTCCCGGGA 
Pnky GT R1: TCAGGGACAAAGAACCAAAACGAGC 
Pnky GT R2: AATGCTCCCTCTGAGCCTCAATT 
Reaction products: 120bp (Pnkynull), 221bp (Pnky+), and 348 (PnkyF). Since BACPnky 
contains unaltered Pnky, this will produce the 221bp product, even in the absence of 
endogenous Pnky (see next section: Quantitative PCR (qPCR)-based genotyping for BACPnky). 
Primers for BACPnky: 
BAC GT F: CACCTGCTACCTGATATAGGA 
BAC GT R: CAGCAGTAATAGCAAGAGCA 
Reaction product: 416bp (contains BACPnky). No amplification in the absence of BACPnky. 
Quantitative PCR (qPCR)-based genotyping for BACPnky 
Because BACPnky contains unmodified Pnky, it is indistinguishable from Pnky+ in 
standard PCR-based genotyping. Therefore, certain genetic crosses required the use of qPCR 
to determine the endogenous Pnky alleles. This was done using 25ng of sample DNA (prepared 
as described above), along with 4µL SYBR green (Roche) and 2µL of primer mix (with each 
primer at 5µM) per 8µL qPCR reaction. Reactions were amplified on a LightCycler 480 II 
(Roche) using standard conditions. To quantify the number of copies of particular endogenous 
Pnky alleles, the DDCt method was used: a control genomic region was used to normalize for 
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DNA content per reaction, and multiple samples with known endogenous Pnky alleles were 
used to compare to unknown samples. 
Primers for control genomic region: 
Ctrl qPCR GT F: TGGTCGTTCTACAGGCCTTC 
Ctrl qPCR GT R: GGACCGGTGACAGAGAACTG 
Primers for Pnkynull allele: 
Pnky qPCR GT F: AGTTGGTCGTCCGCGTACGGTAC 
Pnkynull qPCR GT R (same as Pnky GT R1): TCAGGGACAAAGAACCAAAACGAGC 
Product: 97bp from Pnkynull allele. No amplification from other Pnky alleles or BACPnky. 
Primers for PnkyF allele: 
Pnky qPCR GT F: AGTTGGTCGTCCGCGTACGGTAC 
PnkyF qPCR GT R: CCGGATCTTTCCTTTACCCGCAATAAC 
Product: 228bp from PnkyF allele. No amplification from other Pnky alleles or BACPnky. 
BrdU administration 
 Mice were administered 5-bromo-2’-deoxyuridine (BrdU, Millipore Sigma) reconstituted 
in sterile PBS through intraperitoneal injection, at a dose of 50mg BrdU per kg of mouse weight. 
Primary cell culture 
All cells were grown in humidified incubators at 37°C in 5% CO2. 
V-SVZ cultures 
The brains of P7 mice were dissected out of the skull, and then a coronal slab of 
approximately 0.5 mm in thickness was obtained manually or by using a vibratome. Dissections 
were performed in ice-cold L15 medium (ThermoFisher 11415064) to collect the V-SVZ region 
along the lateral walls of the lateral ventricles. The tissue was dissociated with 300 µL of 0.25% 
trypsin-EDTA (ThermoFisher 25200056) with occasional agitation for 20 min at 37°C, and then 
the trypsin was quenched with 600 µL of N5 growth medium (see below). Cells were dissociated 
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by trituration and then pelleted by centrifugation at 300 g for 5 min. Cells were resuspended in 
fresh N5 growth medium and plated in one well of a 12-well tissue culture plate per mouse. 
 Cells were grown in N5 growth medium: DMEM/F-12 with GlutaMAX (ThermoFisher 
10565018) supplemented with 5% Fetal Bovine Serum (Fisher Scientific SH30070.03), N2 
supplement (ThermoFisher 17502048, 1:100), 35 μg/mL bovine pituitary extract (ThermoFisher 
13028014), Antibiotic-Antimycotic (ThermoFisher 15240062, 1:100), 20 ng/mL epidermal growth 
factor (EGF, PeproTech AF-100-15), and 20 ng/mL basic fibroblast growth factor (bFGF, 
PeproTech 100-18B). 
For routine passaging, cells were grown to hyperconfluency and then dissociated using 
0.25% trypsin-EDTA (ThermoFisher 25200056) for 3-5 minutes in the incubator. This was 
diluted with an equal volume of growth medium, and the cells were dissociated by trituration. 
Cells were pelleted as described above, then resuspended in fresh culture medium to plate in 2 
times the original culture area. For recombination using the tamoxifen-inducible UBC-Cre-ERT2 
transgene, cultures were treated with 10nM 4-hydroxytamoxifen (4-OHT) for 48 hours. 4-OHT 
was reconstituted in EtOH, and all experimental cultures were normalized to paired EtOH-
treated control cultures. To differentiate the cells, cultures were grown to hyperconfluency and 
then the medium was replaced without EGF or FGF. 
Cortical neural stem cell cultures 
Tissue culture plates were prepared by coating with 1 mg/mL poly-D-lysine (Millipore A-
003-E) for at least 4 hours in the incubator. This was rinsed twice with PBS or water and 
replaced with 5 µg/mL laminin (ThermoFisher 23017015) in the incubator O/N. As laminin is 
highly sensitive to drying, this was removed well-by-well and immediately replaced with enough 
culture medium to cover the surface of the well. Cells were then plated in the remaining volume. 
Cultures of cNSCs were derived from E12.5 mice as described in (Currle et al., 2007), 
with modifications. The developing cortex was dissected from E12.5 embryos in ice-cold high-
glucose DMEM (ThermoFisher 31053028) and then dissociated with 100 µL of 0.05% trypsin-
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EDTA (ThermoFisher 25300054) for 20 min at 37°C. Trypsinization was halted using 200 µL of 
0.25 mg/mL soybean trypsin inhibitor (ThermoFisher 17075029). Cells were mechanically 
dissociated by trituration and then pelleted by centrifugation at 1000 g for 3 min. Cells were 
resuspended in 1mL of PBS to rinse, and then re-pelleted. Cells were finally resuspended in 
growth medium (see below) and plated in one well of a pre-treated (see above) 12-well tissue 
culture plate per embryo. 
Cells were grown in the following medium slightly modified from (Hudlebusch et al., 
2011): 50% DMEM/F-12 medium (ThermoFisher 11330057) and 50% Neurobasal medium 
(ThermoFisher 21103049) supplemented with N2 (ThermoFisher 17502048, 1:100), B27 
(ThermoFisher 17504044, 1:50), Antibiotic-Antimycotic (ThermoFisher 15240062, 1:100), 
HEPES (ThermoFisher 15630080, 1:200), 2 μg/ml Heparin sodium salt (Millipore Sigma 
H3149), Bovine Albumin Fraction V (ThermoFisher 15260037, 1:750), MEM non-essential 
amino acids (ThermoFisher 11140050, 1:100), GlutaMAX (ThermoFisher 35050061, 1:100), 
Sodium Pyruvate (ThermoFisher 11360070, 1:100), β-mercaptoethanol (Millipore ES-007-E, 
1:5000), 10 ng/ml epidermal growth factor (EGF, PeproTech AF-100-15) and 20 ng/ml basic 
fibroblast growth factor (bFGF, PeproTech 100-18B). 
For routine passaging, cells were grown to confluency and then dissociated using 
StemPro Accutase (ThermoFisher A1110501) for 5 minutes in the incubator. This was diluted 
with an equal volume of growth medium, and the cells were dissociated by trituration. Cells were 
pelleted as described above, then resuspended in fresh culture medium to plate in 3 times the 
original culture area. To differentiate the cells, cultures were grown to confluency and then the 
medium was replaced without EGF or FGF. 
Tissue/cell preparation 
Cultured cells and human cerebral organoids were fixed in 4% paraformaldehyde (PFA, 
Millipore Sigma 158127) for 30 min at RT. Embryonic specimens up to E13.5 were fixed in 4% 
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PFA as whole heads, up to overnight (O/N) at 4°C. For E15.5 samples, brains were dissected 
out of the skull prior to fixation in 4% PFA, up to O/N at 4°C. Transcardiac perfusion was 
performed on postnatal animals with phosphate buffered saline (PBS) followed by 4% PFA. The 
brains were then dissected out of the skull and additionally fixed in 4% PFA O/N at 4°C.  
Cryosectioning 
All specimens were rinsed in PBS and then cryoprotected with 30% sucrose in PBS. 
Cryoprotected samples were then equilibrated in a 1:1 mixture of 30% sucrose and Tissue-Tek 
Optimal Cutting Temperature (OCT) (Thermo Fisher Scientific) for 1 hour (hr) at 4°C, then 
frozen in a fresh batch of the same mixture using dry ice. Frozen blocks were equilibrated in the 
cryostat at -23°C for at least 3 hrs prior to sectioning. Sections (12-14µm thick) were collected 
on Superfrost Plus Microscope Slides (Thermo Fisher Scientific) and stored at -80°C. Prior to 
IHC, tissue slides were rinsed in PBS with rotation for 10 minutes (min) at room temperature 
(RT) to remove sucrose/OCT. 
Immunohistochemistry (IHC) and immunocytochemistry (ICC) 
IHC and ICC were performed using blocking buffer consisting of PBS with 1% BSA 
(Millipore Sigma), 0.3M glycine (Thermo Fisher Scientific), 0.3% TritonX100 (Millipore Sigma), 
and either 10% normal goat serum or 10% normal donkey serum (Jackson ImmunoResearch 
Laboratories) depending on the species of origin of the secondary antibodies to be used.  
IHC was performed on tissue sections and ICC was performed on cells as follows: 
Blocking: incubated in blocking buffer for 1-2 hrs (IHC) or 1 hr (ICC) at RT. 
Primary antibodies: incubated in primary antibodies diluted in blocking buffer O/N at 4°C (IHC) 
or 2 hrs at RT (ICC). 
Wash 1: washed 3 times in PBS at RT for 10 (IHC) or 5 min (ICC). 
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Secondary antibodies: incubated in secondary antibodies (Alexa Fluor antibodies from Thermo 
Fisher Scientific, 1:500) and DAPI (Thermo Fisher Scientific, 1:1000) diluted in blocking buffer 
for 30 min at RT (both IHC and ICC). 
Wash 2: same as wash 1 above. This completed ICC. 
Mounting coverslips: for IHC, slides were mounted with coverslips using Aqua Poly/Mount 
(Polysciences). 
Antigen Retrieval 
For certain antibodies (see below), antigen retrieval was performed using 10mM sodium 
citrate (pH 6.0) prior to IHC. Slides were incubated horizontally with 500µL of sodium citrate on 
top of the tissue for 2-3 min at RT. This was replaced with fresh sodium citrate, and the slides 
were moved to a pre-heated vegetable steamer. After 15 min, the slides were removed from the 
steamer and allowed to cool for 2-3 min at RT. The sodium citrate was then dumped off of the 
tissue and the slides were rinsed in PBS. 
Primary antibodies for IHC/ICC 
Please see Key Resources Table for antibody specifications. Antibodies were used as 
follows: Tuj1: diluted 1:1000 for ICC. POU3F2: diluted 1:250 for IHC (performed antigen 
retrieval for tissue of all ages). CTIP2: diluted 1:500 for IHC (performed antigen retrieval for 
postnatal tissue). pH3: diluted 1:400 for IHC. pVim: diluted 1:500 for IHC. CUX1: diluted 1:500 
for IHC (performed antigen retrieval for postnatal tissue). BrdU: diluted 1:200 for IHC 
(performed antigen retrieval for tissue of all ages). tdTomato (Takara or Sicgen): diluted 1:500 
for IHC or ICC (does not work after antigen retrieval, see below). 
IHC for tdTomato in combination with antigen retrieval 
IHC for tdTomato was performed as described above, then the tissue was re-fixed with 
4% PFA for 45 minutes at RT. Slides were rinsed in PBS, then antigen retrieval was performed 
followed by IHC for the other antigens as described above. 
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In Situ Hybridization (ISH) – Mouse tissue 
ISH was performed on tissue sections (prepared as described above) using the 
RNAscope 2.5 HD Assay — BROWN. Probes targeting the mouse Pnky transcript were used 
(RNAscope Probe-Mm-Pnky). 
Sample Preparation: Followed the Sample Preparation Technical Note for Fixed Frozen Tissue 
with the following modifications:  
1. Before starting the protocol, let slides dry and then drew a barrier around tissue sections 
using ImmEdge Hydrophobic Barrier PAP Pen (Vector Laboratories). Let barrier dry, then 
rinsed tissue in PBS for 10 min at RT with rotation to remove sucrose/OCT. Post-fixed with 
4% PFA for 20 min at RT, then rinsed in PBS for 5 min at RT. Started at Part 2: Tissue 
Pretreatment section of the Technical Note. 
2. Instead of submerging slides in boiling Target Retrieval solution, added pre-heated Target 
Retrieval solution on top of horizontal slides and incubated in pre-heated vegetable steamer. 
3. Used Protease III instead of Protease Plus. Incubated for 10 min at RT. 
ISH: Followed the standard RNAscope 2.5 Assay protocol except for the following modifications: 
1. Hybridized probes for 3 hrs. 
2. Hybridized AMP 5 for 90 min. 
3. Incubated in DAB for 1 hr. 
4. For all wash steps, incubated for 2 min with gentle rotation instead of agitating (to preserve 
tissue integrity). 
In Situ Hybridization (ISH) – Human cerebral organoids 
ISH was performed as previously described (see Chapter 2) (Jensen and Wallace, 1997). 
Microscopy and image analysis 
Samples were imaged using Leica TCS SP5 X confocal, Leica DMi8, Leica DMI4000 B, 
and Keyence BZ-X710 inverted microscopes. For tissue samples that had received in utero 
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injection of Ad:Cre, the contralateral hemisphere was analyzed whenever possible. For all other 
tissue samples, both hemispheres were analyzed from 2-4 non-adjacent regions. All image 
analysis and quantification was performed using Fiji (Schindelin et al., 2012). To quantify Tuj1+ 
area (Figures 3.4H-I), the “threshold” and “measure” functions of Fiji were used.  
RNA isolation 
Total RNA was isolated from tissue and cultured cells using TRIzol (Thermo Fisher 
Scientific) and purified using Direct-zol RNA Purification Kits (Zymo Research). DNAse 
digestion was performed as suggested. 
Quantitative reverse transcription PCR (qRT-PCR) 
cDNA synthesis was performed using the Transcriptor First Strand cDNA synthesis kit 
(Roche). qRT-PCR was performed using SYBR green (Roche) on a LightCycler 480 II (Roche). 
Relative gene expression was calculated using the DDCt method, using Rplp0 as a 
housekeeping gene for differential gene expression analyses. All qRT-PCR assays were 
performed using technical triplicate wells. See Key Resources Table for primer sequences. 
RNA-seq library preparation 
Prior to library preparation, RNA integrity was assessed using TapeStation 4200 
(Agilent). Strand-specific poly(A) selected cDNA libraries were generated using TruSeq 
Stranded mRNA kit (Illumina). Paired-end, 150bp sequencing of libraries was performed on a 
HiSeq 4000 (Illumina) by Novogene. 
RNA Immunoprecipitation (RIP) 
RIP using an antibody against PTBP1 (ThermoFisher) was performed as described 
previously (Ramos et al., 2015; Rinn et al., 2007) from cNSC cultures in 4 technical replicates 
from 2 separate experiments. The immunoprecipitated RNA was quantified by qRT-PCR using 
the percent input method. For each replicate, data were normalized to b-actin levels. U1 was 
used as a negative control. 
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Cre-expressing adenovirus (Ad:Cre) 
Ad:Cre (Merkle et al., 2007) was produced using 293A cells (Thermo Fisher Scientific, 
catalog number R70507). Concentrated adenovirus was prepared using the Fast Trap 
Adenovirus Purification and Concentration Kit (Millipore Sigma, catalog number FTAV00003). 
In utero injections 
Injections were performed on timed-pregnant mice as previously described (Wang and 
Mei, 2013), except as follows: manual pipettes were used instead of mouth pipettes, and 
protocol sections 3.7-3.8 (delivery of electric pulses for electroporation) were skipped. Ad:Cre 
virus was mixed 1:1 with Trypan Blue to enable visualization of the injected solution. ~ 1µL of 
this mixture was injected into one of the lateral ventricles of E13.5 embryos. All protocols and 
procedures followed the guidelines of the Laboratory Animal Resource Center at the University 
of California, San Francisco and were conducted with IACUC approval. 
Figure preparation 
Figures were prepared using Photoshop and Illustrator (Adobe) and Prism (GraphPad). 
Quantification and Statistical Analysis 
All in vivo quantifications were normalized to littermate controls. For in vivo BAC rescue 
experiments, there was a low probability of obtaining all of the relevant experimental genotypes 
(Pnky+/+, Pnkynull/null, and Pnkynull/null;BACPnky) within the same litter. Therefore, we used one set 
of crosses to analyze Pnky+/+ and Pnkynull/null littermates as one group, and another set of 
crosses to analyze Pnkynull/null and Pnkynull/null;BACPnky littermates as a separate group. To 
compare phenotypes between these two groups, we normalized results to the genotype 
common to both (Pnkynull/null), as shown in (Figure 3.S4D). 
For ICC quantification, technical triplicate wells of each genotype and treatment 
combination were analyzed. All cultures were normalized to their own treatment control.  
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The statistical details of each experiment can be found in the relevant figure legends, 
with additional details for RNA-seq experiments described below. 
RNA-seq analysis of Emx1Cre experiments (Figure 3.S1, and Tables 3.1 and 3.2):  
Reads were aligned to the mouse genome mm10 using Hisat2 v2.1.0 (Kim et al., 2015). 
At least 77 million mapped reads were obtained per sample. Differential gene expression was 
analyzed by DESeq2 (Love et al., 2014) and correction for multiple hypothesis testing was 
performed using the R package fdrtool (Strimmer, 2008). Transcription factor motif enrichment 
analysis was performed on differentially-expressed gene sets using the Homer findMotifs.pl 
command (Heinz et al., 2010) with default settings, using all genes detected by RNA-seq as the 
background list (data not shown). 
Analysis of alternative splicing (including alternative exons, micro-exons, 3’ and 5’ splice 
sites, and retained introns) was performed using VAST-TOOLS v.1.0 (Braunschweig et al., 
2014; Irimia et al., 2014). To determine if events were differentially spliced between the cortical 
tissues of Pnky-cKO and control mice, lowly-expressed transcripts (cRPKM < 3) and all events 
with low inclusion (PSI < 5%) were removed. The VAST-TOOLS diff module (Han et al., 2017) 
was used to both calculate the difference in percent spliced in (dPSI) between conditions and to 
identify statistically significant differences in splicing for all events with at least 10 reads support. 
All reported events were found to have significant dPSI: the probability of an event having |dPSI| 
of at least 5% is greater than 95%. Highly supported events have more than 10 reads mapping 
to the event in at least 50% of the profiled samples. 
RNA-seq analysis of cNSC experiments (Figures 3.4 and 3.S4, and Tables 3.3 and 3.4): 
Reads were pseudo-aligned to the Gencode M18 GRCm38.p6 transcriptome with 
Kallisto v0.43.1 (Bray et al., 2016). Differential expression analysis was performed using 
DESeq2 (Love et al., 2014), using the model ( ~ grp + grp:ind.n + grp:cnd) where grp = 
genotype, ind.n = individual biological replicate, and cnd = condition (untreated or +Ad:Cre) to 
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identify genotype-specific effects of Ad:Cre. Correction for multiple hypothesis testing was 
performed using the R package fdrtool (Strimmer, 2008). As described above, transcription 
factor motif enrichment analysis was performed on differentially-expressed gene sets using the 
Homer findMotifs.pl command (Heinz et al., 2010) with default settings, using all genes detected 
by RNA-seq as the background list (data not shown). 
For splicing analysis, the data were aligned to the mouse genome by vast-tools 
(Braunschweig et al., 2014; Irimia et al., 2014), with default options using –mm10. Analysis 
included all events that had at least 10 samples with 95% > PSI > 5% and for which vast-tools 
identified coverage as ‘OK’ or ‘SOK’ in at least 50% of samples. The VAST-TOOLS diff module 
(Han et al., 2017) was used to identify significantly differentially-spliced events, which required a 
minimum of 15 reads (-e 15) and called events significantly different between conditions only if 
|dPSI| > 0.05. A splicing event was deemed to be ‘rescued’ by BACPnky if |dPSI| between 
PnkyF/F;BACPnky untreated and +Ad:Cre samples was < 0.05, |dPSI| between in PnkyF/F 
untreated and +Ad:Cre samples was significant, and if the rescue caused a shift away from 
Pnky-cKO conditions by at least |dPSI| > 0.05. For Ptbp1-KD comparison, we re-analyzed the 
data from previous studies in mouse N2a cells (Raj et al., 2014) and in V-SVZ NSCs (Ramos et 
al., 2015). From these two studies, we generated lists of events which were significantly 
affected by Ptbp1-KD at a |dPSI| > 0.05 cut-off. We compared these events (N=230 overlapping 
events in 227 genes) to those we found to be regulated by Pnky (N=220 events in 182 genes). 
Data and Software Availability 
The RNA-seq datasets generated during this study are available in the public repository 
GEO, available at https://www.ncbi.nlm.nih.gov/geo/. Data are listed with the accession number 
GSE127987. 
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Chapter 4: Loss of Pnky disrupts neurogenesis and long-term neural 
stem cell abundance in the ventricular-subventricular zone 
 
Summary 
Certain long noncoding RNAs (lncRNAs) are now known to carry out important biological 
roles, however there are few examples of lncRNAs that regulate neurogenesis in vivo. Pnky is a 
lncRNA that is enriched in the neural stem cells (NSCs) of the ventricular-subventricular zone 
(V-SVZ). Here we show that Pnky deletion leads to the aberrant formation of intraventricular 
neuroblast nodules. Loss of Pnky also disrupts normal progression through the V-SVZ 
neurogenic lineage, expanding the transit amplifying stage. Furthermore, long-term NSC 
abundance is reduced in Pnky knockout mice, possibly as a consequence of precocious 
neurogenic differentiation. To understand how Pnky carries out its functions at the molecular 
level, we also identified several putative Pnky-binding proteins, many of which are related to the 
process of RNA splicing. Thus, Pnky is an important mediator of V-SVZ neurogenesis in vivo, 
potentially through its interactions with splicing factors. 
 
Introduction 
Tens of thousands of distinct long noncoding RNAs (lncRNAs) – transcripts longer than 
200 nucleotides (nt) that lack evident protein coding potential (Djebali et al., 2012) – are 
produced by the mammalian genome. There is a growing number of lncRNAs that have been 
shown to regulate important biological processes, including those that underlie human disease 
(Batista and Chang, 2013; Briggs et al., 2015; Lee, 2012; Mercer and Mattick, 2013; Rinn and 
Chang, 2012). A remarkable diversity of lncRNAs can be found in the developing and adult 
central nervous system, and many of these lncRNAs seem to be brain-specific (Derrien et al., 
2012; Mercer et al., 2008). However, there have been few genetic studies of lncRNA function in 
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animal models, and therefore the biological significance of most lncRNAs in vivo remains 
unclear (Nakagawa, 2016). This is particularly true for the central nervous system: while several 
lncRNAs have now been found to perform important roles in different neural cell types, (Aprea 
and Calegari, 2015; Briggs et al., 2015; Clark and Blackshaw, 2014; Hart and Goff, 2016; 
Ramos et al., 2016), only a handful have been have been experimentally manipulated in vivo in 
mice (Andersen and Lim, 2018). 
Neural stem cells (NSCs) are glial cells that can self-renew as well as differentiate into 
intermediate progenitors, which divide at least once before producing neuronal progeny 
(Kriegstein and Alvarez-Buylla, 2009). Such NSCs exist in the embryonic cortical ventricular 
zone, and we have previously shown that the lncRNA Pnky regulates neurogenesis in the 
developing neocortex (Andersen et al., 2019). In the mouse, there is also a population of long-
term NSCs that exists within the walls of the lateral ventricles, in a niche known as the 
ventricular-subventricular zone (V-SVZ) (Lim and Alvarez-Buylla, 2014, 2016). The V-SVZ 
neurogenic lineage has been extensively described (Doetsch et al., 1999; Lois and Alvarez-
Buylla, 1994; Luskin, 1998; Peretto et al., 1997): throughout the adult life of a mouse, V-SVZ 
NSCs generate transit amplifying cells, which give rise to multiple neuroblasts. These 
neuroblasts then travel anteriorly through the rostral migratory stream to the olfactory bulb, 
where they terminally differentiate into mature interneurons. 
Pnky was originally identified as a lncRNA enriched in V-SVZ NSCs, and we previously 
found that knockdown or deletion of Pnky promotes neurogenic differentiation in V-SVZ NSC 
cultures (see Chapter 2 and Chapter 3). However, many aspects of the V-SVZ neurogenic 
lineage in vivo cannot be recapitulated using in vitro cultures, and it was unknown whether Pnky 
regulates processes such as neuroblast migration to the olfactory bulbs or long-term NSC 
maintenance. Here we show that genetic deletion of Pnky results in aberrant progression 
through the V-SVZ neurogenic lineage and the formation of intraventricular neuroblast nodules. 
We also find that loss of Pnky leads to reduced long-term NSC abundance. Furthermore, we 
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identify a novel set of putative Pnky binding proteins, many of which are known to regulate RNA 
splicing. Together, these data demonstrate an important role for Pnky in a long-term NSC 
population in vivo and provide new insights into the potential molecular function of this lncRNA. 
 
Results 
We previously described the generation of a conditional Pnky knockout allele with loxP 
sites flanking the entire Pnky gene (see Chapter 3). This genetic tool enabled us to determine 
that deletion of Pnky from V-SVZ cultures results in substantially increased neurogenic output 
(Figure 3.1D-E), similar to the effect of knocking down Pnky transcript levels (Figure 2.1I-J). 
However, monolayer in vitro cultures cannot recapitulate certain important aspects of the V-SVZ 
neurogenic lineage. Therefore, to assess the function of Pnky in the V-SVZ in vivo, we targeted 
deletion of Pnky to the nervous system using Nestin-Cre, and also analyzed constitutive Pnkynull 
knockout mice (both hereafter referred to as Pnky-KO). In both cases, a subset of the Pnky-KO 
mice exhibited a striking phenotype: nodules of cells residing within the ventricles (Figure 4.1A). 
Further analysis revealed that these nodules were comprised of tightly-packed DCX+ 
neuroblasts (Figure 4.1B), consistent with increased neurogenesis upon loss of Pnky. 
Supporting an immature neuroblast identity, we did not detect expression of the mature 
neuronal marker NeuN (data not shown). 
While these neuroblast nodules were not found in any of the littermate control mice, they 
were observed in approximately half of the Pnky-KO mice at a variety of postnatal ages (Figure 
4.1C and Table 4.1). The average dimensions of the nodules were 67 ± 16µm in the 
mediolateral axis and 174 ± 30µm in the dorsoventral axis (Figure 4.1D and Table 4.1). While 
the cells within these nodules were not proliferative (Figure 4.1E), birth dating analysis using 5-
bromo-2’-deoxyuridine (BrdU) in adult mice demonstrated that many of them had been recently 
produced (Figure 4.1F), suggesting an ongoing disruption of postnatal V-SVZ neurogenesis. 
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Some Pnky-KO animals also exhibited additional abnormalities, including neuroblast nodules 
along the walls of the ventricles (Figure 4.1G). Thus, genetic deletion of Pnky disrupts the 
proper architecture of the V-SVZ in vivo. 
We next sought to determine how the intraventricular neuroblast nodules were formed. 
The neuroblasts produced in the V-SVZ normally migrate anteriorly through the rostral migratory 
stream to reach the olfactory bulbs (Lim and Alvarez-Buylla, 2014). However, certain genetic 
mutations, such as loss of the chromatin modifier mixed-lineage leukemia 1 (Mll1), can impair 
neurogenic differentiation and disrupt this migration (Lim et al., 2009). Therefore, we first 
assessed whether deletion of Pnky blocked the migration of neuroblasts to the olfactory bulbs. 
We administered BrdU to control and Pnky-KO littermates at postnatal day (P) 60, and then 
waited two weeks in order to allow sufficient time for the newly-born BrdU+ neuroblasts to 
migrate to the olfactory bulbs. In both control and Pnky-KO mice, we observed many BrdU+ 
cells dispersed throughout the olfactory bulbs (Figure 4.2A). We also found BrdU-labeled cells 
within the core of the olfactory bulbs, which is where the migrating neuroblasts first arrive. 
Therefore, loss of Pnky does not grossly disrupt neuroblast migration from the V-SVZ. 
 In order to analyze progression through the V-SVZ neurogenic lineage, we performed 
additional BrdU labeling experiments. We administered BrdU to P30 mice, and then waited one 
week to allow differentiation into transit amplifying cells and neuroblasts. We found no 
statistically significant difference in the overall number of BrdU+ cells along the V-SVZ in control 
vs Pnky-KO littermates (control: 102.9 ± 24.4; Pnky-KO: 89.0 ± 26.1; ratio paired t test: p = 
0.27). However, loss of Pnky resulted in altered progression through this lineage, leading to an 
increase in the proportion of BrdU+ cells that were DLX2+;DCX- transit amplifying cells and a 
corresponding decrease in the proportion of BrdU+ cells that were DCX+ neuroblasts (Figure 
4.2B). These data are consistent with previous in vitro time lapse imaging results, which 
indicated that depletion of Pnky leads to an expansion of the transit amplifying phase (Figures 
2.2E and 2.S2F). Thus, Pnky regulates neurogenic differentiation in the V-SVZ in vivo. 
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We further sought to determine whether loss of Pnky and altered progression through 
the neurogenic lineage lead to long-term effects on the V-SVZ NSC population. We collected 
wholemount V-SVZ preparations, which enable the en face visualization of the V-SVZ NSC 
pinwheel structure (Mirzadeh et al., 2008) (Figure 4.2C). We quantified the number of apical 
NSC processes from pinwheels in the V-SVZ of 6-month old mice and found that Pnky deletion 
significantly reduced their abundance by 41.5% (Figure 4.2D). Taken together with our previous 
results, these data suggest that loss of Pnky promotes neurogenic differentiation and transit 
amplifying cell expansion at the expense of long-term NSC abundance, and that increased V-
SVZ neurogenesis may underlie the formation of neuroblast nodules within the ventricles. 
While we have now shown that Pnky carries out important roles in multiple neurogenic 
populations in vivo, the molecular mechanisms through which Pnky functions are largely 
unknown. We previously determined that Pnky does not regulate its neighbor Pou3f2 in cis but 
rather acts in trans during cortical development (see Chapter 3). Furthermore, we found that 
Pnky physically interacts with the splicing regulator PTBP1 in NSCs of both the V-SVZ and 
developing cortex, and that depletion or loss of Pnky results in altered splicing in these 
populations (see Chapter 2 and Chapter 3). However, whether Pnky interacts with additional 
proteins to carry out its trans functions remained unclear. 
In order to identify novel Pnky binding partners through an unbiased approach, we used 
human proteome microarrays (Siprashvili et al., 2012). We first in vitro transcribed both mouse 
and human Pnky, as well as a scrambled version of mouse Pnky as a negative control. We then 
covalently labeled the transcripts with fluorescent Cy5 dye at an average labeling density of 
approximately 1 Cy5 molecule per 784 nt of RNA. By incubating the proteome arrays with the 
fluorescent RNA transcripts, we were able to identify a set of proteins that physically interact 
with mouse and/or human Pnky (Table 4.2). A subset of these proteins showed strong 
enrichment of both mouse and human Pnky, suggesting a potentially conserved interaction. 
Interestingly, the proteins found to enrich mouse and/or human Pnky were associated with 
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Gene Ontology terms (Mi et al., 2010; Thomas et al., 2003) related to RNA splicing and 
posttranscriptional regulation of gene expression (Table 4.3). Moving forward, determining 
whether these interactions with Pnky occur in vivo may provide key insights into how this 
lncRNA regulates neurogenesis and long-term neural stem cell abundance. 
 
Discussion 
In this chapter, we have demonstrated that genetic deletion of the lncRNA Pnky, which is 
enriched in V-SVZ NSCs, results in aberrant neurogenic differentiation and reduced long-term 
NSC abundance in the V-SVZ in vivo. Surprisingly, loss of Pnky led to the formation of 
intraventricular neuroblast nodules, which could be found at a variety of postnatal ages. These 
nodules do not seem to result from grossly impaired neuroblast migration, as neuroblasts were 
able to successfully reach the olfactory bulbs in adult Pnky-KO mice. Rather, the nodules may 
arise as a consequence of increased neurogenesis, as previously found with Pnky knockdown 
and knockout in V-SVZ cultures as well as Pnky deletion in the developing cortex. Preliminary 
observations (not shown) indicate that the establishment of V-SVZ NSCs is not affected in 
Pnky-KO mice, suggesting that the decrease in their long-term abundance is due to impaired 
NSC maintenance. Taken together, the data are consistent with a model in which loss of Pnky 
promotes neurogenic differentiation at the expense of the NSC population, and expands the 
transit amplifying phase to further increases neuroblast production. 
 We also identified additional putative Pnky binding proteins through human proteome 
microarrays. While we have previously found that Pnky interacts with PTBP1 in mouse NSCs 
from both the V-SVZ and the embryonic cortex, we did not detect an interaction between the 
Cy5-labeled Pnky transcripts and PTBP1 on the arrays. This may be due to a variety of 
technical issues stemming from how the proteins are produced in yeast and then purified and 
affixed to the arrays. Alternatively, this could reflect a biologically meaningful result; for instance, 
it is conceivable that Pnky may only be able to interact with PTBP1 as part of a larger complex. 
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Therefore, while these proteome arrays cannot provide a comprehensive set of Pnky interacting 
proteins, they can be very useful for identifying highly robust interactions. 
 Interestingly, the putative Pnky-interacting proteins that were identified are enriched for 
Gene Ontology terms related to splicing and posttranscriptional regulation of gene expression. 
As PTBP1 is also a splicing regulator, we have previously analyzed the splicing changes that 
occur upon depletion or loss of Pnky and found that they significantly overlap with PTBP1-
regulated splicing events. It will be important to further analyze the Pnky-dependent splicing 
changes to determine if they also overlap with events regulated by any of the newly-identified 
putative Pnky-interacting proteins. 
Of particular interest, quaking (QKI) was found to strongly interact with both mouse and 
human Pnky transcripts. While a statistically significant interaction was also found with the 
scrambled negative control, the intensity of this interaction was far weaker. QKI has been shown 
to influence neurogenic differentiation (Hayakawa-Yano et al., 2017; Shu et al., 2017), and also 
to regulate splicing networks that overlap with PTBP1-dependent splicing events (Gazzara et 
al., 2014; Hall et al., 2013; Wu et al., 2002). Therefore, unraveling how Pnky affects the 
interplay between these two splicing regulators may prove crucial to understanding the role of 
Pnky in neural stem cells. 
 QKI has also been found to physically interact with another lncRNA called Gomafu 
(Barry et al., 2014) (see Chapter 1). Gomafu orthologs in several species all contain multiple 
QKI consensus recognition sequences (Rapicavoli et al., 2010), however this was not the case 
for mouse or human Pnky. Interestingly, Gomafu also interacts with another splicing regulator 
serine/arginine-rich splicing factor 1 (SRSF1) (Barry et al., 2014), which we found to interact 
with Pnky as well. The related proteins SRSF9 and SRSF10 were also found to weakly interact 
with human PNKY but not mouse Pnky. Since Gomafu has been implicated in regulating 
neurogenic differentiation in the developing cortex (Aprea et al., 2013), it will be important to 
determine whether Pnky and Gomafu functionally influence one another. 
 134 
 As it is now clear that Pnky plays significant roles during neurogenic differentiation in 
vivo, moving forward it will be important to shift focus toward understanding how Pnky functions 
at the molecular level. The list of putative Pnky-binding proteins identified here will serve as a 
useful resource, providing new directions to explore. Further analyses to determine how Pnky 
regulates splicing, and whether its interaction with PTBP1 or other splicing factors is essential 
for this function, will also be revealing. Given that the molecular mechanisms of most lncRNAs 
with in vivo roles are poorly understood, gaining deeper insights into how Pnky functions will 
have broad implications for the field of lncRNA biology.  
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Figure 4.1: Loss of Pnky results in the aberrant formation of neuroblast nodules. 
A, Eosin (pink) with hematoxylin nuclear counterstain (blue), showing the ventral tip of the 
lateral ventricle in coronal sections from P21 mice. Scale bar = 50µm. B, DCX IHC, with DAPI 
nuclear counterstain, showing the ventral tip of the lateral ventricle in coronal sections from P74 
mice. Scale bar = 50µm. C, Frequencies of intraventricular neuroblast nodules within control or 
Pnky-KO mice of various postnatal ages. See also Table 4.1. D, Dimensions of the neuroblast 
nodules, with the average dimensions depicted by a hollow red circle. E, Ki67 IHC, with DAPI 
nuclear counterstain, showing the V-SVZ as in (B). Scale bar = 50µm. F, BrdU IHC, with DAPI 
nuclear counterstain, showing the V-SVZ from the same coronal sections as in (B). BrdU was 
administered 2 weeks prior at P60. Scale bar = 50µm. G, DCX IHC, with DAPI nuclear 
counterstain, showing the lateral ventricle and expanded insets from P37 mice. Scale bars = 
250µm and 25µm (insets).  
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Figure 4.2: Pnky regulates progression through the V-SVZ neurogenic lineage. 
A, BrdU IHC, with DAPI nuclear counterstain, showing the olfactory bulb in coronal sections and 
expanded insets from P74 mice. BrdU was administered 2 weeks prior, at P60. Scale bars = 
500µm and 100µm (insets). B, Quantification of the percentage of BrdU-labeled cells in the V-
SVZ that were transit amplifying cells (TAs, DLX2+;DCX-) or neuroblasts (NBs, DCX+). BrdU 
was administered at P30, and analysis performed 1 week later. * = p < 0.05, paired t test. C, 
IHC for b-catenin and g-tubulin, showing representative V-SVZ pinwheel from en face 
wholemount dissections. Scale bar = 10µm. D, Quantification of NSCs from P180 mice, using 
pinwheel analysis as shown in (C). *** = p < 0.001, ratio paired t test.  
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Table 4.1: Deletion of Pnky results in intraventricular neuroblast nodules. 
Descriptions of the mice in which intraventricular neuroblast nodules were observed, as well as 
the dimensions of the nodules themselves. Mediolateral (M-L) and dorsoventral (D-V) 
dimensions were measured directly in coronal sections. Anteroposterior (A-P) dimensions were 
approximated based on how the cryosectioning was performed. 
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Table 4.2: Mouse and human Pnky RNA physically interact with multiple proteins. 
Interactions between Cy5-RNA and proteins. Z-scores above 3 are considered significant. 
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Table 4.3: Pnky-interacting proteins are associated with RNA processing. 
Gene Ontology (GO) terms significantly enriched by the proteins found to interact with Pnky. 
“Hits” refers to the number of Pnky-interacting proteins associated with each GO term. FDR 
correction was performed to produce adjusted p values (Adj p). 
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Experimental Procedures 
Mus musculus 
Mice were cared for as described in (Chapter 3). Mice of both sexes were used for all 
experiments, and were analyzed at multiple ages between P14 and P180 as described in the 
text and figure legends for each experiment. All samples were analyzed relative to littermates. 
For Nestin-Cre experiments, control samples were Pnky+/+;Nestin-Cre or any combination of 
Pnky alleles in the absence of Nestin-Cre. Details regarding mouse strains are as follows: 
Nestin-Cre: Tg(Nes-cre)1Kln, described in (Tronche et al., 1999). 
PnkyF and Pnkynull: described in (Chapter 3). 
BrdU administration 
 Mice were administered 5-bromo-2’-deoxyuridine (BrdU, Millipore Sigma) reconstituted 
in sterile PBS through intraperitoneal injection, at a dose of 50mg BrdU per kg of mouse weight. 
Tissue preparation 
For samples to be cryosectioned, transcardiac perfusion was performed using 
phosphate buffered saline (PBS) followed by 4% paraformaldehyde (PFA, Millipore Sigma 
158127). The brains were then dissected out of the skull and additionally fixed in 4% PFA 
overnight at 4°C. Fixed specimens were rinsed in PBS and stored at 4°C in PBS with sodium 
azide. Cryosectioning was performed as described in (Chapter 3). 
 Wholemount dissections were performed as described in (Mirzadeh et al., 2010). 
Hematoxylin and eosin staining 
Cryosection slides were incubated serially in the following solutions: 95% EtOH (2 min), 
70% EtOH (2 min), running tap water (5 min), Gill’s hematoxylin (3 min), running tap water (5 
min), Scott’s solution (3 min), running tap water (5 min), eosin (20 sec), 70% EtOH (30 sec), 
95% EtOH (30 sec), 100% EtOH (30 sec), Xylene (5 min). The slides were then allowed to dry 
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completely (at least 5 min) before they were mounted with coverslips using Permount (Fisher). 
Scott’s solution: 2g sodium bicarbonate, 20g MgSO4, 1 liter water. 
Immunohistochemistry (IHC) 
IHC on cryosections was performed as described in (Chapter 3). IHC on wholemount 
dissections was performed as follows:  
Blocking: incubated in blocking buffer for 1 hr at RT. Blocking buffer: PBS with 1% BSA 
(Millipore Sigma), 0.3M glycine (Thermo Fisher Scientific), 0.5% TritonX100 (Millipore Sigma), 
and 10% normal goat serum (Jackson ImmunoResearch Laboratories). 
Primary antibodies: incubated in primary antibodies diluted in blocking buffer for 24 hrs at 4°C. 
Wash 1: rinsed twice in PBS, then washed 3 times in PBS with rotation for 20 min at RT. 
Secondary antibodies: incubated in secondary antibodies (Alexa Fluor antibodies from Thermo 
Fisher Scientific, 1:500) and DAPI (Thermo Fisher Scientific, 1:1000) diluted in blocking buffer 
for 24 hrs at 4°C. 
Wash 2: same as wash 1 above. 
After IHC, the wholemount dissection was completed as described in (Mirzadeh et al., 2010). 
The tissue was then mounted on Superfrost Plus Microscope Slides (Thermo Fisher Scientific) 
with coverslips using Aqua Poly/Mount (Polysciences). 
Primary antibodies for IHC 
Cryosections: 
DCX: Abcam (ab18723) diluted 1:500. 
NeuN: Millipore (MAB377) diluted 1:500. 
Ki67: BD Biosciences (556003) diluted 1:200. Performed citrate antigen retrieval prior to IHC 
(see below). 
BrdU: Abcam (ab6326) diluted 1:200. Performed HCl antigen retrieval prior to IHC (see below).  
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Wholemount dissections 
b-catenin: Sigma (C2206) diluted 1:1000. 
g-tubulin: Abcam (ab11316) diluted 1:1000. 
Citrate antigen retrieval for Ki67 IHC 
For Ki67 IHC, antigen retrieval was performed using 10mM sodium citrate (pH 6.0) prior 
to IHC. Slides were incubated horizontally with 500µL of sodium citrate on top of the tissue for 
2-3 min at RT. This was replaced with fresh sodium citrate, and the slides were moved to a pre-
heated vegetable steamer. After 15 min, the slides were removed from the steamer and allowed 
to cool for 2-3 min at RT. The sodium citrate was then dumped off of the tissue and the slides 
were rinsed in PBS. 
HCl antigen retrieval for BrdU IHC 
For BrdU IHC, antigen retrieval was performed using HCl and boric acid prior to IHC. 
Slides were first rinsed in PBS with rotation for 10 min at RT. The slides were then incubated in 
fresh 2N HCl at 37°C for 30 min. Boric acid (100mM, pH 8.5) was used to rinse the slides to 
remove all HCl. The slides were then incubated in fresh boric acid with rotation for 10 min at RT. 
After rinsing the slides with PBS, IHC was performed as described above. 
If BrdU IHC was to be performed in combination with IHC for other antigens, IHC for 
these antigens was completed first. The tissue was re-fixed in 4% PFA for 30 min at RT and 
rinsed in PBS. HCl antigen retrieval was then performed, followed by BrdU IHC. 
Microscopy and image analysis 
Microscopy and image analysis performed as described in (Chapter 3). 
Human proteome microarrays 
 Mouse and human Pnky RNA transcripts, along with a scrambled mouse Pnky control, 
were produced using the HiScribe T7 High Yield RNA Synthesis Kit (New England Biosciences). 
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RNA was purified using Trizol (Invitrogen). Label IT® Nucleic Acid Labeling Reagents Cy5 Kit 
(Mirus) was used to label RNA with Cy5. Labeled 25µg of RNA per 62.5µL reaction, and 
performed 8 reactions per transcript in order to obtain enough RNA for subsequent proteome 
microarray analysis. In order to achieve a labeling density of approximately 1-3 Cy5 dye 
molecules per transcript (Siprashvili et al., 2012) used Cy5 Label IT Reagent at a ratio of 1:20 
and incubated at 37°C for 3 hours. Extracted labeled RNA using EtOH precipitation. Quantified 
labeling density as described in the Label IT® Nucleic Acid Labeling manual. 
 CDI Laboratories, Inc. performed human proteome microarray analysis using the Cy5-
labeled transcripts described above and the HuProt v4.0 arrays. Interactions with Z-scores 
above 3.0 were statistically significant. 
Scrambled mouse Pnky sequence 
GTGGGTGCTACGCCCCATTATATCCGGGCGACGACAAGCACCGTTCAGCGTAATTA
ACACCTCGTTTCGGAACTTCTGACCACGAAGTTTTGAATGAATGCAGATTAGAGCACCGAT
CCAAATACTCGGTCGGTTGAGAGTGTAGCCGGCGGAACTGTCGTACCGTGTGACGCTTGA
ATCAGTTTACCTAATGTTGAGTAAAACCTCACAGAGAGCGCTACTTGTAAACGTGTGCCCG
ATGCGGGAAACCTATGCATTGTTTCTACCTAGTCAGATTGGGAAACACCCCCGACCGCTTT
GAGTAGCTGTCGCAGGCATCGTGCGACCAGGCCTGCACTTAGACCGAAACGTAAACTGTG
ATAGCCCATCAACCGACAGCGTTGTAGTTAGTTCGCTCTCTGAAACACATTATGGCCCGAC
ACATAACTCACCATGCGCCGAGGGATACGACTCTCGAGTGTTGTCTGGTGCGTCACCCTG
TTTCTTCCACACGGTTGTTAATCGGTGGACCCCTCTTTAGCGGTTCAAAGATGTCTTTAGAT
CCCGCGCCAAGGGTAGCGGCCTACCTATATAGCATCGAGGGCAACCCGTCCGGTGATGC
CCAGGTGTTTGAGCCCCGTTTGTGAAATACATGCGCATACTCGCAGGAGCTATGGGTGTAA
AGATTCTCAGCAGAATAGATTCTAAATCTCCTGTTCCGAATGGATGTAGCCGTACATAACG
GAGTAAAGGGACGGTCGTACATCCTGGCCAGTTCGATCGTCATGTCATACGTTTAAGTACT
CCCACATACTAGCACTGAATAAGACGGTGAAATCAATATGT  
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Gene ontology analysis 
 Gene ontology analysis was performed using the Panther Classification System (Mi et 
al., 2010; Thomas et al., 2003), with the Pnky-interacting proteins listed in (Table 4.2) as the 
experimental set and all proteins present on the HuProt v4.0 microarrays as the background set. 
Performed “GO Biological Process Complete” analysis with FDR correction. 
Figure preparation 
Figures were prepared using Photoshop and Illustrator (Adobe) and Prism (GraphPad). 
Quantification and Statistical Analysis 
All in vivo quantifications were normalized to littermate controls. The statistical details of 
each experiment can be found in the relevant figure legends.  
 145 
Chapter 5: Conclusions and Future Directions 
 
 Long noncoding RNAs (lncRNAs) comprise a class of noncoding transcripts that is 
extremely diverse in terms of biological function and molecular mechanism. While this diversity 
is quite intriguing, it introduces additional complications when attempting to determine what role 
a particular lncRNA might play. Whether a lncRNA has an important cellular function in a given 
tissue, and how the lncRNA might carry out that function at the molecular level, currently remain 
very difficult to predict. Moreover, certain lncRNAs — despite being expressed by multiple cell 
types — seem to have exquisitely cell type-specific biological functions (Liu et al., 2017). 
Because of this, experimental manipulations of lncRNA expression can produce complex 
phenotypes that vary based on the timing of the lncRNA perturbation and the cell type under 
investigation. Combining multiple complimentary approaches may therefore prove particularly 
useful for revealing the functions of lncRNAs. 
 This dissertation illustrates how we have now integrated a variety of experimental 
techniques to determine the role of the lncRNA Pnky in two distinct neural stem cell populations 
in vivo. Chapter 2 describes how we began investigating the function of Pnky by using short 
hairpin RNAs (shRNAs) to deplete Pnky transcripts. These initial experiments predominantly 
relied on cultured neural stem cells (NSCs) from the mouse ventricular-subventricular zone (V-
SVZ), and revealed that Pnky knockdown promotes neurogenic differentiation and expansion of 
the transit amplifying population. We also identified the splicing regulator PTBP1 as a protein 
interacting partner of Pnky. Chapter 3 describes the generation of multiple novel genetic mouse 
lines to analyze the function of Pnky in the developing neocortex. Through conditional Pnky 
deletion in a small cohort of cortical NSCs, we demonstrate that loss of Pnky leads to 
precocious neurogenic differentiation in a cell-autonomous manner. By combining constitutive 
Pnky knockout with BAC transgenic expression of Pnky, we further determine that Pnky 
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regulates transcript abundance and splicing in trans, potentially through its physical interaction 
with PTBP1. Chapter 4 focuses on the role of Pnky in the V-SVZ in vivo, and demonstrates that 
loss of Pnky results in the formation of intraventricular neuroblast nodules. Furthermore, Pnky-
deletion alters progression through the V-SVZ neurogenic lineage by expanding the transit 
amplifying phase, and also leads to reduced long-term NSC abundance. In order to begin 
understanding the molecular function of Pnky, we identified a novel set of putative Pnky-
interacting proteins, which were enriched for roles relating to RNA splicing. Taken together, 
these analyses demonstrate that Pnky is a lncRNA with important functions in neurogenesis in 
vivo, potentially through its physical interactions with splicing regulators. 
As the lncRNA field moves forward, understanding the precise details of their intricate 
molecular mechanisms will be crucial for revealing how particular lncRNAs can play important 
roles in neurogenesis and neurological disorders. Toward this end, we combined multiple 
genetic mouse lines to determine that Pnky does not regulate its neighboring gene Pou3f2 in 
cis, and instead functions in trans (see Chapter 3). Furthermore, we identified the RNA splicing 
regulator PTBP1 as an interacting partner of Pnky (see Chapter 2). PTBP1 is an important 
regulator of neural development (Keppetipola et al., 2012; Shibasaki et al., 2013), direct 
neuronal reprogramming (Xue et al., 2013), and brain tumor growth (Ferrarese et al., 2014), 
making this physical interaction of particular interest. 
Importantly, we determined that depletion or loss of Pnky leads to altered splicing (see 
Chapter 2 and Chapter 3). These splicing changes were found to significantly overlap with 
known PTBP1-regulated splicing events, further suggesting a relationship between Pnky and 
PTBP1. However, the molecular details of how Pnky might affect PTBP1-dependent splicing 
remain unclear. To address this, analyses such as PTBP1 CLIP-seq (Van Nostrand et al., 2016; 
Xue et al., 2009) in wild type and Pnky-deleted NSCs might provide crucial mechanistic insight 
into Pnky function. Such experiments could reveal specific downstream targets that are altered 
upon loss of Pnky and may underlie the phenotypes we have observed. 
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While PTBP1 might be an important contributor to the molecular function of Pnky, it is 
possible that Pnky also carries out PTBP1-independent roles. Therefore, determining whether 
Pnky interacts with additional proteins to carry out its trans functions will be another significant 
focus of future work. We have now identified a new list of putative Pnky-interacting proteins 
using human proteome arrays (see Chapter 4). While these arrays will not provide an 
exhaustive list of all potential protein binding partners, they can identify robust interactions. We 
found that many of the putative Pnky-interacting proteins were related to RNA splicing, further 
implicating Pnky in this process. In particular, the protein QKI was found to interact with both 
mouse and human Pnky. Given the role of QKI in neurogenic differentiation (Hayakawa-Yano et 
al., 2017; Shu et al., 2017), as well as its regulation of splicing networks that overlap with those 
of PTBP1 (Gazzara et al., 2014; Hall et al., 2013; Wu et al., 2002), QKI may be an especially 
important putative binding partner for further analysis. 
Loss of Pnky results in aberrant cortical neurogenesis during embryonic development, 
leading to postnatal alterations in neuronal subtype abundance (see Chapter 3). This raises the 
intriguing possibility that these developmental defects may result in behavioral abnormalities in 
Pnky-KO mice. Interestingly, knockout of the lncRNA Gomafu has been found to produce a mild 
hyperactivity phenotype in mice, which is exacerbated by the psychostimulant 
methamphetamine (Ip et al., 2016). Gomafu binds to the splicing regulators QKI and SRSF1 
(Barry et al., 2014), which we also identified as putative interacting partners of both mouse and 
human Pnky (see Chapter 4). Manipulation of Gomafu levels can also disrupt neurogenic 
differentiation in the developing cortex (Aprea et al., 2013); therefore, it will be useful to explore 
whether Gomafu and Pnky functionally affect one another. 
Assessing whether loss of Pnky leads to behavioral defects will be especially interesting 
given that Pnky is conserved in human. We have previously shown that human PNKY is 
expressed in the developing cortex in a very similar pattern to mouse Pnky, with enrichment in 
the ventricular zone (VZ) where the NSCs reside (see Chapter 2). Many of the putative Pnky 
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binding proteins were also detected to interact with both mouse and human Pnky, consistent 
with a conserved functional role. Interestingly, we also found proteins that seemed to uniquely 
interact with either mouse or human Pnky, suggesting that there may be species-specific 
differences in Pnky-binding partners. We have observed that human PNKY is expressed in 
cerebral organoids and seems to be enriched in the VZ-like regions of the organoids (Figure 
3.5G). Thus, cerebral organoids may serve as a tractable model system that can facilitate future 
studies regarding the function of human PNKY.  
The mammalian central nervous system expresses a large diversity of lncRNAs, but only 
a small set of these lncRNAs have been experimentally manipulated. There are emerging 
examples of lncRNAs that are relevant to neurodevelopmental disorders (Briggs et al., 2015; 
Meng et al., 2015), which highlights the need to functionally characterize the roles of lncRNAs 
during brain development using animal models. There have been attempts to predict the 
functions of lncRNAs based on their underlying DNA sequence or genomic configuration 
(Engreitz et al., 2016; Liu et al., 2017; Luo et al., 2016); however, this currently remains a 
difficult challenge. Therefore, experimentally manipulating individual lncRNAs with a 
combination of approaches will likely be required to uncover important features of their 
biological function and molecular mechanism. In vivo lncRNA studies will provide a critical 
foundation for understanding how this diverse class of noncoding molecules can influence brain 
development and neurological disorders. As we have now shown that Pnky has significant roles 
during neurogenesis in vivo, moving forward it will be valuable to turn our focus toward 
unraveling the molecular mechanism through which Pnky functions. Given that most lncRNAs 
with in vivo roles are poorly understood at the molecular level, gaining deeper insights into how 
Pnky functions will have broad implications for the field of lncRNA biology, and will ultimately 
pave the way toward understanding how this unique class of molecules regulates processes 
from normal development to disease. 
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